

Mary Elizabeth Hartnett, M.D.
 University of Utah
 John A. Moran Eye Center
 65 N Mario Capecchi
 Salt Lake City, UT 84132
 801-581-3357 (fax)
 me.hartnett@hsc.utah.edu

PERSONAL DATA

Birth Place: Lackawanna, NY
 Citizenship: United States
 Languages: English

EDUCATION

<u>Years</u>	<u>Degree</u>	<u>Institution (Area of Study)</u>
9/77 – 5/82	B.S.	Rensselaer Polytechnic Institute (Biology (Combined BS/MD program)) Troy, NY
8/79 – 5/83	M.D	Albany Medical College (Medicine (Combined BS/MD program)) Albany, NY
6/83 – 6/84	Intern	University Hospitals of Cleveland Cleveland, OH
7/84 – 6/87	Resident	University Hospitals of Cleveland, VA Medical Center (Ophthalmology) Cleveland, OH
7/87 – 6/89	Research Fellow	Schepens Eye Research Institute, Harvard Medical School Boston, MA
7/87 – 6/89	Vitreoretinal Fellow	Massachusetts Eye and Ear Infirmary, Harvard Medical School, Schepens Retina Associates (Vitreoretinal Medical/Surgical Training in Adult Retina) Boston, MA
7/88 – 6/89	Chief Fellow	Schepens Retina Associates Boston, MA
7/89 – 6/90	Pediatric Vitreoretinal Fellow	Schepens Retina Associates, Massachusetts Eye and Ear Infirmary, Harvard Medical School (Vitreoretinal Medical/Surgical Training in Pediatric Retina) Boston, MA
7/89 – 6/90	Research Fellow	Harvard University (Senior Research Ophthalmology Fellow) Boston, MA
3/95 – 10/00	Postgraduate Studies	Children's Hospital and Schepens Eye Research Institute, Harvard University (Molecular and Cell

		Biology)
		Boston, MA
7/03 – 2/10	Postgraduate Studies	University of North Carolina, Cell and Developmental Biology

BOARD CERTIFICATIONS

01/01/1989	American Board of Ophthalmology, Diplomate
------------	--

LICENSES/CERTIFICATIONS

1983 - Inactive	State License (OH) - Physician (MD)
1987 - Present	State License (MA) - Physician (MD)
1990 - Inactive	State License (NY) - Physician (MD)
2000 - Inactive	State License (LA) - Physician (MD)
2003 - Inactive	State License (NC) - Physician (MD)
2010 - Present	State License (UT) – Physician (MD)
2011 - 2015	Basic Life Support Certification

PROFESSIONAL EXPERIENCE**Full Time Positions**

8/90 – 6/94	Attending Retina Specialist, Medical and Surgical, Children's Hospital of Buffalo, Buffalo, NY
8/90 – 6/94	Attending Retina Specialist, Medical and Surgical, Millard Fillmore Gates Hospital, Buffalo, NY
8/90 – 6/93	Director, Retina Service, Erie County Medical Center, Buffalo, NY
8/90 – 6/93	Consultant, VA Medical Center, Buffalo, NY
8/90 – 6/93	Attending on Clinical Service, SUNY at Buffalo, Department of Ophthalmology, Buffalo, NY
8/90 – 3/93	Assistant Professor, Retina Service, State University of New York, Buffalo, NY
7/93 – 6/00	Retina Consultant, Spaulding Rehabilitation Hospital, Boston, MA
7/93 – 6/94	Assistant Clinical Ophthalmologist, Massachusetts Eye and Ear Infirmary, Boston, MA
7/93 – 6/00	Attending on Clinical Service, Schepens Retina Associates, Retina Service, Peabody, MA
12/93 – 9/99	Clinical Instructor, Harvard University, Cambridge, MA
7/94 – 10/00	Associate in Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA
7/95 – 10/00	Associate Pediatrician, Department of Newborn Medicine, Brigham and Women's Hospital, Boston, MA
7/95 – 10/00	Assistant Clinical Scientist, Schepens Eye Research Institute, Boston, MA
7/96 – 10/00	Clinical Associate in Surgery, Massachusetts General Hospital, Boston, MA
10/99 – 7/00	Assistant Clinical Professor of Ophthalmology, Harvard University, Cambridge, MA
11/00 – 2/03	Attending on Clinical Service, LSU Retina Service, Department of Ophthalmology, Baton Rouge, LA
11/00 – 2/03	Associate Professor of Ophthalmology, Director of Retina Service, LSU Eye Center, Louisiana State University Health Sciences Center, New Orleans, LA
3/03 – 4/10	Attending on Clinical Service, UNC Retina Service, Department of Ophthalmology, Chapel Hill, NC
3/03 – 5/08	Associate Professor of Ophthalmology with tenure, University of North Carolina, Chapel Hill, NC
5/08 – 4/10	Professor of Ophthalmology with tenure, University of North Carolina, Chapel Hill,

	NC
5/10 - Present	Professor of Ophthalmology with tenure, University of Utah, Salt Lake City, Utah
5/10 - Present	Adjunct Professor in Pediatrics, John A. Moran Eye Center, Salt Lake City, Utah
5/10 - Present	Director of Pediatric Retina, John A. Moran Eye Center, University of Utah, Salt Lake City, Utah
3/12 - Present	Adjunct Professor in Neurobiology and Anatomy, University of Utah, Salt Lake City, Utah
5/15 - 7/15	Co-Director of MD-PhD program, University of Utah
2017 - Present	Director, Co-Director Advances in Pediatric Retina Meeting. Duke University and University of Utah.

Editorial Experience

2009 - Present	Editorial Board for Clinical Ophthalmology
2009 - Present	Editorial Board member for Eye and Brain
2011 - Present	Editor for Molecular Vision, Scientific Review
2012 - Present	Editorial Board Member for the Scientific World Journal
2012 - Present	Editorial Board member for PlosOne
2012 - Present	Editor for American Academy of Pediatric Ophthalmology and Strabismus
2012 - Present	Editorial Board American Journal of Ophthalmology
2020 - Present	Editorial Board EyeNet magazine
2020 - Present	Editor Retina Section EyeWiki

Reviewer Experience

1999 - Present	Ad hoc reviewer for American Journal of Ophthalmology
1999 - Present	Ad hoc reviewer for Experimental Eye Research
2001 - Present	Ad hoc reviewer for Current Eye Research
2001 - Present	Ad hoc reviewer for Ophthalmic Epidemiology
2001 - Present	Ad hoc reviewer for Trends in Cardiovascular Medicine
2003 - Present	Ad hoc reviewer for Archives of Ophthalmology
2003 - Present	Ad hoc Reviewer for Retina
2004 - Present	Ad hoc reviewer for Journal of Cellular Physiology
2004 - Present	Ad hoc reviewer for Journal of Ocular Pharmacology & Therapeutics
2004 - Present	Ad hoc reviewer for Molecular Vision
2004 - Present	Ad hoc reviewer for Ophthalmology
2005 - Present	Ad hoc reviewer for Acta Ophthalmologica Scandinavica
2005 - Present	Ad hoc reviewer for Investigative Ophthalmology & Visual Sciences
2005 - Present	Ad hoc reviewer for Survey of Ophthalmology
2006 - Present	Ad hoc reviewer for Developmental Dynamics
2006 - Present	Ad hoc reviewer for Graefe's Archive Clin Exp Ophthalmol
2006 - Present	Ad hoc reviewer for Journal of American Academy of Pediatric Ophthalmology and Strabismus
2006 - Present	Reviewer for Developmental Dynamics
2007 - Present	Ad hoc reviewer for British Journal of Ophthalmology
2007 - Present	Ad hoc reviewer for Journal of Anatomy
2009 - Present	Ad hoc reviewer for Journal of Molecular and Cellular Cardiology
2015 - Present	Reviewer for Pediatric Research
2012 - Present	Reviewer American Journal of Pathology
2018 - Present	Reviewer for Ophthalmology Retina
2019 - Present	Reviewer for Journal of Vitreoretinal Diseases
2019 - Present	Reviewer for Ophthalmic Surgery, Lasers and Imaging Retina

SCHOLASTIC HONORS & AWARDS

1981	Perrin Oncology Fellowship in Research, University of Pittsburgh, Pittsburgh, PA
1982 - 1983	Alpha Omega Alpha Honor Society, Albany Medical College, Albany, NY
1982	Graduated summa cum laude, Rensselaer Polytechnic Institute
1983	Arthur W. Wright Award, Albany Medical College, Albany, NY
1988 - 1989	Charles de Gunzburg Fellowship in Clinical Retina Research, Schepens Eye Research Institute, Boston, MA
1998	Honor Award, American Academy of Ophthalmology, San Francisco, CA
2000 - 2003	Prince Abdul Aziz Bin Ahmed Bin Abdul Aziz Al Saud Endowed Chair of Retinal Disease, Louisiana State University
2002 - 2003	American College of Surgeons, Louisiana Chapter, Young Surgeon Representative
2005	Research to Prevent Blindness Physician-Scientist Merit Award
2005 - 2011	“Best Doctors in America”
2006	Finalist for the Burroughs Wellcome Fund Clinical Scientist Awards in Translational Research
2010	Accepted to the American Ophthalmology Society
2011	Appointed as Permanent Member of Biology and Disease of the Posterior Eye (BDPE)
2012	Appointed as Permanent Member of Disease and Pathophysiology of the Visual System (DPVS)
2013	Best Doctors in America
2013	ARVO Silver Fellow
2013	Scientific Advisory Board for Knights Templar Eye Foundation
2013 - 2015	Appointed Chair of Disease and Pathophysiology of the Visual System (DPVS)
2014	Women in Ophthalmology Scientific Contribution Award
2014	Women in Ophthalmology Honorary Lecture Award
2015	ARVO Gold Fellow
2015	Recipient of the Paul Henkind Award given by The Macula Society, Miami Beach FL.
2015	Selected as a Castle Connolly 2017 Top Doctor
2016	Recipient of the Weisenfeld Award 2018 at ARVO 2017 Annual Meeting. Baltimore MD.
2017	Received special recognition for leading/developing the Module on Human Subject’s research, at the General Business meeting at ARVO 2017 annual meeting. Baltimore, MD.
2017-2018	Best Doctors in America
2018	Recipient of the University of Utah Calvin S. and JeNeal N. Hatch Presidential Endowed Chair.
2018	2018 Future Vision Award from the Future Vision Foundation, Cleveland OH, November 17, 2018.
2019	Recipient of the Arnall Patz Medal Award given by The Macula Society, Bonita Springs FL, February 13-16, 2019.
2019	Distinguished Professor Award, University of Utah. Salt Lake City, UT. May 3, 2019.
2019	Recipient of the Paul Kayser/RRF Global Award. “Toward a Safe and Effective Treatment for Retinopathy of Prematurity”. XXXIV Pan-American Congress of Ophthalmology, Cancun, Mexico. May 25, 2019.
2018-2020	Best Doctors in America

ADMINISTRATIVE EXPERIENCE**Administrative Duties**

- 1990 - 1993 Medical Director of Photography & Fluorescein Angiography Service, State University of New York, Buffalo, NY
- 1994 - 1995 Quality Assurance Committee, Specialty Care Associates, Boston, MA
- 2000 Co-Director, Macular Degeneration Research Center, Schepens Eye Research Institute, Boston, MA
- 2001 - 2003 Co-Founder, Pediatric Retina Clinic, Children's Hospital, New Orleans, LA

Professional Organization & Scientific Activities

- 1999 Chair, National Institutes of Health, NIH special R01 section for Research Project Grants, Washington, DC
- 2001 - Present Member, Association of Pediatric Retinal Surgeons, Pediatric Retina Surgery Study Group
- 2002 - 2003 Representative, American College of Surgeons: Louisiana Chapter, Young Surgeon Representative, Chicago, IL
- 2002 - 2003 Representative, American College of Surgeons, Louisiana Chapter, Young Surgeons Advisory Board Member, Chromosome 18 Registry & Research Society, World Congress on Chromosomal Abnormalities; San Antonio, TX, (International Congress)
- 2004 Advisory Committee Member, Chromosome 18 Registry & Research Society, 2004 Inaugural World Congress on Chromosome Abnormalities, San Antonio, TX
- 2006 Moderator, Association for Research in Vision and Ophthalmology, ARVO Summer Eye Research Conference 2006, "Toward the Prevention of Age-Related Macular Degeneration", Sanibel, FL. Session VI, Inflammation and Other Potential Approaches for Prevention of AMD (International Meeting)
- 2007 Founding Member, American Society of Retina Specialists, Women in Retina (WinR)
- 2007 Co-Moderator, Association for Research in Vision and Ophthalmology, ARVO Annual Meeting: Inflammation and Immunity in AMD, paper session for Retinal Cell Biology
- 2008 Member, Association for Research in Vision and Ophthalmology, Ethics and Regulations in Human Research Committee
- 2008 Co-Moderator, Association for Research in Vision and Ophthalmology, ARVO Annual Meeting: Pediatric Retina Section, paper session for session for Retina
- 2008 Moderator, American Academy of Ophthalmology, Breakfast Roundtable, Developing Both Research and Clinical Careers as a Clinician Scientist
- 2009 Appointed Member, American Diabetes Association, Research Policy Board
- 2010 Co-Moderator for Ethics Committee. Conflict of Interest and Full Disclosure: An Ongoing Issue for Practitioners, Companies, and Government. Association for Research in Vision and Ophthalmology (ARVO). Ft. Lauderdale, Florida
- 2010 AFER host-a-researcher. Association for Research in Vision and Ophthalmology (ARVO). Ft. Lauderdale, Florida
- 2011 Moderator, Macula Society, Scientific Session on Basic Science
- 2012 - Present Representatives Nominated by Retina Society for Practicing Ophthalmologists Curriculum
- 2012 - Present Member, Telehealth, Steering Committee, University of Utah
- 2012 - Present Program Committee Member, Association for Research in Vision and Ophthalmology, Retinal Cell Biology
- 2012 - Present Women in Ophthalmology, Audit Committee

2012 - Present	Member, Women in Eye and Vision Research, Networking Committee
2013 - 2015	Chair, National Institutes of Health Center for Scientific Review, Study Section on Diseases and Pathophysiology of the Visual System
2013	Chair, Prevent Blindness America Grant Review, ARVO
2013	Reorganizer of the ADA Grant Submission & Review Process
2014	Affiliate Member, American Association for Pediatric Ophthalmology and Strabismus (AAPOS)
2015	Chair, Association for Research in Vision and Ophthalmology, Ethics and Regulations in Human Research Committee
2015 - Present	Member of the Education Committee Utah Ophthalmology Society (UOS)
2017	Moderator Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Novel therapies and imaging techniques for retinal disorders- Minisymposium. Baltimore, MD.
2017	Moderator Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. ROP: Basic mechanisms. Poster Session. Baltimore, MD.
2018 - Present	Chair Elect Publications Committee of ARVO.
2019 - Present	Council Member NEI's National Advisory Eye Council (NAEC).
2020 - Present	Member International Classification of ROP (ICROP) committee.
2020 - Present	Member Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC).
2020 - Present	Member of the Global Burden of Disease (GBD) Collaborator Network.
2020 - Present	Chair of Research Council of Macula Society.

Grant Review Committee/Study Section

1997	NIH study section for Small Business Innovation Research (SBIR) Grants. National Institutes of Health, Washington, DC. Participated in 3 meetings.
1998	NIH study section for Small Business Innovation Research (SBIR) Grants. National Institutes of Health, Washington, DC. Participated in 3 meetings.
1999	NIH study section for Small Business Innovation Research (SBIR) Grants. National Institutes of Health, Washington, DC. Participated in 3 meetings.
2000	NIH study section for Small Business Innovation Research (SBIR) Grants. National Institutes of Health, Washington, DC. Participated in 3 meetings.
2001	NIH study section for Small Business Innovation Research (SBIR) Grants. National Institutes of Health, Washington, DC. Participated in 3 meetings.
2002	NIH study section for Small Business Innovation Research (SBIR) Grants. National Institutes of Health, Washington, DC. Participated in 3 meetings.
2003	NIH study section for Small Business Innovation Research (SBIR) Grants. National Institutes of Health, Washington, DC. Participated in 3 meetings.
2004	NIH/NEI FO1 Fellowship Study Section
2004	NEI Special Emphasis Panel, Clinical Vision Research Applications. National Eye Institute (April 13, 2004, December 8, 2004)
2004 - 2005	American Diabetes Association, Lions' Sight First Review Panel. (May 7, 2004, October 17, 2004, March 29, 2005)
2004	Action Medical Research in the UK
2004 - 2012	American Diabetes Association Research Grants. (October 17, 2004, April 16, 2005, October 22, 2005, April 22, 2006, October 7, 2006, March 12, 2008, 2009, November 2010)
2004	NIH study section for Small Business Innovation Research (SBIR) Grants. National Institutes of Health, Washington, DC. Participated in 3 meetings.
2005	Thrasher Research Fund
2005	NIH/CSR Special emphasis panel for Retinal Diseases
2006	Special Emphasis Panel, NIH/CSR

2006	NIH study section for Small Business Innovation Research (SBIR) Grants. National Institutes of Health, Washington, DC. Participated in 3 meetings.
2006	Dutch Diabetes Research Foundation
2007	International Retinal Research Foundation, grant review
2007	DRCR.net, January meeting
2007 - 2010	Ad Hoc member of BDPE/DPVS Study Section, R01 Grant Review for NIH.
2008	March of Dimes grant review
2008	DRCR.net, January meeting
2008	National Institute of Health, review of K grants
2009	Biology and Disease of Posterior Eye
2009	American Diabetes Association, spring grant review
2009	Challenge grant review, NEI
2009	NIH study section for Small Business Innovation Research (SBIR) Grants. National Institutes of Health, Washington, DC. Participated in 3 meetings.
2009	R24 NEI grant review
2009	Fight For Sight Eye Research grant review (UK)
2010 - 2015	Permanent Member of BDPE/DPVS Study Section, R01 Grant Review for NIH
2010 - 2015	NIH/DPVS Grant Review (chair 2013-2015)
2011 - 2014	Prevent Blindness America grants review - ARVO 2011
2012	Thrasher Research Fund
2012 - Present	Grant Reviewer, Women in Ophthalmology
2013 - Present	Knights Templar Eye Foundation Grant Review
2016	NIH Review Committee for NEI T32/T35/K12, ZEY1 VSN (03), Washington DC
2017	NIH Clinical Review, Washington DC.

PROFESSIONAL SERVICE

National / International Organizations

2002	Member, Schepens Eye Research Institute, National Advisory Board, Task Force
2005 - 2008	Member, Diabetic Retinopathy Clinical Research Network, Protocol Steering Committee for anti-VEGF agents
2009	Representative, Women's Eye Health.org, Gender and Blindness Press Conference, April 30, 2009, National Press Club, Washington, DC
2009 - Present	Committee Member, VISION 2020, International Consortium
2009	Representative, Women's Eye Health.org, Inaugural meeting of NGOs on Gender and Blindness, April 30, 2009, Stone Center, NIH campus, Bethesda, MD
2009	Executive Board Member, Women's Eye Health.org
2009 - 2010	Director, Women's Eye Health.org
2009	Interviewee, VISION 2020, World Sight Day, Women Urged to Take Charge of their Eye Health, video. Published on UNC (https://www.med.unc.edu/empnews/archives/vital-signs-oct-9-2009/video-women-urged-to-take-charge-of-their-eye-health/) and YouTube
2012	Host and organizer of the Association of Pediatric Retina Surgeons (APRS) annual meeting, Park City, Utah.
2012 - 2015	Member, Macula Society Credentials Committee.
2013	Research in Retinopathy of Prematurity. Interviewee, American Association of Ophthalmology (AAO) Annual Meeting. New Orleans, LA.
2014	Affiliate Member, American Association for Pediatric Ophthalmology and Strabismus (AAPOS)
2014 - 2018	Member, AOS Credentials Committee

2016 – 2020 Member, Retina Society Credentials Committee
 2018 - Present Medical Director Women’s Eye Health (WEH)
 2020 – Present Council Member International Society for Eye Research (ISER). Vice President Americas.

PROFESSIONAL COMMUNITY ACTIVITIES

1993 Physician, Perkins School for the Blind, Retinopathy of Prematurity, Patient Education, Watertown, MA
 1994 - 1995 Member, Specialty Care Associates, Quality Assurance Committee, Boston, MA
 1994 Physician, Beverly Hospital, Diabetic Retinopathy, Diabetes Mellitus Support Group, Beverly, MA
 2000 Medical Director, Lions Club, LA Lions Club Sight Program
 2003 Interviewee, Louisiana State University Medical Center, Healthcall, Local Public Service Television Program (questions and answers from callers), Medical Center of Louisiana New Orleans and WLAE-TV-32, New Orleans, LA
 2005 Interviewee, University of North Carolina, UNC TV session on AMD
 2008 Interviewee, WRAL News, WRAL/TV NC interview on DRCR.net clinical trial
 2008 Interviewee, ReachMD, Radio interview on Diabetic Macular Edema and DRCR.net clinical trial

UNIVERSITY COMMUNITY ACTIVITIES

University Level

2012 - 2015 Member, Academic Senate
 2011 - 2013 Member of Academic Retention Promotion and Tenure Committee School of Medicine, University of Utah
 2013 - 2014 Chair of Academic Retention Promotion and Tenure Committee School of Medicine, University of Utah
 2014 - Present Member, MD/PhD Applicant Review Committee, University of Utah
 2014 - Present Member, University Promotion and Tenure Committee (UPTAC) School of Medicine Representative, University of Utah
 2015- 2016 Co-Director of MD-PhD program for University of Utah
 2017 - 2019 University of Utah Subcommittee For Undergraduate Input Into UPTAC
 2020 – Present Co-Chair of Presidential Commission on the Status of Women (PCSW) University of Utah.
 2020 – Present Chair-Elect for the School of Medicine College Council.
 2020 – Present Co-Chair One U Thriving Steering Committee, University of Utah.
 2020 – Present Distinguished Professor Advisory Committee, University of Utah.

University Hospitals & Clinics

2012 - Present Member, Telehealth Steering Committee

College Level

2010 - 2014 Member, Resident and Fellowship Applicant Committee, School of Medicine

SERVICE AT PREVIOUS INSTITUTIONS

1982 - 1988	Member, Albany Medical College, Biomedical Program Admissions Committee
1992	Physician, University at Buffalo, State University of New York, Age-Related Macular Degeneration Support Group, Buffalo, NY
1995 - 2000	Member, Schepens Eye Research Institute, Human Studies Committee
1995 - 2000	Member, Schepens Eye Research Institute, Committee for Responsible Conduct in Research
1995 - 1999	Member, Schepens Eye Research Institute, Fellowship Training Committee
1997 - 2000	Member, Schepens Eye Research Institute/Massachusetts Eye and Ear Infirmary, Joint Governing Committee for a Joint Clinical Research Center
1997 - 1998	Director of Fellowship, Schepens Eye Research Institute.
1998 - 2000	Member, Schepens Eye Research Institute, Strategic Planning Committee
1998 - 2000	Member, Schepens Eye Research Institute, Research Planning and Review Committee
1999 - 2000	Member, Schepens Eye Research Institute, Internal Communications Committee
2002 - 2003	Ad Hoc Reviewer, Louisiana State University, LSUHSC Institutional Review Board, Health Sciences Center
2002	Director, Louisiana State University, Diabetic Retinopathy, Retinopathy of Prematurity, Macular Degeneration. LSU Retina Clinic, New Orleans, LA
2002	Director, Louisiana State University, Retinal Service Patient Education Pamphlets, Development and Publication, LSU Retina Clinic, New Orleans, LA
2003	Member, University of North Carolina, Department of Ophthalmology Research Committee, Hosted visiting Professor from the UK: Alan Stitt, PhD (8/27/04)
2004 - 2010	Member, University of North Carolina, Carolina Cardiovascular Biology Center
2004 - 2010	Associate Member, University of North Carolina, UNC Lineberger Comprehensive Cancer Center
2005 - 2010	Board Member, University of North Carolina, Association of Professional Women in Medical School
2007 - 2010	Member, University of North Carolina, Surgical Operating Room Technical Committee (representing Ophthalmology)
2007 - 2010	Member, University of North Carolina, Surgical Operating Room Task Force (representing Ophthalmology)
2008	Member, University of North Carolina, Search committee for Assistant Dean for Core Facilities
2008	Member, University of North Carolina, Search committee for Anesthesia Chair
2008 - 2010	Elected Member, University of North Carolina, Faculty Council

MEMBERSHIPS IN PROFESSIONAL SOCIETIES

1983 - Present	Member, American Medical Association
1987 - 1991	Member, American Academy of Ophthalmology
1991 - Present	Fellow, American Academy of Ophthalmology
1992 - 1993	Member, Medical Society of the County of Erie
1993 - Present	Fellow, American College of Surgeons
1993 - 2000	Member, American College of Surgeons: Massachusetts Chapter
1993 - 2000	Member, Massachusetts Medical Society
1993 - 2000	Member, Massachusetts Society of Eye Physicians and Surgeons
1993 - Present	Member, Schepens International Society
1993 - 2003	Member, Vitreous Society
1999 - Present	Member, Macula Society
2001 - 2003	Member, American College of Surgeons: Louisiana Chapter+

2001 - 2005	Member, American Society for Laser Medicine and Surgery
2001 - 2003	Member, Orleans Parish Medical Society
2004 - 2006	Member, North Carolina Society of Eye Physicians and Surgeons
2004 - Present	Member, Retina Society
2006 - Present	Member, American Association of Pediatric Retinal Surgeons
2010 - Present	Member Vision 2020 USA
2011 - Present	Board Member, Women's Eye Health
2011 - Present	Member, American Society of Retina Specialists
2011 - Present	Member, International Society for Eye Research
2011 - Present	Member, Pan American Association of Ophthalmology
2011 - Present	Member, The American Ophthalmological Society
2011 - Present	Member, Utah Ophthalmology Society
2012 - Present	Member, Prevent Blindness America, Grant Review Committee
2013 - Present	Member, WEAVR
2013 - Present	Member, Women in Ophthalmology
2014 - Present	Member, American Association for Pediatric Ophthalmology & Strabismus (AAPOS)
2016 - Present	Member of the Food and Drug Administration FDA's Dermatologic and Ophthalmic Drugs (DODAC)

FUNDING

Active Grants

04/01/16-04/30/21	T35 EY026511 (NEI/NIH)	Hartnett, ME (PI)
	Medical Student Research Program in Eye Health and Disease	
	Major Goals: The major goal of this project is ignite in medical students a life-long interest in conducting or collaborating in research related to the eye, while also building their skills in creative and critical thinking.	
	Role: <u>Principal Investigator</u>	
12/02/04 – 08/31/2024	2R01 EY015130 (NEI/NIH)	Hartnett, ME (PI)
	Mechanisms of Angiogenesis in Retinopathy of Prematurity	
	Major Goals: The objectives of the grant are to determine mechanisms of intravitreal neovascularization and those of vascularization of previously avascular retina with focus on signaling of VEGF isoforms.	
	Role: <u>Principal Investigator</u>	
04/01/07 - 02/29/22	R01 EY017011 (NEI/NIH)	Hartnett, ME (PI)
	Endothelial Transmigration in Neovascular Age-related Macular Degeneration	
	Major goals: To study mechanisms involved in choroidal endothelial cell transmigration into the neurosensory retina as it relates to age-related macular degeneration.	
	Role: <u>Principal Investigator</u>	

Pending Grants**Past Grants/Contracts**

01/01/91 - 01/01/92 Light: Retinopathy of Prematurity Pilot Study
Women & Children's Hospital of Buffalo Foundation
Role: Co-Investigator

07/01/92 - 12/31/94 Correlation of Clinical Retinal Vascular Findings, Lipid Peroxide, and
Antioxidant Enzymes in Diabetes Mellitus
Principal Investigator: Mary Elizabeth Hartnett
American Heart Association
Role: Principal Investigator

01/01/93 - 01/01/94 STOP-ROP (Supplemental Therapeutic Oxygen to Prevent Retinopathy of
Prematurity) Multicenter grant, Boston, MA
National Institutes of Health
Role: Investigator

06/30/94 - 06/30/95 Free Radical Induced Injury and Neovascularization in the Rabbit Retina
American Heart Association
Role: Co-Investigator

01/01/95 - 01/01/96 Multiply Scattered Light Tomography for Glaucoma Management, Phase I,
SBIR
United States Small Business Administration
Role: Consultant

05/01/95 - 04/30/98 Spatial Extent of Retinal Damage
National Eye Institute
Role: Co-Investigator

01/01/97 - 12/31/97 Stabilized Imaging for the Scanning Laser Ophthalmoscope, SBIR with PSI,
Phase I
National Eye Institute
Role: Consultant

01/01/98 - 12/31/98 Regulation of RPE Blood-retinal Barrier: Impact in Choroidal
Neovascularization
Principal Investigator: Mary Elizabeth Hartnett
Schepens Eye Research Institute
Role: Principal Investigator

01/01/99 - 12/31/99 Cytokines in Retinopathy of Prematurity
Beverly Hospital, funding from Children's Hospital
Lions Clubs International Foundation (LCIF)
Role: Co-Investigator

01/01/99 - 12/31/99 A Novel Approach Targeting Ocular Neovascularization Based on
Combinatorial Chemistry
Scientific Partnership Fund between MIT and Harvard University
Principal Investigator(s): Ram Sasisekharan; Peter Seeberger
Massachusetts Institute of Technology
Role: Co-Investigator

07/01/99 - 06/30/04 Spatial Extent of Retinal Damage
National Eye Institute
Role: Consultant

01/01/00 - 01/01/02 Studies into the Mechanisms of Development of Choroidal Neovascularization
in Age-related Macular Degeneration: The Effects of Cell-Cell Interactions and
Growth Factors on the Barrier Properties of the Retinal Pigment Epithelium

LSU Eye Center, Louisiana State University Health Sciences Center, New Orleans
Principal Investigator: Mary Elizabeth Hartnett
Evelyn Lilly Lutz Foundation
Role: Principal Investigator

01/01/01 - 01/01/04 Louisiana Biomedical Research Network (BRIN)
Louisiana State University, Baton Rouge, LA, Mentor to students, postdoctoral researchers, and faculty
National Institutes of Health
Role: Mentor

01/01/01 - 01/01/03 Systems Development of a Template for Diabetic Eye Care Targeted for Maximum Patient Care and Applied Research in Existing Care Delivery
Louisiana State University Biomedical Research Fund. LSU Eye Center, Louisiana State University, New Orleans
Principal Investigator: Mary Elizabeth Hartnett
Pfizer, Inc.
Role: Principal Investigator

01/01/01 - 01/01/03 Building Research Infrastructure and Capacity (BRIC) Program
Louisiana State University Health Services Research Program. Louisiana State University Health Sciences Center, New Orleans
National Institutes of Health (NIH)
Agency for Healthcare Research and Quality
Role: Co-Investigator

01/01/01 - 01/01/04 The ROP Photographic Screening Trial (PHOTO-ROP)
The Louisiana Computation and Visualization Network. Children's Hospital LSU Health Sciences Center, New Orleans
Louisiana State University
Role: Site Principal Investigator

01/01/01 - 01/01/05 A Multicenter, Randomized, Masked, Controlled Study to Evaluate Reinsert, an Intravitreal Fluocinolone Acetonide Implant, in the Treatment of Patients with Diabetic Macular Edema
Louisiana State University Health Sciences Center, New Orleans, LA
Reimbursed \$533 per subject
Principal Investigator: Mary Elizabeth Hartnett
Control Delivery Systems Inc.
Role: Site Principal Investigator

01/01/01 - 01/01/04 Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2 (PKC-DRS2)
LSU Eye Center, Louisiana State University Health Sciences Center, New Orleans
Reimbursed \$11,046 per subject
Principal Investigator: Mary Elizabeth Hartnett
Eli Lilly and Company
Role: Principal Investigator

01/01/02 - 01/01/04 Leukostasis and Retinal Avascularity in Retinopathy of Prematurity
Research Institute for Children and the Department of Pediatrics at LSU Health Sciences Center
Principal Investigator: Mary Elizabeth Hartnett
Louisiana State University
Role: Principal Investigator

01/01/02 - 01/01/03 General Diabetic Research, Grand Aerie, Grove City, OH

Principal Investigator: Mary Elizabeth Hartnett
 Fraternal Order of Eagles
 Role: Principal Investigator
 01/01/03 - 02/28/10 Diabetic Retinopathy Clinical Research Network (DRCR.net)
 University of North Carolina, Chapel Hill, NC
 Chapel Hill, N.C.
 Principal Investigator: Mary Elizabeth Hartnett
 National Eye Institute
 Role: Site Principal Investigator
 01/01/03 - 01/01/07 Studies on Endothelial Transmigration Across the RPE Barrier. Funding
 provided by NEI Small Grants for Pilot Research (RO3)
 Principal Investigator: Mary Elizabeth Hartnett
 National Eye Institute
 Role: Principal Investigator
 01/01/04 - 12/30/10 The Longitudinal Study of Ocular Complication of AID (LSOCA)
 University of North Carolina, Chapel Hill, NC
 Principal Investigator: Mary Elizabeth Hartnett
 National Eye Institute
 Role: Principal Investigator
 01/01/04 - 01/01/07 Physician-Scientist Merit Award. Unrestricted funds for laboratory research
 Principal Investigator: Mary Elizabeth Hartnett
 Research to Prevent Blindness, Inc.
 Role: Principal Investigator
 01/01/04 - 12/31/04 An Evaluation of Efficacy and Safety of Posterior Juxtasclear Administrations
 of Anecortave Acetate for Depot Suspension (15 mg or 30 mg) versus Sham
 Administration in Patients (Enrolled in Study “A” or Study “B”) at Risk for
 Developing Sight-Threatening Choroidal Neovascularization (CNV) Due to
 Exudative Age-Related Macular Degeneration (AMD)
 Alcon Laboratories
 Role: Investigator
 01/01/04 - 02/28/10 Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
 University of North Carolina, Chapel Hill, NC
 Principal Investigator: Mary Elizabeth Hartnett
 National Eye Institute
 Role: Site Principal Investigator
 01/01/04 - 12/31/04 UNC Medical Alumni Endowment Fund. VEGF and ICAM-1 as clinical
 indicators to predict diabetic post-operative macular thickening and ischemia
 Principal Investigator: Mary Elizabeth Hartnett
 University of North Carolina at Chapel Hill
 Role: Principal Investigator
 01/01/04 - 01/01/08 Mechanisms of Angiogenesis in Retinopathy of Prematurity
 Principal Investigator: Mary Elizabeth Hartnett
 National Eye Institute
 Role: Principal Investigator
 01/01/04 - 01/01/06 The Role of Leukemia Inhibitory Factor (LIF) and oxidative stress in retinal
 avascularity and retinopathy of prematurity
 Principal Investigator: Mary Elizabeth Hartnett
 University of North Carolina Research Council
 Role: Principal Investigator
 01/01/04 - 12/30/10 A Pilot Study of Laser Photocoagulation for Diabetic Macular Edema
 (DRCR.net)

University of North Carolina, Chapel Hill, NC
Principal Investigator: Mary Elizabeth Hartnett
National Eye Institute
Role: Principal Investigator

01/01/04 - 12/31/04 Diabetes Retinopathy Clinical Research Network Protocol #1A, A Pilot Study of Laser Photocoagulation for Diabetic Macular Edema
Principal Investigator: Mary Elizabeth Hartnett
National Eye Institute
Role: Principal Investigator

01/01/04 - 01/01/05 The Role of Cell-Associated VEGF Isoforms in Endothelial Cell Transmigration Across the Retinal Pigment Epithelium
Principal Investigator: Mary Elizabeth Hartnett
Macula Society
Role: Principal Investigator

01/01/04 - 12/31/04 Assessment of Steroid Treatment of Diabetic Retinopathy through Analysis of Pro-inflammatory VEGF164 Levels
Carolina Cardiovascular Biology Center Mentor Program
University of North Carolina
Role: Mentor to medical student

01/01/04 - 12/31/05 Posurdex Study. A Six-Month Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 microgram and 350 microgram Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System) in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion of Branch Retinal Vein Occlusion
Allergan, Inc.
Role: Site Principal Investigator

01/01/04 - 12/31/05 FVF3192g-A Phase IIIb, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subfoveal Choroidal Neovascularization (CNV) with or without Classic CNV Secondary to Age-Related Macular Degeneration
Genentech, Inc.
Role: Investigator

2004 -2010 EY14231 (NIH/NEI)
Diabetes Retinopathy Clinical Research Network Protocols
Major Goals: Use network to pool resources and run multicenter clinical trials to address diabetic retinopathy
National Eye Institute
Role: University of Utah's PI through 2013, now a co-investigator

01/01/05 - 12/30/10 The Standard Care vs. Corticosteroid Retinal Vein Occlusion (SCORE) Study
Intravitreal Triamcinolone for Branch and Central Retinal Vein Occlusion
University of North Carolina, Chapel Hill, NC
Principal Investigator: Mary Elizabeth Hartnett
National Eye Institute
Role: Site Principal Investigator

01/01/05 - 12/30/10 A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema
University of North Carolina - Chapel Hill, NC

Principal Investigator: Mary Elizabeth Hartnett
National Eye Institute
Role: Site Principal Investigator
01/01/05 - 01/01/08 An Investigation of Retinal Nonperfusion and its Inhibition: A Strategy to Prevent Proliferative Diabetic Retinopathy
Principal Investigator: Mary Elizabeth Hartnett
American Diabetes Association
Role: Principal Investigator
12/01/05 - 04/30/10 Endothelial Transmigration un Neovascular Age-related Macular Degeneration
Principal Investigator: Mary Elizabeth Hartnett
National Institutes of Health
Role: Principal Investigator
01/01/06 - 12/31/06 RPB Departmental internal award to Abhineet Uppal for medical student project on supplemental oxygen's effect on HIF-1 α expression in a model of ROP
Research to Prevent Blindness, Inc.
Role: Mentor
01/01/06 - 12/30/10 A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema 'DRCR.net
University of North Carolina, Chapel Hill, NC
Principal Investigator: Mary Elizabeth Hartnett
National Eye Institute
Role: Principal Investigator
01/01/06 - 12/31/06 UNC Medical Alumni Endowment Fund. Measurement of complement function in Age-related Macular Degeneration
Principal Investigator: Mary Elizabeth Hartnett
University of North Carolina at Chapel Hill
Role: Principal Investigator
01/01/06 - 02/28/10 An Observational Study of the Development of Diabetic Edema Following Scatter Laser Photocoagulation
DRCR.net
University of North Carolina, Chapel Hill, NC
Principal Investigator: Mary Elizabeth Hartnett
National Eye Institute
Role: Site Principal Investigator
01/01/07 - 02/29/12 Endothelial Transmigration in Neovascular Age-related Macular Degeneration
Principal Investigator: Mary Elizabeth Hartnett
National Eye Institute
Role: Principal Investigator
01/01/07 - 02/28/10 Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy.
DRCR.net
University of North Caroline, Chapel Hill, NC
Principal Investigator: Mary Elizabeth Hartnett
National Eye Institute
Role: Site Principal Investigator
12/30/07 - 06/01/12 Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy.
Principal Investigator: Mary Elizabeth Hartnett
National Institutes of Health
Role: Site Principal Investigator
01/01/08 - 12/31/08 RPB Departmental internal award to Justin Miller to optimize silencing of

VEGF164 in Mueller cells
 Research to Prevent Blindness, Inc.
 Role: Mentor
 01/01/08 - 01/01/09 Shaw University M-RISP Minority Elderly Research (SUMMER*) Center
 National Institutes of Health (NIH)
 Agency for Healthcare Research and Quality
 Role: Mentor
 01/01/08 - 01/01/11 To determine a non-destructive neuroprotective treatment for severe retinopathy
 of prematurity
 Principal Investigator: Mary Elizabeth Hartnett
 March of Dimes
 Role: Principal Investigator
 01/01/08 - 12/31/08 Faisal Ahmad, UNC grant through NIDDK STRT, "Effects of Extracellular
 Matrix on Choroidal Endothelial Phenotype"
 National Institute of Diabetes and Digestive and Kidney Diseases
 Role: Mentor
 01/01/08 - 12/31/08 RFA: Projects to identify and validate targets against diabetic complications.
 Complications Translation [Invitees Only]: "Blocking the interaction between
 IAP and SHPS-1 will impede the development of diabetic retinopathy"
 Principal Investigator: David Clemmons
 Juvenile Diabetes Research Foundation
 Role: Key Collaborator
 01/01/09 - 12/31/09 John Hartmann, UNC 4th year medical student and Holderness Fellowship
 awarded, Pigment Epithelium-Derived Factor (PEDF) Signaling in Retinopathy
 of Prematurity
 Holderness Fellowship
 University of North Carolina
 Role: Mentor
 01/01/09 - 11/01/12 3R01 EY017011 03S1- Endothelial Transmigration in Neovascular Age-related
 Macular Degeneration, instrument supplement
 Principal Investigator: Mary Elizabeth Hartnett
 National Institutes of Health
 Role: Principal Investigator
 01/01/09 - 12/31/09 Phosphorylations of liver x receptor-A as a regulatory mechanism to promote its
 function as transcriptional repressor
 Principal Investigator: Haibo Wang (post-doctoral student)
 American Heart Association
 Role: Co-sponsor
 06/25/09 - 06/30/10 Bridge Funding
 Principal Investigator: Mary Elizabeth Hartnett
 National Eye Institute
 Role: Principal Investigator
 07/01/09 - 06/30/11 Fellowship For Haibo Wang - Phosphorylation of LiverX Receptor-2
 Principal Investigator(s): Mary Elizabeth Hartnett; Gregory M. Jones; Haibo
 Wang
 American Heart Association
 Role: Principal Investigator
 2009 - 2014
 EY018400-01A1
 Communication about glaucoma and patient outcomes
 Major Goals: Qualitative analyses of patient-doctor communication on

adherence
to glaucoma therapy
Role: Sleath, B (PI), Collaborator (MEH)

05/01/10 - 02/29/12 Endothelial Transmigration
Principal Investigator(s): Mary Elizabeth Hartnett; Gregory M. Jones
National Institutes of Health
Role: Principal Investigator

05/01/10 - 05/31/11 To determine a non-destructive neuroprotective treatment for severe retinopathy of prematurity. (Transferred from UNC to the Univ. of Utah)
Principal Investigator: Mary Elizabeth Hartnett
March Of Dimes Utah Chapter
Role: Principal Investigator

05/01/10 - 06/30/10 Mechanisms (Bridge Funds)
Principal Investigator(s): Mary Elizabeth Hartnett; Gregory M. Jones
National Institutes of Health
Role: Principal Investigator

05/01/10 - 05/31/11 Treatment of Neovascular AMD
University of Utah, Salt Lake City, Utah
Principal Investigator: Mary Elizabeth Hartnett
Axikin Pharmaceuticals
Role: Principal Investigator

05/10/10 - 06/30/10 Mechanisms of Angiogenesis in ROP
Principal Investigator: Mary Elizabeth Hartnett
National Eye Institute
Role: Principal Investigator

06/01/10 - 06/30/10 Mechanisms Grant of Angiogenesis in ROP
2R01EYO15130-06
Principal Investigator(s): Mary Elizabeth Hartnett; Gregory M. Jones
National Institute of Health
Role: Principal Investigator

12/01/10 - 11/30/11 Ccr3 In Neovascularization
Principal Investigator: Mary Elizabeth Hartnett
Axikin Pharmaceuticals
Role: Principal Investigator

06/01/13 - 05/31/16 March of Dimes 6-FY13-75 Hartnett ME (PI)

Studies on Angiogenic Mechanisms and Safety regarding Erythropoietin in Retinopathy of Prematurity: Seeking a Safe Treatment
Major Goals: To understand crosstalk between VEGFR2 and EPOR with in vitro techniques. To use a model of intrauterine growth restriction in fluctuating oxygen and determine the effect of systemic EPO on brain and retinal health and intravitreal neovascularization.
Role: Principal Investigator

03/01/16-02/28/18 R21 EY025813-01A1 Hartnett ME
Quantitative regional analysis of vitreoretinal adhesion with age
Major Goals: To quantify vitreoretinal adhesive forces and the effects from different compounds within the vitreous structure.
Role: Co-Investigator

- 05/13/19-05/15/19 R13 EY029900-01 (NEI/NIH) Hartnett, ME
 Second Advances in Pediatric Retina Meeting.
 Major Goals: bring together leading expert clinician/surgeons and pediatric ophthalmologists to discuss timely management of pediatric retina problems and optimize vision development in developing infants and children.
 Role: Course Director
- 08/01/18-05/31/20 1R21EY029384 (NEI/NIH) Toth, Cynthia MD (PI)
 Bedside Optical Coherence Tomography of Hypoxic Ischemic Encephalopathy (HIE) in Infants.
 Major Goals: The major goal of this study is to develop a novel noninvasive bedside optical coherence tomography (OCT) imaging technique in newborn infants with Hypoxic Ischemic Encephalopathy (HIE) that improves the ability to assess the spectrum of retinal effects from HIE and to diagnose and monitor treatments of HIE.
 Role: Key Personnel

TEACHING RESPONSIBILITIES/ASSIGNMENTS

Courses Directed

- 1990 - 1993 Course Director for Residency Education in Retina, Director of Retina Services, State University of New York, Buffalo, NY
- 1995 - 1999 Course Director for Fellowship Education in Retina, Schepens Retina Associates, Boston, MA
- 2000 - 2003 Course Director for Residency Education in Retina, Director of Retina Services, Louisiana State University, New Orleans, LA

Course Lectures

- Sept 6-16, 1994 Instructor, Ophthalmology Elective, 6 students, Harvard Medical School. 3 hour sessions; 8 sessions/year
- Aug 31-Sept 30, 1999 Instructor, Ophthalmology Elective, 6 students, Harvard Medical School. 3 hour sessions; 5 sessions/year
- 2003 Lecturer, Basic Science Course, University of North Carolina. Complex Retinal Detachments
- 2004 Lecturer, Basic Science Course, University of North Carolina. CRVO/Branch Retinal Vein Occlusion
- 2004 Lecturer, Basic Science Course, University of North Carolina. Proliferative Retinopathies: ROP and Sickle Cell
- 2005 Lecturer, Basic Science Course, University of North Carolina. Mechanisms of Angiogenesis
- 2005 Lecturer, Basic Science Course, University of North Carolina. Retinal Drawing
- 2005 Lecturer, Basic Science Course, University of North Carolina. Posterior Vitreous Detachment and Retinal Detachment #1
- 2005 Lecturer, Basic Science Course, University of North Carolina. Posterior Vitreous Detachment and Retinal Detachment #2
- 2006 Lecturer, Basic Science Course, University of North Carolina. Cystoid Macular Edema and other Complications with Anterior Segment Surgery
- 2006 Lecturer, Basic Science Course, University of North Carolina. Lecture and Quiz. Management of Retinal Breaks and Retinal Detachment
- 2007 Lecturer, Basic Science Course, University of North Carolina. Lecture and Quiz. Retinovascular Diseases and Retinopathy of Prematurity update

2007	Lecturer, Basic Science Course, University of North Carolina. Lecture and Quiz. PVD and Complex Retinal Detachments
2008	Lecturer, Basic Science Course, University of North Carolina. Retinal Landmarks
2008	Lecturer, Basic Science Course, University of North Carolina. Diseases associated with Aberrant Retinal Angiogenesis: ROP, Vein occlusions, Ocular Ischemia, and Sickle Cell Retinopathy
2009	Lecturer, Basic Science Course, University of North Carolina. PVD and Retinal Detachments/Complex Retinal Detachments
2009	Lecturer, Basic Science Course, University of North Carolina. Introduction to Retinal Landmarks
2011	Instructor, Basic Science Course. Age-related Macular Degeneration., University of Utah, Ophthalmology/Visual Sciences
2011	Instructor, Basic Science Course, Pediatric Retina., University of Utah, Ophthalmology/Visual Sciences
2012	Instructor, Basic Science Course, Diabetic Retinopathy, University of Utah, Ophthalmology/Visual Sciences
2012	Instructor, Retinal and Choroidal Vascular Diseases, University of Utah, Ophthalmology/Visual Sciences
2015	Visual Neuroscience Course, University of Utah. Retinal Vascular Development and Disease.

Clinical Teaching

1993 - 1999	Surgeon teaching vitreoretinal surgery to fellows at Schepens Eye Research Institute, Boston, MA
1995 - 1999	Surgeon teaching surgical skills, medical retina; indications, treatment, follow-up for patients requiring surgery or laser; and diagnostic skills to surgical fellows at Schepens Eye Research Institute, Boston, MA. Two Surgical Fellows/year; 1-5 Fellows from other retina fellowships
1995 - 1999	Children's Hospital, Boston, MA; Consultant; Pediatric retina such as trauma, retinopathy of prematurity, etc.; 1 Fellow and 3-4 Residents/ year; 1-2 hours/week
1996	Retinal Disease (Emergency Room, Operating Room); Harvard Medical School, Boston, MA; 3-5 ophthalmology residents/year; 50 hours/year
1996 - 2000	Teaching Vitreoretinal Fellows, Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA
August-Oct. 98	Ophthalmology Clinic, Schepens Retina Associates, Boston, MA; 1 postgraduate medical student; 3 hours/week
2000 - 2003	Clinician and Course Director in clinic teaching Ophthalmology LSU Residents and Fellows at LSU Eye Clinic, New Orleans, LA. Twenty-eight residents; each one on six week rotation; three fellows
2000 - 2003	Clinician on rounds and Course Director teaching Pediatric Residents and Fellows at Children's Hospital NICU and clinic, New Orleans, LA. Two new residents every month; two fellows always
2000 - 2003	Clinician in clinic teaching Ophthalmology Residents at Charity Hospital, New Orleans, LA. Three new residents every six weeks
2000 - 2003	Surgeon teaching Ophthalmology Residents at University Hospital, New Orleans, LA. Twenty-eight residents; each one on six week rotation
2000 - 2003	Instructor teaching Fluorescein and indocyanine green angiography in clinic setting. One fellow
2003 - 2010	Retinal clinician and surgical teaching for Ophthalmology residents at UNC. Eight residents, one/3 month rotation
2005 - 2010	Vitreoretinal surgical fellowship training at UNC

2010 – Present	Vitreoretinal surgical fellowship training at University of Utah.
2017	Hartnett, ME. Coats Disease. Moran CORE. Available at http://morancore.utah.edu/section-12-retina-and-vitreous/coats-disease/ . Accessed August 23, 2017.
2017	Hartnett, ME. Retinopathy of Prematurity (ROP). Moran CORE. Available at http://morancore.utah.edu/section-12-retina-and-vitreous/retinopathy-of-prematurity-rop/ . Accessed August 23, 2017.
2017	Hartnett, ME. Familial Exudative Vitreoretinopathy (FEVR). Moran CORE. Available at http://morancore.utah.edu/section-12-retina-and-vitreous/familial-exudative-vitreoretinopathyfevr/ . Accessed August 25, 2017.
2017	Hartnett, ME. Incontinentia Pigmenti. Moran CORE. Available at http://morancore.utah.edu/section-12-retina-and-vitreous/incontinentia-pigmenti/ . Accessed August 25, 2017.
2018	Hartnett, ME. Stickler Syndrome. Moran CORE. Available at http://morancore.utah.edu/section-12-retina-and-vitreous/stickler-syndrome/ . Accessed June 26, 2018.
2018	Hartnett, ME. Choroideremia. Moran CORE. Available at http://morancore.utah.edu/section-12-retina-and-vitreous/choroideremia-2/ . Accessed September 3, 2018.

Laboratory Teaching

2002 - 2003	Hartnett Lab Meetings, LSU Eye Center, New Orleans, LA
2002 - 2003	Angiogenesis Research Group periodic meetings, LSU Eye Center, New Orleans, LA
2003 - 2010	Hartnett Lab Meetings, held weekly, Chapel Hill, NC
2005	Age-related Macular Degeneration. Presentation to Burrige and Hartnett labs
2010 - Present	Hartnett Lab Meetings, held weekly, Salt Lake City, Utah

Small Group Teaching

2002 – 2003	Ophthalmology Journal Club, Residents, Fellows, and Medical Students. Louisiana State University
2003 – 2010	Ophthalmology Journal Club, Residents, Fellows, and Medical Students. University of North Carolina.
2010 - Present	Ophthalmology Journal Club, Residents, Fellows, and Medical Students. University of Utah.

Teaching through Publications

Trainee Supervision

Fellow

1993 - 2000	Supervisor, Harvard Medical School, Schepens Eye Research Institute. Trained fellows in vitreoretinal surgery; Fluorescein angiography conferences; Reviewed cases
2002 - 2003	Advisor/Mentor, Armand Daccache, MD, Louisiana State University. LSU Eye Center, surgical approaches in stage 4 retinopathy of prematurity, New Orleans, LA
2005 - 2007	Advisor/Mentor, Pinchas Rosenberg, MD, University of North Carolina. 1st year vitreoretinal surgical fellow, observer agreement study between diabetic fundus examinations and reading of digital fundus photographs; correlation of serum and aqueous factors with macular thickening post cataract surgery
2007 - 2008	Advisor/Mentor, Usha Pinninti, MD, 1st year retina fellow, study on herpes simplex

	retinitis in new born preterm infant
2008 - 2010	Advisor/Mentor, Jan Niklas Ulrich, MD. University of North Carolina. vitreoretinal surgical fellow, phenotypic presentations of Norrie disease mutations
2010 - 2011	Advisor/Mentor, Karyn Bourke, MD. University of Utah. V Retinal Surgical Fellow
2010 - 2012	Advisor/Mentor, Julia Shulman, MD. University of Utah. V. Retinal Surgical fellow, research on preeclampsia and retinopathy of prematurity association
2011 - 2013	Advisor/Mentor, Akbar Shakoor, MD. University of Utah. V. Retinal Surgical Fellow
2012 - 2014	Advisor/Mentor, Ron Hobbs, MD. University of Utah. Retinal Surgical Fellow <i>Trainee's Current Career Activities:</i> Research on Development of the Hyaloid Vasculature
2013 - 2015	Advisor/Mentor, Nikhil Batra, MD. University of Utah. Retinal Surgical Fellow
2014 - 2016	Advisor/Mentor, Jim Bell, MD. University of Utah. Retinal Surgical Fellow
2015 - 2017	Advisor/Mentor, James Zimmerman, MD University of Utah. Retinal Surgical Fellow
2016 - 2018	Advisor/Mentor, Daniel Churgin, MD University of Utah. Retinal Surgical Fellow
2017 - 2019	Advisor/Mentor, Charles Calvo, MD University of Utah. Retinal Surgical Fellow
2018 - 2020	Advisor/Mentor, Eric Hansen, MD University of Utah. Retinal Surgical Fellow
2018 - 2019	Advisor/Mentor, Christopher Komanski, MD University of Utah. Retinal Surgical Fellow
2019 - 2020	Advisor/Mentor, Nikko Ronquillo, MD University of Utah. Retinal Surgical Fellow
2020 - 2021	Advisor/Mentor, Hong-Gam Le, MD University of Utah. Retinal Surgical Fellow
2020 - 2021	Advisor/Mentor, Joseph Simonet, MD University of Utah. Retinal Surgical Fellow
2020 - 2021	Advisor/Mentor, Wen Hu, MD University of Utah. Retinal Surgical Fellow

Resident

2000 - 2003	Advisor/Mentor, Sri Maguluri, MD, Louisiana State University. 1st Year Resident, mechanisms to improve eye care delivery to diabetic patients at the Medical Center of Louisiana, New Orleans; LSU Eye Center Retina Service, New Orleans, LA.
2000 - 2003	Supervisor, Louisiana State University. Ophthalmology Residency Training; Interact daily with retina residents and residents at Charity Hospital, teaching one-on-one in clinical and operative settings
2005 - 2008	Advisor/Mentor, Yulia Radiochenko MD, University of North Carolina. 1st year ophthalmology resident, UNC; correlation of serum and aqueous factors with macular thickening post cataract surgery
2005 - 2007	Advisor/Mentor, Miriah Teeter, Ophthalmology resident, designing a study to assess outcome of treatment for CMV retinitis based on PCR measurement of vitreous humor
2005 - 2008	Advisor/Mentor, Michael Wells, MD, University of North Carolina. 1st year ophthalmology resident, effects of fetal hemoglobin in severity of retinopathy of prematurity
2005 - 2007	Advisor/Mentor, George Escaravage, Ophthalmology resident, quantifying hyperfluorescence from fluorescein angiograms in diabetic patients after cataract surgery as part of a study to compare with visual acuity outcomes and quality of life indicators
2006 - 2007	Advisor/Mentor, Lourdes Garcia, MD PhD, University of North Carolina. 2nd year ophthalmology resident, vessel tortuosity and dilation in rat OIR model as an indicator of severity of OIR disease
2012	Advisor/Mentor, Leah Owen, MD, University of Utah. Trainee's Current Career Activities: Aqueous cytokine levels as a predictor of outcomes in diabetic macular edema

- 2012 Advisor/Mentor, Dan Bettis, MD, University of Utah
- 2013 Advisor/Mentor, Jim Bell, MD. University of Utah. Psychiatric medication use associated with central serous retinopathy.
- 2014 Mentor through Women in Ophthalmology, Hema Ramkumar
- 2015 Advisor/Mentor, Reese Feist MD. University of Utah, OCT features of familial exudative vitreoretinopathy.
- 2016 Advisor/Mentor Hema Bretz.. Stanford University. Omega-3 Fatty Acids to Reduce ROP.
- 2016 Advisor/Mentor Christopher Conrady. University of Utah. Anti-VEGF in Clinical ROP.

MD, PhD (Post-Doctoral Fellowships)

- 2005 - 2007 Advisor/Mentor, Yuta Saito, MD, University of North Carolina. Effect of reactive oxygen species on intravitreal neovascularization in oxygen-induced retinopathy, Chapel Hill, NC
- 2005 – 2007 Advisor/Mentor, Lynda Peterson, PhD, University of North Carolina. Post-doctoral fellow, effect of neutralizing VEGF bioactivity in oxygen induced retinopathy, Chapel Hill, NC
- 2007 – 2008 Advisor/Mentor, William D. Culp, PhD. University of North Carolina. 1st year post-doctoral student, Rap1 isoforms in barrier properties of retinal pigment epithelium and the effects of VEGF isoforms in AMD
- 2007 - 2009 Advisor/Mentor, Grace Byfield, PhD. University of North Carolina. 2nd year post-doctoral student, gp130 transducing protein signaling in oxygen-induced retinopathy
- 2008 - 2009 Advisor/Mentor, Mohamed Zayed, MD, PhD, University of North Carolina. PhD student, 3rd year, correlations in maternal and fetal risks with HELLP and eclampsia
- 2009 – 2010 Advisor/Mentor, Haibo Wang, MD, PhD. University of North Carolina. post-doctoral student, effect of VEGF189 knockdown on endothelial transmigration across the retinal pigment epithelium
- 2010 - 2013 Advisor/Mentor Haibo Wang, MD. PhD, University of Utah. VEGF-mediated STAT3 activation inhibits retinal vascularization by downregulating erythropoietin expression.
- 2010 - 2012 Advisor/Mentor, Tyler Smith, PhD. University of Utah. Post-doctoral student, role of VEGFR2 signaling on disordered developmental angiogenesis.
- 2010 Advisor/Mentor, Eiichi Nishimura, MD, PhD. University of Utah. Post-doc from Showa University. The role of Rap1 on Choroidal Neovascularization.
- 2011 – 2012 Advisor/Mentor, James Tucker, MD, PhD. University of Utah. Thesis advisory committee for PhD
- 2012 – 2013 Advisor/Mentor, Zhiyong Yang, PhD. University of Utah. Post-doctoral student, role of IGF-1 regulation in ROP
- 2013 – 2015 Advisor/Mentor, Deeksha Gambhir, PhD. University of Utah. Post-doctoral student, Role of constitutively active Rap1 isoforms in restricting choroidal neovascularization.
- 2015 - 2020 Advisor/mentor, Colin Bretz, PhD University of Utah, Post-doctoral student, Role of STAT3 in aberrant angiogenesis
- 2015 – 2017 Advisor/mentor, Silke Becker, PhD University of Utah, Post-doctoral student, Inhibition of VEGF splice variants on retinal safety and aberrant angiogenesis
- 2016 – 2019 Advisor/Mentor, Ahmad Saleem, PhD University of Utah, Post-doctoral student. (Gaming) technology to detect amblyopia. Imagine Cup US Finals, Best Innovation Prize 2016, San Francisco California.
- 2017 – 2020 Advisor/Mentor, Aaron B. Simmons, PhD University of Utah, Post-doctoral student. The effects of interactions between VEGF and EPO signaling on pathological retinal angiogenesis.

2020 - Present Advisor/Mentor, Sravani Ramisetty, PhD University of Utah, Post-doctoral student. Role of EPO-Signaling in UPI/Preterm OIR Model.

Medical Student

2003 - 2004 Advisor/Mentor, Eric Eason, 1st Year Medical Student, NYCOM, worked in laboratory studying VEGF isoforms in developing rat retina (6 week rotation)

2004 - 2005 Advisor/Mentor, Jay Simhan, University of North Carolina. 1st Year Medical Student, received Holderness award to study steroid injections on VEGF164 regulation in newborn rats under fluctuating oxygen, summer 2004, presented at Annual Medical Student Research Day UNC, January, 2005

2006 - 2008 Advisor/Mentor, Abhineet Uppal, University of North Carolina. first year medical student, effect of supplementation of oxygen on HIF 1 alpha signaling in oxygen-induced retinopathy; presented at Annual Medical Student Research Day UNC, January 2008

2006 - 2010 Advisor/Mentor, David Sutton, MD, University of North Carolina. Research fellow, effect of complement factors on choroidal EC transmigration

2007 - 2009 Advisor/Mentor, Jessica Watson, 1st year medical student (co-mentoring with Seema Garg, MD PhD), the effects of Avastin on neovascular age-related macular degeneration

2008 - 2009 Advisor/Mentor, Faisal Ahmad, University of North Carolina. 2nd year medical student, Effects of Extracellular Matrix on Choroidal Endothelial Phenotype, presented at Annual Medical Student Research Day UNC, January 2009

2008 - 2009 Advisor/Mentor, Nicholas Tinkham, Aqueous VEGF as a predictor of pseudophakic macular edema in diabetic patients

2008 - 2009 Advisor/Mentor, Christopher Moser, University of North Carolina. Effects of pre-eclampsia on Retinopathy of Prematurity

2008 - 2009 Advisor/Mentor, Augustus Parker, University of North Carolina. Effects of VEGF on NADPH oxidase activation in Choroidal Endothelial Cells

2009 - 2010 Advisor/Mentor, John Hartmann, University of North Carolina. Holderness Fellowship awardee, Pigment Epithelium-Derived Factor (PEDF) Signaling in Retinopathy of Prematurity

2012 Advisor/Mentor, Logan Beebe, University of Utah. Preeclampsia association with retinopathy of prematurity

2014 Advisor/Mentor, Sam Beckstead, University of Utah. Preeclampsia association with retinopathy of prematurity

2015 Advisor/Mentor Jacob Basilius. University of Utah. Structural Abnormalities of the Inner Macula in Incontinentia

2016 - 2017 Advisor/Mentor Taylor Webster, University of Utah. Sports Related Ocular Injuries.

2016 - 2017 Advisor/Mentor, Jason Nguyen, University of Utah. X-Linked Retinoschisis.

2016 - 2017 Advisor/Mentor Nathan Lambert, University of Utah. A Case of Coats Disease and Concurrent Anisometropic Amblyopia.

2018 - Present Advisor/Mentor, Aniket Ramshekar, University of Utah. Rap1/IQGAP1 interactions in Macular Degeneration.

Masters

2005 - 2008 Advisor/Mentor, Bradley King, post-baccalaureate student, working on retinal pigment epithelium (RPE) and choroidal endothelial cell (CEC) isolation in newborn and embryonic mice; siRNA methods in ARPE-19, a cell line of human RPE.

2007 - 2010 Advisor/Mentor Steven Budd. University of North Carolina. The Role of VEGF in Pathologic Angiogenesis.

Undergraduate

2005 - 2008	Advisor/Mentor, David Martiniuk, Pre-baccalaureate student; studying the effect of triamcinolone or dexamethasone on retinal vascular growth in newborn rats exposed to fluctuating oxygen
2008 - 2009	Advisor/Mentor, Justin Miller, University of North Carolina. Developing shRNA using microRNA techniques to silence VEGF164 in Mueller cells
2009	Advisor/Mentor, Srikar Bongu, University of North Carolina. effects of oxygen stresses on HIF1alpha regulation in model of Retinopathy of Prematurity
2014	Advisor/Mentor, Native American Research Intern, Cheryl Cook. "Effect of Intrauterine growth restriction on retinopathy of prematurity."
2015	Advisor/Mentor, Native American Research Intern, Romine Brooke. "Rap1GTPase and its potential role to curb the development of abnormal blood vessels in neovascular age-related macular degeneration, a leading cause of blindness worldwide."
2016	Advisor/mentor, Aniket Ramshekar, University of Utah, MD-PhD student, Role of VEGF in endothelial cell permeability
2016	Advisor/mentor, Kevin Rodriguez University of Utah, Medical student, Role of erythropoietin receptor signaling on choroidal neovascularization
2016	Advisor/mentor, Randy Brown University of Utah, Medical student, Role of Wnt signaling in intrauterine growth restriction and in aberrant angiogenesis
2016	Advisor/mentor, Christopher Hamilton, University of Utah, Medical student, Role of hypoxia and VEGF inhibition on Mueller cell health
2016	Advisor/Mentor, Mariam Alam, University of Utah, Biology Student, Genotype – Phenotype relationship in choroidal neovascularization
2016 - present	Advisor/Mentor Alex Cheng. Automated Computer Analysis of Vascular patterns in OIR. First Place in the Engineering Electrical & Computer Science Senior Division, Salt Lake City Valley Science and Engineering Fair in The University of Utah. Salt Lake Valley Science and Engineering Fair SLVSEF "Using Machine Learning and Image Segmentation to Analyze Retinal Blood Vessel Densities.
2018	Advisor/mentor Alexandra Montoya University of Utah Medical Student. Peripheral retinal findings in eyes of patients with Coats' disease.
2020	Advisor/mentor John Mark Albrecht. University of Utah Medical Student. Classification and analysis of distinct IVNV characteristics using generic Unet machine learning architecture.

Faculty

2001 - 2003	Advisor/Mentor, Janet McColm, PhD, Louisiana State University. Senior Research Associate, LSU Eye Center, New Orleans, LA
2003 - 2006	Advisor/Mentor, Janet McColm, PhD, University of North Carolina. Effect of leukemia inhibitory factor in retinal development, Senior Research Associate, Chapel Hill, NC
2009 – 2010	Advisor/Mentor, Erika Wittchen, University of North Carolina. Assistant professor in molecular and cell biology, effects of Rap1a and ap1b on RPE barrier function and models of AMD
2011 - Present	Advisor/Mentor, Marielle Young, MD. University of Utah. Retinopathy of Prematurity
2012 - Present	Advisor/Mentor, Julia Shulman, MD. University of Utah. Preeclampsia risk in ROP
2013 - Present	Advisor/Mentor Haibo Wang MD-PhD, University of Utah. Activation of RAP1 Inhibits NADPH oxidase-dependent ROS generation in retinal pigment epithelium and reduces choroidal neovascularization.

- 2016 – Present Advisor/Mentor, Stela Vujosevic, MD. Contract Professor at The School of Ophthalmology University of Padova Italy. The Leadership Development Program for Women at ARVO.
- 2020 Advisor/Mentor, Irina De la Huerta MD PhD. Assistant Professor of Ophthalmology, Vanderbilt University School of Medicine. Effects of glucose in photoreceptor expression of inflammatory cytokines in diabetic retinopathy.

Graduate Students

- 2007 - 2008 Advisor/Mentor, Pete Geisen, first year graduate student, the role of VEGF189 in choroidal endothelial migration and neovascular AMD
- 2012 Advisor/Mentor, Sai Karthik Vemuri, University of Utah. Quantification of retinal plexuses in animal models of VEGF regulations.
- 2013 Advisor/Mentor, Jeff Yarch. University of Utah. Neurobiology & Anatomy student.

Mentorship

- Xi Chen, MD PhD
- Irina de la Huerta, MD PhD
- Eileen Hwang, MD PhD
- Brian Stagg, MD PhD
- Ann Marie Lobo Chan, MD
- Jesse Berry, MD
- Shilpa Kodati, MD
- Sally Ong, MD

Educational Lectures

Didactic Lectures

- 1990 - 1993 Ophthalmic Photography Teaching Lectures, SUNY Buffalo, Buffalo, NY; Director of Ophthalmic Photography Services; 8-10 Ophthalmic photography students, COMTs and COTs/year; 100 hours/year
- 1990 - 1993 Didactic Lectures on Retinal Disease, SUNY Buffalo, Buffalo NY; Chief of the Retina Service; 9-12 Residents and 3 medical students/year; Twelve 1 hour courses/year
- 1993 Management of Retinal Tears Without Detachment; New England Medical Center, Boston MA; 9-12 Ophthalmology Residents; 1 hour lecture
- 1995 Retinopathy of Prematurity; New England Medical Center, Boston, MA; 9-12 Ophthalmology Residents; 1 hour lecture
- 1997 Features in AMD Support Ischemia in Pathogenesis; Macular Disease Research Center; Schepens Eye Research Institute, Harvard University; 1 hour lecture
- 1997 Retinal Disease Cell Biology; Schepens Eye Research Institute, Harvard University; 1 hour lecture
- 1997 Retinopathy of Prematurity: Current Thinking and Management; Retina Conference, New England Eye Center, Tufts University School of Medicine, Boston, MA, 8-12 Ophthalmology Residents; 1 hour lecture
- 1999 Current Management in Retinopathy of Prematurity; Retina Conference, New England Eye Center, Tufts Residents; 1 hour session University School of Medicine, Boston, MA; 9-12 Ophthalmology Residents
- 2000 Current Management in Retinopathy of Prematurity; New England Medical Center, Boston, MA; 10-12 residents; 1 hour talk, New England Medical Center, Tufts University School of Medicine

- 2000 Current Treatment in ARMD; Macular Disease Research Center, Harvard University; 1 hour lecture
- 2000 Clinical Diseases Associated with Angiogenesis; Massachusetts Institute of Technology, Boston, MA; 15 graduate students; 3 hour talk
- 2001 Non-Diabetic Retinal Vascular Disease, Inherited Macular Disease, and Acquired Macular Disease, Ophthalmology Residency Training, Louisiana State University
- 2001 Vitreous Surgery, Retinal Detachment Repair, and Retinal Laser Surgery, Ophthalmology Residency Training, Louisiana State University
- 2001 Laser: Retinal Implications, Ophthalmology Residency Training Louisiana State University
- 2002 - 2003 Founded REST: Retinal Educational Sessions on Tuesdays. Weekly one and one-half hour educational session with two fellows, residents, and technicians. Includes didactic lessons where residents and fellows present fluorescein angiography sessions open to residents, fellows, and researchers with invited PhDs and clinician scientists (Initiated September 2002) Louisiana State University.
- 2002 Residency Lecture Session, Ophthalmology Residency Training, Louisiana State University
- 2002 Diabetic Retinopathy and the Eye Exam; LSU Medical Student Lecture, 2 ½ hour case discussions with 160 freshman students
- 2006 Orientation for New Residents, Retinal Drawing and Basic Anatomy, University of North Carolina
- 2009 Residents' Day, Gender and Eye Health: World Sight Day, University of North Carolina, Chapel Hill, NC
- 2010 Resident's talk at the University of North Carolina on "Proliferative Retinopathies Sickle Cell, ROP, Vein Occlusion." Chapel Hill, North Carolina
- 2010 Resident's Talk at the University of North Carolina on "Immune Responses and Inflammation in Ophthalmic Diseases.", Chapel Hill, North Carolina
- 2010 Resident's talk at the John A. Moran Eye Center on "Age-Related Macular Degeneration."
- 2011 Resident's talk at the John A. Moran Eye Center, "Pediatric Retina."
- 2012 Resident's talk at the John A. Moran Eye Center, "AMD."
- 2012 Resident's talk at the John A. Moran Eye Center, "Pediatric Retina."
- 2013 Resident's talk at the John A. Moran Eye Center, "Diabetic Retinopathy."
- 2013 Medical Research Interest Group, monthly lecture "Medical Research Interest Group". University of Utah.
- 2014 Retinal Vascular Development and Disease. Visual Neuroscience Course Lecture Series. University of Utah, School of Medicine.
- 2014 Residents talk. John A. Moran Eye Center, "AMD"
- 2014 Residents talk. John A. Moran Eye Center, "Pediatric Retina"
- 2014 Residents talk. John A. Moran Eye Center, "Hypothesis Generation"
- 2015 Utah Ophthalmology Society, "Women's Eye Health"
- 2015 Residents talk John A. Moran Eye Center "Generating a Hypothesis"
- 2016 Residents talk John A. Moran Eye Center "Generating a Hypothesis"
- 2017 Residents talk John A. Moran Eye Center "Diabetic Retinopathy Part 1" Roles
- 2018 Interdepartmental Program in Neuroscience Student Retreat Talk, "Angiogenesis in Ocular Diseases". University of Utah.
- 2018 Residents talk John A. Moran Eye Center "Generating a Hypothesis"
- 2018 Residents talk John A. Moran Eye Center AMD1
- 2019 Invited Speaker for the Loris and David Rich Lecture Series in Visual Science at University of Alabama. "Regulation of Angiogenesis in AMD". January 2019.
- 2019 Invited Speaker Vision Research Seminar University of Colorado. "Inhibiting

- Pathologic Angiogenesis and Extending Physiologic Angiogenesis in ROP". April 2019.
- 2019 Residents talk John A. Moran Eye Center "Generating a Hypothesis"
- 2019 "Regulation of Angiogenesis in Retinal Disease". Basic Science Seminar Talk. Emory University.
- 2020 "Science as a Clinician" Creative and Critical Thinking Talk MSRP University of Utah May 27, 2020.

Department/Division Conferences

- 1990 - 1993 Fluorescein Angiogram Conferences, SUNY Buffalo, Buffalo NY; Chief of the Retina Service; 9-12 Residents/20-30 medical students/year; Weekly, 1-1½ hours
- 1997 - 1999 Fluorescein Angiography Conferences; Director of Retina Fellowship at Schepens Retina Associates; 2 Surgical Fellows/year and 1-7 Fellows from other local & international retina fellowships; 1 hour sessions; 2 years

Continuing Education

CE Courses Developed

- 2011 Overview of utilization of Bevacizumab (Avastin) for ROP - AAO. Orange County Convention Center. Orlando, Florida

CE Courses Taught

- 1991 - 1993 Early Treatment Diabetic Retinopathy Study; American Academy of Ophthalmology annual national meeting, Anaheim, CA; Atlanta, GA; Chicago, IL; 3 hour course
- 1991 - 1993 Combined Clinical/Ophthalmic Photography Fluorescein Angiography Conferences; SUNY Buffalo, Rochester Institute of Technology; 3 hour course
- 1991 Age-Related Macular Degeneration CME course; Buffalo Optometric Society, Buffalo, NY (Regional Meeting)
- 1994 Examination of Macula; New England College of Optometry; 1 hour course
- 1994 Clinical Features of Age-related Macular Degeneration; New England College of Optometry; 1 hour course
- 1997 Recent Work on Angiogenesis in Retinal Diseases; Schepens Eye Research Institute Clinical Faculty Meeting, Boston, MA, November 11, 1997; 20-30 SERI Scientists and Clinicians; 1 hour lecture
- 2001 Retinopathy of Prematurity; invited lecture to area pediatricians; Louisiana State University; Baton Rouge, LA
- 2002 Retinopathy of Prematurity; article for Pediatric Review, Children's Hospital; New Orleans, LA
- 2003 Dietary Supplements in ARMD; invited lecture for NC Society of Eye Physicians and Surgeons and UNC Ophthalmology department, Grandover Resort and Conference Center; Greensboro, NC
- 2008 UNC Eye Symposium: Insights and Updates. New Treatments for ROP: Data from Lab and Clinical Research.
- 2009 UNC Eye Symposium: What's New in ROP? Chapel Hill, NC
- 2011 - 2012 Overview of utilization of Bevacizumab (Avastin) for ROP. American Association of Ophthalmology. Orange County Convention Center. Orlando, FL
- 2014 Women's Eye Health. Live PowerPoint webinar presentation and quiz. Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO).

PEER-REVIEWED JOURNAL ARTICLES

1. Krohel GB, Tobin DR, **Hartnett ME**, Barrows NA. (1982). Divergence paralysis. *Am J Ophthalmol*, 94(4), 506-10.
2. Mangan KF, **Hartnett ME**, Matis SA, Winkelstein A, Abo T. (1984). Natural killer cells suppress human erythroid stem cell proliferation in vitro. *Blood*, 63(2), 260-9.
3. Lazarus HM, **Hartnett ME**, Reed MD, Murphy BF, Lass JH. (1987). Comparison of the prophylactic effects of 2-deoxycytidine and prednisolone for high-dose intravenous cytarabine- induced keratitis. *Am J Ophthalmol*, 104(5), 476-80.
4. **Hartnett ME**, Gilbert MM, Richardson TM, Krug JH Jr, Hirose T. (1990). Anterior segment evaluation of infants with retinopathy of prematurity. *Ophthalmology*, 97(1), 122-30.
5. **Hartnett ME**, Weiter JJ, Garsd A, Jalkh AE. (1992). Classification of retinal pigment epithelial detachments associated with drusen. *Graefes Arch Clin Exp Ophthalmol*, 230(1), 11-9.
6. **Hartnett ME**, Hirose T, Richardson TM, Garsd A, Gilbert MM, Krug J Jr. (1992). Intraocular pressure determination in infants with severe retinopathy of prematurity. *Graefes Arch Clin Ex Ophthalmol*, 230(5), 406-10.
7. **Hartnett ME**, Gilbert MM, Hirose T, Richardson TM, Katsumi O. (1993). Glaucoma as a cause of poor vision in severe retinopathy of prematurity. *Graefes Arch Clin Ophthalmol*, 231(8), 433-8.
8. **Hartnett ME**, Coles WH. (1993). Lens clarity after vitrectomy in traumatic lens perforation and vitreous penetration. *Am J Ophthalmol*, 116(2), 250-1.
9. **Hartnett ME**, Katsumi O, Hirose T, Richardson TM, Walton DS. (1994). Improved visual function in retinopathy of prematurity after lowering high intraocular pressure. *Am J Ophthalmol*, 117(1), 113-5.
10. **Hartnett ME**, Pruett RC, DaSilva KC, Burkart PT. (1994). Antiphospholipid antibody syndrome associated with microscotomata. *Am J Ophthalmol*, 118(3), 397-8.
11. Steidl S, Hirose T, **Hartnett ME**. (1995). Open-sky vitrectomy for posterior segment reconstruction in eyes with severe trauma. *Int Ophthalmol Clin*, 35(1), 175-80.
12. **Hartnett ME**, Elsner AE. (1996). Characteristics of exudative age-related macular degeneration determined in vivo with confocal and indirect infrared imaging. *Ophthalmology*, 103(1), 58-71.
13. Steidl SM, Hirose T, Sang D, **Hartnett ME**. (1996). Difficulties in excluding the diagnosis of retinoblastoma in cases of advanced Coats' disease: a clinicopathologic report. *Ophthalmologica*, 210(6), 336-40.
14. **Hartnett ME**, Weiter JJ, Staurengi G, Elsner AE. (1996). Deep retinal vascular anomalous complexes in advanced age-related macular degeneration. *Ophthalmology*, 103(12), 2042-53.
15. Armstrong D, Ueda To, Ueda Ta, Browne R, Al-Jada A, Spengler R, Chou R, Fukuda S, Buch P, Dandona P, **Hartnett ME**, Sasisekharan R, Dorey KC. (1997). Expression of TNF-alpha and VEGF during retinal neovascularization is initiated by lipid hydroperoxide. *Angiogenesis*, 2, 174-84.
16. Beausencourt E, Elsner AE, **Hartnett ME**, Trempe CL. (1997). Quantitative analysis of macular holes with scanning laser tomography. *Ophthalmology*, 104(12), 2018-29.
17. **Hartnett ME**, Hirose T. (1998). Cyanoacrylate glue in the repair of retinal detachment associated with posterior retinal breaks in infants and children. *Retina*, 18(2), 125-9.
18. Armstrong D, Ueda T, Ueda T, Aljada A, Browne R, Fukuda S, Spengler R, Chou R, **Hartnett M**, Buch P, Dandona P, Sasisekharan R, Dorey CK. (1998). Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-alpha, vascular endothelial growth factor and platelet-derived growth factor. *Angiogenesis*, 2(1), 93-104.

19. Kunze C, Elsner AE, Beausencourt E, Moraes L, **Hartnett ME**, Trempe CL. (1999). Spatial extent of pigment epithelial detachments in age-related macular degeneration. *Ophthalmology*, 106(9), 1830-40.
20. Remky A, Beausencourt E, **Hartnett ME**, Trempe CL, Arend O, Elsner AE. (1999). Infrared imaging of cystoid macular edema. *Graefes Arch Clin Exp Ophthalmol*, 237(11), 897-901.
21. **Hartnett ME**, Garcia CM, D'Amore PA. (1999). Release of bFGF, an endothelial cell survival factor, by osmotic shock. *Invest Ophthalmol Vis Sci*, 40(12), 2945-51.
22. Sheindlin JA, Hirose T, **Hartnett ME**. (1999). Ophthalmic endoscopy: applications in intraocular surgery. *Int Ophthalmol Clin*, 39(1), 237-47.
23. Andrews AP, **Hartnett ME**, Hirose T. (1999). Surgical advances in retinopathy of prematurity. *Int Ophthalmol Clin*, 39(1), 275-90.
24. The STOP-ROP Multicenter Study Group. (2000). Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), A randomized, controlled trial. I: Primary Outcomes. *Pediatrics*, 105, 295-310.
25. Beausencourt E, Remky A, Elsner AE, **Hartnett ME**, Trempe CL. (2000). Infrared scanning laser tomography of macular cysts. *Ophthalmology*, 107(2), 375-85.
26. **Hartnett ME**, Stratton RD, Browne RW, Rosner BA, Lanham RJ, Armstrong D. (2000). Serum markers of oxidative stress and severity of diabetic retinopathy. *Diabetes Care*, 23(2), 234-40.
27. Miura M, Elsner AE, Beausencourt E, Kunze C, **Hartnett ME**, Lashkari K, Trempe CL. (2002). Grading of infrared confocal scanning laser tomography and video displays of digitized color slides in exudative age-related macular degeneration. *Retina*, 22(3), 300-8.
28. PhotoROP International Study **Hartnett ME**. (2003). Photo Essay: Inadvertent Skip Areas in Treatment of Zone 1 Retinopathy of Prematurity. *Retina*, 23, 128-131.
29. Kempen JH, Martin BK, Wu A, Barron B, Thorne JE, Jabs DA for the Studies of Ocular Complications of AIDS Research Group. (2003). The effect of cytomegalovirus retinitis on the quality of life of patients with acquired immune deficiency syndrome in the era of highly active anti-retroviral therapy. *Ophthalmology*, 110, 987-995.
30. Holbrook JT, Jabs DA, Weinberg DV, Lewis RA, Davis MD, Friedberg D for the Studies of Ocular Complications of AIDS Research Group. (2003). Visual loss in patients with cytomegalovirus retinitis and AIDS before widespread availability of highly active antiretroviral therapy. *Arch Ophthalmol*, 121(1), 99-107.
31. **Hartnett ME**, Laposata M, Van Cott E. (2003). Antiphospholipid antibody syndrome in a six-year-old female patient. *Am J Ophthalmol*, 135(4), 542-4.
32. **Hartnett ME**. (2003). Features associated with surgical outcome in patients with stages 4 and 5 retinopathy of prematurity. *Retina*, 23(3), 322-9.
33. **Hartnett ME**, Rodier DW, McColm JR, Thompson HW. (2003). Long-term vision results measured with Teller Acuity Cards and a new Light Perception/Projection Scale after management of late stages of retinopathy of prematurity. *Arch Ophthalmol*, 121(7), 991-6.
34. Maguluri S, **Hartnett ME**. (2003). Radial choroidal ruptures in sclopetaria. *J Am Coll Surg*, 197(4), 689-90.
35. **Hartnett ME**, Lappas A, Darland D, McColm JR, Lovejoy S, D'Amore PA. (2003). Retinal pigment epithelium and endothelial cell interaction causes retinal pigment epithelial barrier dysfunction via a soluble VEGF-dependent mechanism. *Exp Eye Res*, 77(5), 593-9.
36. Marshall BC, Jacobson MA, Adler SP in collaboration with the Studies of Ocular Complications of AIDS Research Group. (2004). Avidity of antibodies to cytomegalovirus in HIV-seropositive patients with and without CMV retinitis. *Viral Immunol*, 17, 101-108.

37. Jabs DA, Van Natta ML, Thorne JE, Weinberg DV, Meredith TA, Kuppermann BD, Sepkowitz K, Li HK for the Studies of Ocular Complications of AIDS Research Group. (2004). Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. *Ophthalmology*, *111*, 2232-2239.
38. Jacobson MA, Maecker HT, Orr PL, D'Amico R, Van Natta M, Li XD Pollard RB, Bredt BM for the Adult AIDS Clinical Trials Group and the Studies of Ocular Complications of AIDS Research Group. (2004). Results of a CMV-specific CD8+/IFN γ + cytokine flow cytometry assay correlate with clinical evidence of protective immunity in AIDS patients with CMV retinitis. *J Infect Dis*, *189*, 1362-1373.
39. **Hartnett ME**, McColm JR. (2004). Retinal features predictive of progressive stage 4 retinopathy of prematurity. *Retina*, *24*(2), 237-41.
40. Van Cott EM, Laposata M, **Hartnett ME**. (2004). Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis. *Blood Coagul Fibrinolysis*, *15*(5), 393-7.
41. McColm JR, Geisen P, **Hartnett ME**. (2004). VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. *Mol Vis*, *10*, 512-20.
42. **Hartnett ME**, Magaluri S, Thompson HW, McColm JR. (2004). Comparison of retinal outcomes after scleral buckle or lens-sparing vitrectomy for stage 4 retinopathy of prematurity. *Retina*, *24*(5), 753-7.
43. **Hartnett ME**, Key IJ, Loyacano NM, Horswell RL, Desalvo KB. (2005). Perceived barriers to diabetic eye care: qualitative study of patients and physicians. *Arch Ophthalmol*, *123*(3), 387-91.
44. Thorne JE, Jabs DA, Kempen JH, Holbrook JT, Nichols C, Meinert CL, for the Studies of Ocular Complications of AIDS Research Group. (2006). Causes of Visual Acuity Loss Among Patients with AIDS and Cytomegalovirus in the Era of Highly Active Antiretroviral Therapy. *Ophthalmology*, *113*, 1441-1445.
45. PKC-DRS2 Group (PI for LSU site). (2006). Effect of Ruboxistaurin on visual loss in patients with diabetic retinopathy. *Ophthalmology*, *113*, 2221-2230.
46. Kempen JH, Min Y-I, Freeman WR, Holland GN, Friedberg DN, Dieterich DT, Jabs DA for the Studies of Ocular Complications of AIDS Research Group. (2006). Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. *Ophthalmology*, *113*, 684-694.
47. Geisen P, McColm JR, **Hartnett ME**. (2006). Choroidal endothelial cells transmigrate across the retinal pigment epithelium but do not proliferate in response to soluble vascular endothelial growth factor. *Exp Eye Res*, *82*(4), 608-19.
48. Escaravage GK Jr, Cohen KL, Patel SB, **Hartnett ME**, Armstrong BD, Janowski CM. (2006). Quantification of macular and optic disc hyperfluorescence after phacoemulsification in diabetes mellitus. *J Cataract Refract Surg*, *32*(5), 803-11.
49. McColm JR, Geisen P, Peterson LJ, **Hartnett ME**. (2006). Exogenous leukemia inhibitory factor (LIF) attenuates retinal vascularization reducing cell proliferation not apoptosis. *Exp Eye Res*, *83*(2), 438-46.
50. Geisen P, McColm JR, King BM, **Hartnett ME**. (2006). Characterization of barrier properties and inducible VEGF expression of several types of retinal pigment epithelium in medium-term culture. *Curr Eye Res*, *31*(9), 739-48.
51. **Hartnett ME**, McColm JR. (2006). Fibrovascular organization in the vitreous following laser for ROP: implications for prognosis. *Retina*, *26*(7 Suppl), S24-31.

52. Balasubramanian M, Capone A Jr, **Hartnett ME**, Pignatto S, Trese MT. (2006). The Photographic Screening for Retinopathy of Prematurity Study (Photo-ROP): study design and baseline characteristics of enrolled patients. *Retina*, 26(7 Suppl), S4-10.
53. **Hartnett ME**, Martiniuk DJ, Saito Y, Geisen P, Peterson LJ, McColm JR. (2006). Triamcinolone reduces neovascularization, capillary density and IGF-1 receptor phosphorylation in a model of oxygen-induced retinopathy. *Invest Ophthalmol Vis Sci*, 47(11), 4975-82.
54. Diabetic Retinopathy Clinical Research Network. (2006). Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema. *Arch Ophthalmol*, 124(12), 1701-7.
55. Steering Committee of Diabetic Retinopathy Clinical Research Network. (2007). A phase 2 randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. *Ophthalmology*, 114, 1860-1867.
56. Saito Y, Geisen P, Uppal A, **Hartnett ME**. (2007). Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity. *Mol Vis*, 13, 840-53.
57. Jabs DA, Van Natta ML, Holbrook JT, Kempen JH, Meinert CL, Davis MD, for the Studies of Ocular Complications of AIDS Research Group. (2007). Longitudinal Study of the Ocular Complications of AIDS. 1. Ocular diagnoses at enrollment. *Ophthalmology*, 114, 780-786.
58. Jabs DA, Van Natta ML, Holbrook JT, Kempen JH, Meinert CL, Davis MD, for the Studies of Ocular Complications of AIDS Research Group. (2007). Longitudinal Study of the Ocular Complications of AIDS. 2. Ocular examination results at enrollment. *Ophthalmology*, 114, 787-793.
59. Zeng G, Taylor SM, McColm JR, Kappas NC, Kearney JB, Williams LH, **Hartnett ME**, Bautch VL. (2007). Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation. [This was a plenary paper with a commentary]. *Blood*, 109(4), 1345-52.
60. Diabetic Retinopathy Clinical Research Network. (2007). Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. *Ophthalmology*, 114(3), 525-36.
61. Diabetic Retinopathy Clinical Research Network. (2007). Comparison of the modified early treatment diabetic retinopathy study and mild macular grid laser photocoagulation strategies for diabetic macular edema. *Arch Ophthalmol*, 125(4), 469-80.
62. Peterson LJ, Wittchen ES, Geisen P, BurrIDGE K, **Hartnett ME**. (2007). Heterotypic RPE-choroidal endothelial cell contact increases choroidal endothelial cell transmigration via PI 3-kinase and Rac1. *Exp Eye Res*, 84(4), 737-44.
63. Diabetic Retinopathy Clinical Research Network. (2007). Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. *Ophthalmology*, 114(8), 1520-5.
64. Bhavsar AR, Ip MS, Glassman AR, DRCRnet and the SCORE Study Groups. (2007). The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. *Am J Ophthalmol*, 144(3), 454-6.
65. Zayed MA, Yuan W, Leisner TM, Chalothorn D, McFadden AW, Schaller MD, **Hartnett ME**, Faber JE, Parise LV. (2007). CIB1 regulates endothelial cells and ischemia-induced pathological and adaptive angiogenesis. *Circ Res*, 101(11), 1185-93.
66. Diabetic Retinopathy Clinical Research Network. (2008). A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. *Ophthalmology*, 115, 1445-1456.

67. Scott IU, Bressler NM, Bressler SB, Browning DJ, Chan CK, Danis RP, Davis MD, Kollman C, Qin H and the and the Diabetic Retinopathy Clinical Research Network Study Group. (2008). Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. *Retina*, 28(1), 36-40.
68. Geisen P, Peterson LJ, Martiniuk D, Uppal A, Saito Y, **Hartnett ME**. (2008). Neutralizing antibody to VEGF reduces intravitreal neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity. *Mol Vis*, 14, 345-57.
69. Jacobson MA, Tan QX, Girling V, Poon C, Van Natta M, Jabs DA, Inokuma M, Maecker HT, Bredt B, and Sinclair E, for the Studies of Ocular Complications of AIDS Research Group. (2008). Poor predictive value of cytomegalovirus (CMV)-Specific T cell assays for the development of CMV retinitis in patients with AIDS. *Clin Infect Dis*, 46, 458-466.
70. Writing Committee for The Photographic Screening for Retinopathy of Prematurity Study (Photo-ROP). (2008). Primary Outcomes Ophthalmology. *Retina*, 28, S47-S54.
71. Vinekar A, Trese MT, Capone A Jr on behalf of PhotoROP group. (2008). Evolution of retinal detachment in posterior retinopathy of prematurity: impact on treatment approach. *Am J Ophthalmol*, 145(3), 548-555.
72. **Hartnett ME**, Board RJ, Houghton O. (2008). Subretinal hemorrhage after lens-sparing vitrectomy in infants born at or under 24 weeks gestation. *Retina*, 28(3 Suppl), S69-74.
73. Saito Y, Uppal A, Byfield G, Budd S, **Hartnett ME**. (2008). Activated NAD(P)H oxidase from supplemental oxygen induces neovascularization independent of VEGF in retinopathy of prematurity model. *Invest Ophthalmol Vis Sci*, 49(4), 1591-8.
74. Davis MD, Bressler SB, Aiello LP, Bressler NM, Browning DJ, Flaxel CJ, Fong DS, Foster WJ, Glassman AR, **Hartnett ME**, Kollman C, Li HK, Qin H, Scott IU. (2008). Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema. *Invest Ophthalmol Vis Sci*, 49(5), 1745-52.
75. Ip MS, Bressler SB, Antoszyk AN, Flaxel CJ, Kim JE, Friedman SM, Qin H for Health Research and the Diabetic Retinopathy Clinical Research Network. (2008). A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. *Retina*, 28(7), 919-30.
76. **Hartnett ME**, Martiniuk D, Byfield G, Geisen P, Zeng G, Bautch VL. (2008). Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP: relevance to plus disease. *Invest Ophthalmol Vis Sci*, 49(7), 3107-14.
77. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, **Hartnett ME**. (2008). Vascular endothelial growth factor in eye disease. *Prog Retin Eye Res*, 27(4), 331-71.
78. Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H for DRCR.net. (2008). Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. *Ophthalmology*, 115(8), 1366-71, 1371.e1.
79. Reynolds R, **Hartnett ME**, Rosner B, Atkinson J, Giclas PC, Seddon JM. (2009). Plasma Complement Components and Activation Fragments are Associated with Age-Related Macular Degeneration Genotypes and Phenotypes. *Invest Ophthalmol Vis Sci*.
80. Brucker AJ, Qin H, Antoszyk AN, Beck RW, Bressler NM, Browning DJ, Elman MJ, Glassman AR, Gross JG, Kollman C, Wells JA 3rd. (2009). Observational study of the

- development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. *Arch Ophthalmol*, 127(2), 132-40.
81. Ulmasov B, Bruno J, Gordon N, **Hartnett ME**, Edwards JC. (2009). Chloride intracellular channel protein-4 functions in angiogenesis by supporting acidification of vacuoles along the intracellular tubulogenic pathway. *Am J Pathol*, 174(3), 1084-96.
 82. Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, Jumper JM, Figueroa M and the SCORE Study Investigator Group. (2009). SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion. *Ophthalmology*, 116(3), 504-12.
 83. Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C. (2009). Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. *Arch Ophthalmol*, 127(3), 245-51.
 84. Scott IU, Blodi BA, Ip MS, Vanveldhuisen PC, Oden NL, Chan CK, Gonzalez V and the SCORE Study Investigator Group. (2009). SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type. *Ophthalmology*, 116(4), 756-61.
 85. Byfield G, Budd S, **Hartnett ME**. (2009). The role of supplemental oxygen and JAK/STAT signaling in intravitreal neovascularization in a ROP rat model. *Invest Ophthalmol Vis Sci*, 50(7), 3360-5.
 86. Takeda A, Baffi JZ, Kleinman ME, Cho WG, Nozaki M, Yamada K, Kaneko H, Albuquerque RJ, Dridi S, Saito K, Raisler BJ, Budd SJ, Geisen P, Munitz A, Ambati BK, Green MG, Ishibashi T, Wright JD, Humbles AA, Gerard CJ, Ogura Y, Pan Y, Smith JR, Grisanti S, **Hartnett ME**, Rothenberg ME, Ambati J. (2009). CCR3 is a target for age-related macular degeneration diagnosis and therapy. *Nature*, 460(7252), 225-30.
 87. Budd S, Byfield G, Martiniuk D, Geisen P, **Hartnett ME**. (2009). Reduction in endothelial tip cell filopodia corresponds to reduced intravitreal but not intraretinal vascularization in a model of ROP. *Exp Eye Res*, 89(5), 718-27.
 88. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M, SCORE Study Research Group. (2009). A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. *Arch Ophthalmol*, 127(9), 1115-28.
 89. IP MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH, SCORE Study Research Group. (2009). A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. *Arch Ophthalmol*, 127(9), 1101-14.
 90. **Hartnett ME**, Tinkham N, Paynter L, Geisen P, Rosenberg P, Koch G, Cohen KL. (2009). Aqueous vascular endothelial growth factor as a predictor of macular thickening following cataract surgery in patients with diabetes mellitus. *Am J Ophthalmol*, 148(6), 895-901.e1.
 91. Chan RP, Yonekawa Y, Morrison MA, Sun G, Wong RK, Perlman JM, Chiang MF, Lee TC, **Hartnett ME**, Deangelis MM. (2010). Association between assisted reproductive technology and advanced retinopathy of prematurity. *Clin Ophthalmol*, 4, 1385-90.

92. Budd SJ, **Hartnett ME**. (2010). Increased angiogenic factors associated with peripheral avascular retina and intravitreal neovascularization: A model of retinopathy of prematurity. *Arch Ophthalmol*, 128(5), 589-95.
93. **Hartnett ME**. (2010). The effects of oxygen stresses on the development of features of severe retinopathy of prematurity: knowledge from the 50/10 OIR model. *Doc Ophthalmol*, 120(1), 25-39.
94. Sleath B, Blalock SJ, Robin A, **Hartnett ME**, Covert D, DeVellis B, Giangiacomo A. (2010). Development of an instrument to measure glaucoma medication self-efficacy and outcome expectations. *Eye (Lond)*, 24(4), 624-31.
95. Zayed M, Uppal A, **Hartnett ME**. (2010). New-Onset Maternal Gestational Hypertension and Risk of Retinopathy of Prematurity. *Invest Ophthalmol Vis Sci*. 51(10), 4983-8.
96. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aletto LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott RJ, Stockdale CR, Sun JK. (2010). Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology*, 117(6), 1064-77. PMID: PMC2937272.
97. Haller JA, Bandello F, Belfort R Jr., Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM, OZURDEX GENEVA Study Group. (2010). Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. *Ophthalmology*, 117(6), 1134-46.
98. ACCORD Study Group, ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis BP, Gangatrupa S, Grevan CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr., Cushman WC, Ginsberg HN, Elam MB, Geruth S, Gerstein HCV, Schubert U, Fine LJ. (2010). Effects of medical therapies on retinopathy progression in type 2 diabetes. *N Engl J Med*, 363(3), 233-44. PMID: PMC4026164.
99. Budd SJ, Thompson H, **Hartnett ME**. (2010). Association of retinal vascular endothelial growth factor with avascular retina in a rat model of retinopathy of prematurity. *Arch Ophthalmol*, 128(8), 1014-21. PMID: PMC3723353.
100. Monaghan-Benson E, Hartmann J, Vendrov AE, Budd S, Byfield G, Parker A, Ahmad F, Huang W, Runge M, Burridge K, Madamanchi N, **Hartnett ME**. (2010). The role of vascular endothelial growth factor-induced activation of NADPH oxidase in choroidal endothelial cells and choroidal neovascularization. *Am J Pathol*, 177(4), 2091-102. PMID: PMC2947302.
101. **Hartnett ME**. (2010). Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an american ophthalmological society thesis). *Trans Am Ophthalmol Soc*, 108, 96-119. PMID: PMC3016082.
102. Haller JA, Bandello F, Belfort R Jr., Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM, Ozurdex GENEVA Study Group, Li J. (2011). Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. *Ophthalmology*, 118(12), 2453-60.
103. Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, **Hartnett ME**, Cohen G. (2011). Standard Care versus Corticosteroid for Retinal Vein Occlusion Study Investigator Group. Baseline Predictors of Visual Acuity and Retinal Thickness Outcomes in Patients with Retinal Vein Occlusion: Standard Care versus Corticosteroid for Retinal Vein Occlusion: Standard Care versus Corticosteroid for Retinal Vein Occlusion Study Report. SCORE Study Report 10. *Ophthalmology*, 118(2), 345-52. PMID: PMC3020981.

104. Wang H, Geisen P, Wittchen ES, King B, Burridge K, D'Amore PA, **Hartnett ME**. (2011). The role of RPE cell-associated VEGF in choroidal endothelial cell transmigration across the RPE. *Invest Ophthalmol Vis Sci*, 52(1), 570-8. PMID: PMC3053298.
105. Wang H, Wittchen S, **Hartnett ME**. (2011). Breaking barriers: Insight into the pathogenesis of neovascular age-related macular degeneration. *Eye Brain*, 3, 19-28. PMID: PMC5082183.
106. Howard DL, Kim MM, **Hartnett ME**. (2011). Predicting Glaucoma Diagnosis in an Elderly Sample: Revisiting the Established Populations for Epidemiologic Studies of the Elderly. *J Natl Med Assoc*, 103(4), 332-41.
107. Hartmann JS, Thompson H, Wang H, Kanekar S, Huang W, Budd SJ, **Hartnett ME**. (2011). Expression of vascular endothelial growth factor and pigment epithelial-derived factor in a rat model of retinopathy of prematurity. *Mol Vis*, 17(17), 1577-87. PMID: PMC3123158.
108. Wallace DK, Freedman SF, **Hartnett ME**, Quinn GE. (2011). Predictive Value of Pre-plus Disease in Retinopathy of Prematurity. *Arch Ophthalmol*, 129(5):591-6. PMID: PMC3729934.
109. Wittchen ES, **Hartnett ME**. (2011). The small GTPase Rap1 is a novel regulator of RPE cell barrier function. *Invest Ophthalmol Vis Sci*, 52(10):7455-63. PMID: PMC3183976.
110. Moreno-Miralles I, Ren R, Moser M, **Hartnett ME**, Patterson C. (2011). Bone morphogenetic protein endothelial cell precursor-derived regulator regulates retinal angiogenesis in vivo in a mouse model of oxygen-induced retinopathy. *Arterioscler Thromb Vasc Biol*, (10), 2216-22. PMID: PMC3184390.
111. Wang H, Wittchen ES, Jiang Y, Ambati B, Grossniklaus HE, **Hartnett ME**. (2011). Upregulation of CCR3 by Age-Related Stresses Promotes Choroidal Endothelial Cell Migration via VEGF-Dependent and Independent Signaling. *Invest Ophthalmol Vis Sci*, 52(11), 8271-7. PMID: PMC3208059.
112. Moshirfar M, Hsu M, Schulman J, Armenia J, Sikder S, **Hartnett ME**. (2012). The Incidence of Central Serous Chorioretinopathy after Photorefractive Keratectomy and Laser In Situ Keratomileusis. *J Ophthalmol*, 2012, 27-32. PMID: PMC3306965.
113. Maile LA, Gollahon K, Wai C, Byfield G, **Hartnett ME**, Clemmons D. (2012). Disruption of the association of integrin-associated protein (IAP) with tyrosine phosphatase non-receptor type substrate-1 (SHPS)-1 inhibits pathophysiological changes in retinal endothelial function in a rat model of diabetes. *Diabetologia*, 55(3), 835-44. PMID: PMC3725181.
114. Wang H, Byfield G, Jiang Y, Smith GW, McCloskey M, **Hartnett ME**. (2012). VEGF-mediated STAT3 activation inhibits retinal vascularization by down-regulating local erythropoietin expression. *Am J Pathol*, 180(3), 1243-53. PMID: PMC3349887.
115. Wu C, Lofqvist C, Smith L, VanderVeen, Hellstrom A, WINROP Consortium. (2012). Importance of Early Postnatal Weight Gain for Normal Retinal Angiogenesis in Very Preterm Infants. *Arch Ophthalmol*, 1-8. PMID: PMC4059056.
116. Bourne R, Price H, Stevens G, GBD Vision Loss Expert Group. (2012). Global burden of visual impairment and blindness. *Arch Ophthalmol*, 130(5):645-7.
117. Blair MP, Shapiro MJ, **Hartnett ME**. (2012). Fluorescein-angiography to estimate normal peripheral retinal nonperfusion in children. *J AAPOS*, 16(3):234-7.
118. **Hartnett ME**, Penn JS. (2012). Mechanisms and management of retinopathy of prematurity. *N Engl J Med*, 367(26), 15-26. PMID: PMC3695731.
119. Wang, H, Zhang SX, **Hartnett ME**. (2013). Signaling pathways triggered by oxidative stress that mediate features of severe retinopathy of prematurity. *JAMA Ophthalmol*, 131(1), 80-5. PMID: PMC3703446.

120. Blair MP, Ulrich, J. Niklas, **Hartnett ME**, Shapiro MJ (2013). Peripheral retinal nonperfusion in fellow eyes in Coats Disease. *Retina. Issue: Volume 33*(8), September 2013, p 1694–1699.
121. McCloskey M, Wang H, Jiang Y, Smith GW, Strange J, **Hartnett ME**. (2013). Anti-VEGF antibody leads to later atypical intravitreal neovascularization and activation of angiogenic pathways in a rat model of ROP. *Invest Ophthalmol Vis Sci*, 54(3): 2020-6. PMID: PMC3621501.
122. **Hartnett ME**, Owen L. (2013). Soluble mediators of diabetic macular edema: the diagnostic role of aqueous VEGF and cytokine levels in diabetic macular edema. *Curr Diab Rep*. 13(4): 476-80. PMID: PMC3703469.
123. **Hartnett ME**, Lane R. (2013). Effects of oxygen on the development and severity of retinopathy of prematurity. *Journal of the American Association for Pediatric Ophthalmology and Strabismus*. 17(3): 229-34. PMID: PMC3740273.
124. **Hartnett ME**, Penn JS. (2013). Mechanisms and management of retinopathy of prematurity. *N Engl J Med*, 368(12), 1162-3.
125. Wittchen ES, Nishimura E, McCloskey M, Wang H, Quilliam LA, Chrzanowska-Wodnicka M, and **Hartnett ME**. (2013). Rap1 GTPase activation and barrier enhancement in RPE inhibits choroidal neovascularization in vivo. *PLOS ONE*. PMID: PMC3769400.
126. Wang H, Smith GW, Yang Z, Jiang Y, McCloskey M, Greenberg K, Geisen P, Culp WD, Flannery J, Kafri T, Hammond S, **Hartnett ME**. (2013). Short hairpin RNA mediated knockdown of VEGFA in Müller cells reduces intravitreal neovascularization in a rat model of ROP. *American Journal of Pathology*. PMID: PMC3763762.
127. Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, Grover S, Miller DG, Diabetic Retinopathy Clinical Research Network. (2013). Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. *JAMA Ophthalmol*, 131(8): 1033-40. PMID: PMC4162127.
128. Yang Z, Tsuchiya H, Zhang Y, **Hartnett ME**, Wang L. (2013). MicroRNA-433 inhibits liver cancer cell migration by repressing the protein expression and function of cAMP response element-binding protein. *J Biol Chem*, 288(40): 28893-9. PMID: PMC3789984.
129. Wittchen ES, Nishimura E, McCloskey M, Wang H, Quilliam LA, Chrzanowska-Wodnicka M **Hartnett ME**. (2013). Rap1 GTPase activation and barrier enhancement in RPE inhibits choroidal neovascularization in vivo. *PLoS One*. 2013 Sep 10;8(9):e73070. doi: 0.1371/journal.pone.0073070. eCollection. PMID: PMC3769400.
130. Wang H, Jiang Y, Shi D, Quilliam LA, Chrzanowska-Wodnicka M, Wittchen ES, Li DY, **Hartnett ME**. (2014). Activation of Rap1 inhibits NADPH oxidase-dependent ROS generation in retinal pigment epithelium and reduces choroidal neovascularization. *FASEB J*, 28(1):265-74. Epub 2013, Sept. PMID: PMC3868836.
131. Wang H, Yang Z, Jiang Y, **Hartnett, ME**. (2014). Endothelial NADPH oxidase 4 mediates vascular endothelial growth factor receptor 2-induced intravitreal neovascularization in a rat model of retinopathy of prematurity. *Mol Vis*, 20, 231-xxx. PMID: PMC3945806.
132. Jiang Y, Wang H, Culp D, Yang Z, Fotheringham L, Flannery J, Hammond S, Kafri T, **Hartnett ME**. (2014). Targeting Muller cell-derived VEGF 164 to reduce intravitreal neovascularization in the rat model of retinopathy of prematurity. *Invest Ophthalmol Vis Sci*, 55(2), 824-31. PMID: PMC3920823.
133. Wang H, Yang Z, Jiang Y, Flannery J, Hammond S, Kafri T, Vemuri SK, Jones B, **Hartnett ME**. (2014). Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity. *Invest Ophthalmol Vis Sci*, 55(2), 737-44. PMID: PMC3915769.

134. Yang Z, Wang H, Jiang Y, **Hartnett ME**. (2014). VEGFA Activates Erythropoietin Receptor and Enhances VEGFR2-mediated Pathological Angiogenesis. *Am J Pathol*, 184(4), 1230-9. PMID: PMC3969997.
135. Sleath BL, Blalock SJ, Muir KW, Carpenter DM, Lawrence SD, Giangiacomo AL, Goldsmith JA, **Hartnett ME**, Slota C, Robin AL. (2014). Determinants of Self-reported Barriers to Glaucoma Medicine Administration and Adherence: A Multisite Study. *Ann Pharmacother*. Epub ahead of print.
136. Young MP, Sawyer BL, **Hartnett ME**. (2014). Ophthalmologic findings in an 18-month-old boy with focal dermal hypoplasia. *J AAPOS*, 18(2):205-7. PMID: PMC3998842.
137. Slota, C, Sayner R, Vitko M, Carpenter DM, Blalock SJ, Robin AL, Muir KW, **Hartnett ME**, Sleath B. (2015). Glaucoma patient expression of medication problems and nonadherence. *Optometry and vision science : official publication of the American Academy of Optometry* 92, 537-543, doi:10.1097/OPX.0000000000000574. PMID: PMC4409514.
138. Christensen RD, Ilstrup SJ, **Hartnett ME**. (2014). Retinopathy of prematurity and transfusion practice. *Transfusion*. 54(4):960-1.
139. Sleath B, Blalock SJ, Carpenter DM, Muir KW, Sayner R, Lawrence S, Giangiacomo AL, **Hartnett ME**, Tudor G, Goldsmith J, Robin AL. (2014). Provider Education about Glaucoma and Glaucoma Medications During Videotaped Medical Visits. *J Ophthalmol*. Epub. PMID: PMC4020294.
140. Bourne RR, Jonas JB, Flaxman SR, Keeffe J, Leasher J, Naidoo K, Parodi MB, Pesudovs K, Price H, White RA, Wong TY, Resnikoff S, Taylor HR, Vision Loss Expert Group of the Global Burden of Disease Study. (2014). Prevalence and Causes of Vision Loss in High-Income Countries and in Eastern and Central Europe: 1990-2010. *Br J Ophthalmol*. May; 98(5):629-38. Epub, Mar 12. PMID: PMC4020294.
141. Khairallah M, Kahloun R, Flaxman SR, Jonas JB, Keeffe J, Leasher J, Naidoo K, Pesudovs K, Price H, White RA, Wong TY, Resnikoff S, Taylor HR, Bourne RR, **Vision Loss Expert Group**. (2014). Prevalence and Causes of Vision Loss in North Africa and the Middle East: 1990-2010. *Br J Ophthalmol*. May; 98(5):605-11. Epub Mar 3.
142. Naidoo K, Gichuhi S, Basanez MG, Flaxman SR, Jonas JB, Keeffe J, Leasher JL, Pesudovs K, Price H, Smith JL, Turner HC, White RA, Wong TY, Resnikoff S, Taylor HR, Bourne RR, **Vision Loss Expert Group**. (2014). Prevalence and Causes of Vision Loss in sub-Saharan Africa: 1990-2010. *Br J Ophthalmol*. May; 98(5): 612-18. Epub Feb 25.
143. Leasher JL, Lansingh V, Flaxman SR, Jonas JB, Keeffe J, Naidoo K, Pesudovs K, Price H, Silva JC, White RA, Wong TY, Resnikoff S, Taylor HR, Bourne RR, **Vision Loss Expert Group**. (2014). Prevalence and Causes of Vision Loss in Latin America and the Caribbean: 1990-2010. *Br J Ophthalmol*. May; 98(5):619-28. Epub Feb 11.
144. **Hartnett ME**, Morrison MA, Smith S, Yanovitch TL, Young TL, Colaizy T, Momany A, Dagle J, Carlo WA, Clark EA, Page G, Murray J, DeAngelis MM, Cotten CM; Genomics Subcommittee. (2014). Genetic variants associated with severe retinopathy of prematurity in extremely low birth weight infants. *Invest Ophthalmol Vis Sci*. Aug 12;55(10):6194-203. Doi:10.1167/iovs.14-14841. PubMed PMID: 25118269; PubMed Central PMCID: PMC4188045.
145. **Hartnett ME**. (2015). Pathophysiology and mechanisms of severe retinopathy of prematurity. *Ophthalmology*. Jan;122(1):200-10. doi: 10.1016/j.ophtha.2014.07.050. Epub 2014 Oct 14. Review. PMID: PMC4277936.
146. Basilius J, Young MP, Michaelis TC, Hobbs R, Jenkins G, **Hartnett ME**. (2015). Structural Abnormalities of the Inner Macula in Incontinentia Pigmenti. *JAMA Ophthalmol*. Sep; 133(9):1067-72. doi: 10.1001/jamaophthalmol.2015.1700. PMID: PMC4710467.

147. Xu M, Gelowani V, Eblimit A, Wang F, Young MP, Sawyer BL, Zhao L, Jenkins G, Creel DJ, Wang K, Ge Z, Wang H, Li Y, **Hartnett ME**, Chen R. (2015). vATF6 Is Mutated in Early Onset Photoreceptor Degeneration With Macular Involvement. *Invest Ophthalmol Vis Sci.* Jun; 56(6):3889-95. doi: 10.1167/iovs.15-16778. PMID: PMC4468593.
148. Sayner R, Carpenter DM, Blalock SJ, Robin AL, Muir KW, **Hartnett ME**, Giangiacomo AL, Tudor G, Goldsmith JA, Sleath B. (2015). How glaucoma patient characteristics, self-efficacy and patient-provider communication are associated with eye drop technique. *Int J Pharm Pract.* 2016 Apr; 24(2):78-85. doi: 10.1111/ijpp.12215. Epub Aug 25. PMID: PMC5599214.
149. Carpenter DM, Tudor GE, Sayner R, Muir KW, Robin AL, Blalock SJ, **Hartnett ME**, Giangiacomo AL, Sleath BL. (2015). Exploring the influence of patient-provider communication on intraocular pressure in glaucoma patients. *Patient Educ Couns.* Jul 6. pii: S0738-3991(15)30010 doi: 10.1016 / j.pec. 2015.07.001. PMID: PMC4703566.
150. Sleath B, Carpenter DM, Blalock SJ, Sayner R, Muir KW, Slota C, Giangiacomo AL, **Hartnett ME**, Tudor G, Robin AL. (2015). Applying the resources and supports in self-management framework to examine ophthalmologist-patient communication and glaucoma medication adherence. *Health Educ Res.* Oct; 30(5):693-705. doi: 10.1093/her/cyv034. Epub 2015 Sep 2. PMID: PMC4668753.
151. Wang H, Fotheringham L, Wittchen ES, **Hartnett ME**. (2015). Rap1 GTPase Inhibits Factor- α -Induced Choroidal Endothelial Migration via NADPH Oxidase- and NF- κ B-Dependent Activation of Rac1. *Am J Pathol.* Dec; 185(12):3316-25. doi: 10.1016/j.ajpath.2015.08.017. Epub 2015 Oct 23. PMID: PMC4729241.
152. **Hartnett ME**, Cotten CM. (2015). Genomics in the neonatal nursery: Focus on ROP. *Semin Perinatol.* Dec; 39(8):604-10. doi: 10.1053/j.semperi.2015.09.007. Epub 2015 Oct 23. Review. PMID: PMC4644692.
153. Carpenter DM, Sayner R, Blalock SJ, Muir KW, **Hartnett ME**, Lawrence SD, Giangiacomo AL, Goldsmith JA, Tudor GE, Robin AL, Sleath BL. The Effect of Eye Drop Technique Education in Patients With Glaucoma. *Health Commun.* 2016 Aug; 31(8):1036-42. doi: 10.1080/ 10410236. 2015.1020263. Epub 2016 Jan 11.
154. Wang H, Han X, Wittchen ES, **Hartnett ME**. TNF- α mediates choroidal neovascularization by upregulating VEGF expression in RPE through ROS-dependent β -catenin activation. *Mol Vis.* 2016 Feb 3; 22:116-28. eCollection 2016. PMID: PMC4736754.
155. Carpenter DM, Blalock SJ, Sayner R, Muir KW, Robin AL, **Hartnett ME**, Giangiacomo AL, Tudor GE, Sleath BL. Communication Predicts Medication Self-Efficacy in Glaucoma Patients. *Optom Vis Sci.* 2016 Jul;93(7):731-7. doi: 10.1097. PMID: PMC4915983.
156. Wang H, **Hartnett ME**. Regulation of signaling events involved in the pathophysiology of neovascular AMD. *Mol Vis.* 2016 Feb 27; 22:189-202. eCollection 2016. Review.
157. **Hartnett ME**, Capone Jr A. Advances in diagnosis, clinical care, research, and treatment in retinopathy of prematurity. *Eye and Brain.* 2016 May 19, 2016(8): 27-29.doi: 10.2147/EB.S105319. PMID: PMC5082184.
158. Lambert NG, Hoffman RO, **Hartnett ME**. A case of coats disease and concurrent anisometric amblyopia. *American Journal of Ophthalmology.* doi: 10.1016/ajoc.2016.07.004. PMID: PMC5223778.
159. Yonekawa Y, Wu WC, Kusaka S, Robinson J, Tsujioka D, Kang KB, Shapiro MJ, Padhi TR, Jain L, Sears JE, Kuriyan AE, Berrocal AM, Quiram PA, Gerber AE, Paul Chan RV, Jonas KE, Wong SC, Patel CK, Abbey AM, Spencer R, Blair MP, Chang EY, Papakostas TD, Vavvas DG, Sisk RA, Ferrone PJ, Henderson RH, Olsen KR, **Hartnett ME**, Chau FY, Mukai S, Murray TG, Thomas BJ, Meza PA, Drenser KA, Trese MT, Capone

- A Jr. Immediate Sequential Bilateral Pediatric Vitreoretinal Surgery: An International Multicenter Study. *Ophthalmology* **123**, 1802-1808,doi:10.1016/j.ophtha.2016.04.033 (2016). PMID: PMC5522749.
160. Wang H, Han X, Gambhir D, Becker S, Kunz E, Liu AJ, **Hartnett ME**. Retinal Inhibition of CCR3 Induces Retinal Cell Death in a Murine Model of Choroidal Neovascularization. *PLoS One*. 2016 Jun 16; 11(6):e0157748. doi: 10.1371/journal.pone.0157748. eCollection 2016. PMID: PMC4911089.
161. Wang H, Han X, Bretz CA, Becker S, Gambhir D, Smith GW, Samulski RJ, Wittchen ES, Quilliam LA, ChrzanowskioWodnicka M, **Hartnett ME**. Retinal Pigment epithelial cell expression of active Rap 1a by scAAV2 inhibits choroidal neovascularization. *Mol Ther Methods Clin Dev*. 2016 Aug 24;3:16056. doi: 10.1038/mtm.2016.56. eCollection 2016. PMID: PMC4996131.
162. **Hartnett, ME**. Advances in Understanding and Management of Retinopathy of Prematurity. *Surv. Ophthalmol.*, doi:10,1016/j.survophthal.2016.12.004 (2016). PMID: PMC5401801.
163. Sleath B, Sayner R, Vitko M, Carpenter DM, Blalock SJ, Muir KW, Giangiacomo AL, **Hartnett ME**, Robin AL. Glaucoma patient-provider communication about vision quality-of-life. *Patient Educ Couns.*,doi:10.1016/j.pec.2016.11.018 (2016). PMID: PMC 5385288.
164. Wang, H., Han, X., Kunz, E. & **Hartnett, ME**. Thy-1 Regulates VEGF-Mediated Choroidal Endothelial Cell Activation and Migration: Implications in Neovascular Age-Related Macular Degeneration. *Invest Ophthalmol Vis Sci* **57**, 5525-5534, doi:10.1167/iovs.16-19691 (2016). PMID: PMC5080948.
165. **Hartnett ME**. Role of cytokines and treatment algorithms in retinopathy of prematurity. *Curr Opin Ophthalmol*. 2017 May;28(3):282-288. doi:10.1097/ICU.0000000000000360. Review. PubMed PMID: 28141765; PubMed Central PMID: PMC5495148.
166. Friddle KM, Yoder BA, **Hartnett ME**, Henry E, DiGeronimo RJ. Can a Risk Factor Based Approach Safely Reduce Screening for Retinopathy of Prematurity? *Int J Pediatr*. 2017; 2017:9372539. doi: 10.1155/2017/9372539. PMID: PMC5253483.
167. Becker S, Wang H, Yu B, Brown R, Han X, Lane RH, **Hartnett ME**. Protective effect of maternal uteroplacental insufficiency on oxygen-induced retinopathy in offspring: removing bias of premature birth. *Sci Rep*. 2017 Feb 14;7:42301. doi: 10.1038/srep42301. PMID: PMC5307308.
168. **Hartnett ME**. Breakdown of the Retinal Pigmented Epithelium Blood-Retinal Barrier. *Sciencedirect*. Reference Module in Neuroscience and Biobehavioral Psychology 2017. Doi:10.1016
169. **Hartnett, ME**. (2017). Electroretinographic Responses in the Smallest Eyes. *JAMA Ophthalmol*, 135 (8), 862-863.
170. **Hartnett, M.E.**, Baehr, W., & Le, Y.Z. (2017). Diabetic retinopathy, an overview. *Vision Res*.
171. Kartchner, J.Z., & **Hartnett, M.E.** (2017). Familial exudative vitreoretinopathy presentation as persistent fetal vasculature. *Am J Ophthalmol Case Rep*, 6, 15-17. PMID: PMC5388355.
172. Todorich B, Thanos A, Yonekawa Y, Thomas BJ, Faia LJ, Chang E, Shulman J, Olsen KR, Blair MP, Shapiro MP, Ferrone P, Vajzovic L, Toth CA, Lee TC, Robinson J, Hubbard B, Kondo H, Besirli CG, Nudleman E, Wong SC, Kusaka S, Walsh M, Chan RVP, Berrocal A, Caputo G, Murray TG, Sears J, Schunemann R, Harper CA 3rd, Kychental A, Dorta P, Cernichiaro-Espinosa LA, Wu WC, Campbell JP, Martinez-Castellanos MA, Quiroz-Mercado H, Hayashi H, Quiram P, Amphornphruet A, **Hartnett ME**, Tsui I, Ells A, John V, Moshfeghi D, Capone A Jr, Drenser KA, Trese MT. Correspondence. *Retina* **37**, e52-e54, doi:10.1097/iae.0000000000001602 (2017).

173. Wallace DK, Kraker RT, Freedman SF, Crouch ER, Hutchinson AK, Bhatt AR, Rogers DL, Yang MB, Haider KM, VanderVeen DK, Siatkowski RM, Dean TW, Beck RW, Repka MX, Smith LE, Good WV, **Hartnett ME**, Kong L, Holmes. JMA assessment of Lower Doses of Intravitreal Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study. *JAMA ophthalmology* **135**, 654-656, doi:10.1001/jamaophthalmol.2017.1055 (2017). PMID: PMC5521814.
174. Wang, H., & **Hartnett, M.E.** (2017). Roles of Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Oxidase in Angiogenesis: Isoform-Specific Effects. *Antioxidants (Basel)*, 6 (2) PMID: PMC5488020.
175. Nguyen, J. & **Hartnett, M. E.** Successful management of post-traumatic vancomycin-resistant enterococcus endophthalmitis. *American journal of ophthalmology case reports* **5**, 117-118, doi:10.1016/j.ajoc.2016.12.022 (2017). PMID: PMC5571869.
176. Becker, S., Wang, H., Stoddard, G. J. & **Hartnett, M. E.** Effect of subretinal injection on retinal structure and function in a rat oxygen-induced retinopathy model. *Mol Vis* **23**, 832-843 (2017). PMID: PMC5723151.
177. Zhu W, Shi DS, Winter JM, Rich BE, Tong Z, Sorensen LK, Zhao H, Huang Y, Tai Z, Mleynek TM, Yoo JH, Dunn C, Ling J, Bergquist JA, Richards JR, Jiang A, Lesniewski LA, **Hartnett ME**, Ward DM, Mueller AL, Ostanin K, Thomas KR, Odelberg SJ, Li DY. Small GTPase ARF6 controls VEGFR2 trafficking and signaling in diabetic retinopathy. *J Clin Invest*, doi:10.1172/jci91770 (2017). PMID: PMC5707163.
178. Schulman, J. P., Weng, C., Wilkes, J., Greene, T. & **Hartnett, ME.** Association of Maternal Preeclampsia with Infant Risk of Premature Birth and Retinopathy of Prematurity. *JAMA ophthalmology* **135**, 947-953, doi:10.1001/jamaophthalmol.2017.2697 (2017). PMID: PMC5710540.
179. Becker S, Wang H, Simmons AB, Suwanmanee T, Stoddard GJ, Kafri T, **Hartnett ME.** Targeted Knockdown of Overexpressed VEGFA or VEGF164 in Müller cells maintains retinal function by triggering different signaling mechanisms. *Sci Rep.* 2018 Jan 31;8(1):2003. doi: 10.1038/s41598-018-20278-4. PubMed PMID: 29386650; PubMed Central PMID: PMC5792486.
180. Bretz CA, Divoky V, Prchal J, Kunz E, Simmons AB, Wang H, **Hartnett ME.** Erythropoietin Signaling Increases Choroidal Macrophages and Cytokine Expression, and Exacerbates Choroidal Neovascularization. *Sci Rep.* 2018 Feb 1;8(1):2161. doi:10.1038/s41598-018-20520-z. PubMed PMID: 29391474; PubMed Central PMID:PMC5795007.
181. Simmons AB, Bretz CA, Wang H, Kunz E, Hajj K, Kennedy C, Yang Z, Suwanmanee T, Kafri T, **Hartnett ME.** Correction to: Gene therapy knockdown of VEGFR2 in retinal endothelial cells to treat retinopathy. *Angiogenesis.* 2018. Epub 2018/05/08. doi: 10.1007/s10456-018-9618-5. PubMed PMID: 29730824.
182. Shulman JP, **Hartnett ME.** Pharmacotherapy and ROP: Going Back to the Basics. *Asia-Pacific journal of ophthalmology* (Philadelphia, Pa). 2018. Epub 2018/04/28. doi: 10.22608/apo.201853. PubMed PMID: 29701429.
183. Calvo CM, **Hartnett ME.** The utility of ultra-widefield fluorescein angiography in pediatric retinal diseases. *International journal of retina and vitreous.* 2018;4:21. Epub 2018/07/12. doi: 10.1186/s40942-018-0122-2. PubMed PMID: 29992045; PubMed Central PMID: PMC5987662.
184. Wallace DK, Dean TW, **Hartnett ME**, Kong L, Smith LE, Hubbard GB, McGregor ML, Jordan CO, Mantagos IS, Bell EF, Kraker RT. A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments. *Ophthalmology.*

2018. Epub 2018/06/12. doi: 10.1016/j.ophttha.2018.05.001. PubMed PMID: 29887334. PMCID: PMC6402322.
185. Birch DG, Bernstein PS, Iannacone A, Pennesi ME, Lam BL, Heckenlively J, Csaky K, **Hartnett ME**, Winthrop KL, Jayasundera T, Hughbanks-Wheaton DK, Warner J, Yang P, Fish GE, Teske MP, Sklaver NL, Erker L, Chegarnov E, Smith T, Wahle A, VanVeldhuisen PC, McCormack J, Lindblad R, Bramer S, Rose S, Zilliox P, Francis PJ, Weleber RG. Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial. *JAMA ophthalmology*. 2018;136(8):849-56. Epub 2018/06/08. doi: 10.1001/jamaophthalmol.2018.1171. PubMed PMID: 29879277. PMCID: PMC6142953.
 186. Yarishkin O, Phuong TTT, Bretz CA, Olsen KW, Baumann JM, Lakk M, Crandall A, Heurteaux C, **Hartnett ME**, Križaj D. TREK-1 channels regulate pressure sensitivity and calcium signaling in trabecular meshwork cells. *The Journal of general physiology*. 2018 Dec 3;150(12):1660-1675. doi: 10.1085/jgp.201812179. PubMed PMID: 30446509; PubMed Central PMCID: PMC6279358. eng.
 187. Greene T, **Hartnett ME**. Programming Error Led to Underestimate of Effect Sizes in Study of Association of Maternal Preeclampsia and Risk of Infant Retinopathy of Prematurity. *JAMA ophthalmology*. 2018 Oct 25. doi: 10.1001/jamaophthalmol.2018.5055. PubMed PMID: 30422231; eng.
 188. Simmons MA, Cheng AV, Becker S, Gerkin RD, **Hartnett ME**: Automatic analysis of the retinal avascular area in the rat oxygen-induced retinopathy model. *Molecular vision* 2018, 24:767-77.
 189. Mangalesh, S., Bleicher, I. D., Chen, X., Viehland, C., LaRocca, F., Izatt, J. A., Freedman, S. F., **Hartnett, M. E.**, & Toth, C. A. (2019). Three-dimensional pattern of extraretinal neovascular development in retinopathy of prematurity. *Graefes Arch Clin Exp Ophthalmol*. 2019;257(4):677-688. doi:10.1007/s00417-019-04274-6
 190. Han X, Kong J, **Hartnett ME**, Wang H. Enhancing Retinal Endothelial Glycolysis by Inhibiting UCP2 Promotes Physiologic Retinal Vascular Development in a Model of Retinopathy of Prematurity. *Invest Ophthalmol Vis Sci*. 2019;60(5):1604-1613. doi:10.1167/iovs.19-26553
 191. Jeng-Miller, K. W., Soomro, T., Scott, N. L., Rao, P., Marlow, E., Chang, E. Y., Ells, A., Chau, F., Nudleman, E., Calvo, C. M., Patel, N., Schwartz, R., Cernichiario-Espinosa, L. A., Montoya, A. G., Goldstein, J., Harper, C. A., 3rd, Bauman, C. R., **Hartnett, M. E.**, Harbour, J. W., Besirli, C. G., ... Yonekawa, Y. (2019). Longitudinal Examination of Fellow-Eye Vascular Anomalies in Coats' Disease With Widefield Fluorescein Angiography: A Multicenter Study. *Ophthalmic surgery, lasers & imaging retina*, 50(4), 221–227. doi: 10.3928/23258160-20190401-04.
 192. **Hartnett ME**, Toth CA. Experimental Evidence Behind Clinical Trial Outcomes in Retinopathy of Prematurity. *Ophthalmic surgery, lasers & imaging retina*. 2019;50(4):228-234.
 193. Mastey RR, Georgiou M, Langlo CS, Kalitzeos A, Patterson EJ, Kane T, Singh N, Vincent A, Moore AT, Tsang SH, Lin JH, Young MP, **Hartnett ME**, Héon E, Kohl S, Michaelides M, Carroll J. Characterization of Retinal Structure in ATF6-Associated Achromatopsia. *Invest Ophthalmol Vis Sci*. 2019;60(7):2631-2640. doi:10.1167/iovs.19-27047.
 194. **Hartnett ME**. Discovering Mechanisms in the Changing and Diverse Pathology of Retinopathy of Prematurity: The Weisenfeld Award Lecture. *Invest Ophthalmol Vis Sci*. 2019;60(5):1286-1297. doi:10.1167/iovs.18-25525.
 195. Hicks PM, Melendez SAC, Vitale A, Self W, **Hartnett ME**, Bernstein P, Morgan DJ, Feehan M, Shakoor A, Kim I, Owen LA, DeAngelis MM. Genetic Epidemiologic Analysis of Hypertensive Retinopathy in an Underrepresented and Rare Federally Recognized Native

- American Population of the Intermountain West. *J Community Med Public Health*. 2019;3(1):152.
196. Han X, Kong J, **Hartnett ME**, Wang H. Enhancing Retinal Endothelial Glycolysis by Inhibiting UCP2 Promotes Physiologic Retinal Vascular Development in a Model of Retinopathy of Prematurity. *Invest Ophthalmol Vis Sci*. 2019;60(5):1604-1613. doi:10.1167/iovs.19-26553
 197. Hansen ED, **Hartnett ME**. A review of treatment for retinopathy of prematurity. *Expert Rev Ophthalmol*. 2019;14(2):73-87. doi: 10.1080/17469899.2019.1596026. Epub 2019 Mar 29. PubMed PMID: 31762784; PubMed Central PMCID: PMC6874220.
 198. Wang H, Kunz E, Stoddard GJ, Hauswirth WW, **Hartnett ME**. Optimal Inhibition of Choroidal Neovascularization by scAAV2 with VMD2 Promoter-driven Active Rap1a in the RPE. *Sci Rep*. 2019 Oct 31;9(1):15732. doi: 10.1038/s41598-019-52163-z.
 199. Bretz CA, Simmons AB, Kunz E, Ramshekar Aniket, Kennedy arson, Cardenas Ivan, **Hartnett, ME**. Erythropoietin Receptor Signaling Supports Retinal Function after Vascular Injury. *The American Journal of Pathology*. 2020;190(3):630-641.
 200. Dalvin LA, **Hartnett ME**, Bretz CA, Hann CR, Cui RZ, Marmorstein AD, Sheikh-Hamad D, Fautsch MP, Roddy GW. Stanniocalcin-1 is a Modifier of Oxygen-Induced Retinopathy Severity. *Curr Eye Res*. 2020;45(1):46-51. doi:10.1080/02713683.2019.1645184
 201. Global Retinoblastoma Study Group, Fabian ID, Abdallah E, et al. Global Retinoblastoma Presentation and Analysis by National Income Level [published online ahead of print, 2020 Feb 27]. *JAMA Oncol*. 2020;6(5):1-12. doi:10.1001/jamaoncol.2019.6716
 202. Wallace DK, Kraker RT, Freedman SF, Crouch ER, Bhatt AR, **Hartnett ME**, Yang MB, Rogers DL, Hutchinson AK, VanderVeen DK, Haider KM, Siatkowski RM, Dean TW, Beck RW, Repka MX, Smith LE, Good WV, Kong L, Cotter SA, Holmes JM; Pediatric Eye Disease Investigator Group (PEDIG). Short-term Outcomes After Very Low-Dose Intravitreal Bevacizumab for Retinopathy of Prematurity. *JAMA Ophthalmol*. 2020 Jun 1;138(6):698-701. doi: 10.1001/jamaophthalmol.2020.0334. PMID: 32324197; PMCID: PMC7180729.
 203. Colin A. Bretz, Aniket Ramshekar, Eric Kunz, Haibo Wang, **M. Elizabeth Hartnett**. Signaling Through the Erythropoietin Receptor Affects Angiogenesis in Retinovascular Disease. *Invest Ophthalmol Vis Sci*. 2020 Aug; 61(10): 23. Published online 2020 Aug 12. doi: 10.1167/iovs.61.10.23. PMCID: PMC7441364
 204. Thornburg CD, Erickson SW, Page GP, Clark EAS, DeAngelis MM, **Hartnett ME**, Goldstein RF, Dagle JM, Murray JC, Poindexter BB, Das A, Cotten CM; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Genetic predictors of severe intraventricular hemorrhage in extremely low-birthweight infants. *J Perinatol*. 2020 Sep 25. doi: 10.1038/s41372-020-00821-w. Epub ahead of print. PMID: 32978526.
 205. Levine ES, Custo Greig E, Mendonça LSM, Gulati S, Despotovic IN, Alibhai AY, Moulton E, Muakkassa N, Quaranta-El Maftouhi M, El Maftouhi A, Chakravarthy U, Fujimoto JG, Bauman CR, Witkin AJ, Duker JS, **Hartnett ME**, Waheed NK. The long-term effects of anti-vascular endothelial growth factor therapy on the optical coherence tomography angiographic appearance of neovascularization in age-related macular degeneration. *Int J Retina Vitreous*. 2020 Aug 20;6:39. doi: 10.1186/s40942-020-00242-z. PMID: 32844038; PMCID: PMC7441632.
 206. Stagg BC, Stein JD, Medeiros FA, Wirostko B, Crandall A, **Hartnett ME**, Cummins M, Morris A, Hess R, Kawamoto K. Special Commentary: Using Clinical Decision Support Systems to Bring Predictive Models to the Glaucoma Clinic. *Ophthalmol Glaucoma*. 2020

- Aug 15:S2589-4196(20)30212-X. doi: 10.1016/j.ogla.2020.08.006. Epub ahead of print. PMID: 32810611.
207. Wang H, Ramshekar A, Kunz E, Sacks DB, **Hartnett ME**. IQGAP1 causes choroidal neovascularization by sustaining VEGFR2-mediated Rac1 activation. *Angiogenesis*. 2020 Aug 11. doi: 10.1007/s10456-020-09740-y. Epub ahead of print. PMID: 32783108.
 208. **Hartnett ME**. Retinopathy of Prematurity: Evolving Treatment With Anti-Vascular Endothelial Growth Factor. *Am J Ophthalmol*. 2020 Oct;218:208-213. doi: 10.1016/j.ajo.2020.05.025. Epub 2020 May 23. PMID: 32450064.
 209. Naidoo K, Kempen JH, Gichuhi S, Braithwaite T, Casson RJ, Cicinelli MV, Das A, Flaxman SR, Jonas JB, Keeffe JE, Leasher J, Limburg H, Pesudovs K, Resnikoff S, Silvester AJ, Tahhan N, Taylor HR, Wong TY, Bourne RRA; Vision Loss Expert Group of the Global Burden of Disease Study. Prevalence and causes of vision loss in sub-Saharan Africa in 2015: magnitude, temporal trends and projections. *Br J Ophthalmol*. 2020 Mar 30;bjophthalmol-2019-315217. doi: 10.1136/bjophthalmol-2019-315217. Epub ahead of print. PMID: 32229517.
 210. Thornburg CD, Erickson SW, Page GP, Clark EAS, DeAngelis MM, **Hartnett ME**, Goldstein RF, Dagle JM, Murray JC, Poindexter BB, Das A, Cotten CM; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Correction: Genetic predictors of severe intraventricular hemorrhage in extremely low-birthweight infants. *J Perinatol*. 2020 Oct 12. doi: 10.1038/s41372-020-00859-w. Epub ahead of print. Erratum for: *J Perinatol*. 2020 Sep 25;: PMID: 33041330.
 211. Hicks PM, Haaland B, Feehan M, Crandall AS, Pettey JH, Nuttall E, Self W, **Hartnett ME**, Bernstein P, Vitale A, Shakoor A, Shulman JP, Sieminski SF, Kim I, Owen LA, Murtaugh MA, Noyes A, DeAngelis MM. Systemic Disease and Ocular Comorbidity Analysis of Geographically Isolated Federally Recognized American Indian Tribes of the Intermountain West. *J Clin Med*. 2020 Nov 7;9(11):3590. doi: 10.3390/jcm9113590. PMID: 33171720; PMCID: PMC7694968.

INVITED PUBLICATIONS

1. **Hartnett ME**. (2010). Advancing technology helpful in pediatric retinal ophthalmology cases. *Ocular Surgery News (US Edition)*, 6, 1385-90.
2. **Hartnett ME**. (2010). ARVO, AMD therapies make inroads. *Ophthalmology Times*, 35(23), 1, 22.

BOOKS

Edited Books

1. Schepens CL, **Hartnett ME**, Hirose T (Eds.). (2000). *Schepens' Retinal Detachment and Allied Diseases*. Boston, MA: Butterworth-Heinemann.
2. Steidl S, **Hartnett ME** (Eds.). (2003). *Clinical Pathways in Vitreoretinal Disease*. New York, NY: Thieme Publishers.
3. **Hartnett ME**, (Ed.). (2005). *Pediatric Retina* (1st ed.). Philadelphia, PA: Lippincott Williams &

4. Wilkins.
Hartnett ME, (Ed.). (2014). *Pediatric Retina* (2nd ed.). Philadelphia, PA: Lippincott Williams &
5. Wilkins.
Hartnett ME, (Ed.). (2020). *Pediatric Retina* (3rd ed.). Philadelphia, PA: Lippincott Williams & Wilkins.

BOOK CHAPTERS

1. **Hartnett ME**. (1996). Age-related macular degeneration. In JW Hunt (Ed.), *Medicine for the Practicing Physician* (pp. 1954-1956). Norwalk, CT: Appleton and Lange, Simon and Schuster.
2. **Hartnett ME**. (1996). Diabetic retinopathy. In JW Hunt (Ed.), *Medicine for the Practicing Physician* (pp. 1924-1927). Norwalk, CT: Appleton and Lange, Simon and Schuster.
3. **Hartnett ME**. (1996). Ocular manifestations of the acquired immunodeficiency syndrome. In JW Hunt (Ed.), *Medicine for the Practicing Physician* (pp. 1951-1953). Norwalk, CT: Appleton and Lange, Simon and Schuster.
4. **Hartnett ME**. (1996). Retinal detachment. In JW Hunt (Ed.), *Medicine for the Practicing Physician* (pp. 1946-1948). Norwalk, CT: Appleton and Lange, Simon and Schuster.
5. Armstrong D, Ueda To, Ueda Ta, Hiramitsu T, Stockton R, Browne R, Al-Jada A, Buch P,
Hartnett ME. (1998). Dose dependent mechanisms of lipid hydroperoxide induced retinal pathology. In K Yagi (Ed.), *Pathophysiology of Lipid Peroxides and Related Free Radicals* (pp. 57-76). Tokyo: Japan: Scientific Societies Press.
6. Elsner AE, Barch D-U, **Weiter JJ and Hartnett ME**. (1999). New devices in retinal imaging and functional evaluation. In W Freeman (Ed.), *Practical Atlas of Retinal Disease and Therapy* (2nd ed.), (pp. 19-55). NY: Lippincott-Raven.
7. **Hartnett ME**. (2000). Basic considerations of preoperative patient management and technical aspects of chorioretinal adhesion. In CL Schepens, ME Hartnett, T Hirose (Eds.), *Schepens' Retinal Detachment and Allied Diseases* (2nd ed.), (pp. 257-270). Boston, MA: Butterworth-Heinemann.
8. **Hartnett ME**. (2000). Complications. In CL Schepens, ME Hartnett, T Hirose (Eds.), *Schepens' Retinal Detachment and Allied Diseases* (2nd ed.), (pp. 721-740). Boston, MA: Butterworth-Heinemann.
9. **Hartnett ME**. (2000). Evaluation of the traumatized eye. In CL Schepens, ME Hartnett, T Hirose (Eds.), *Schepens' Retinal Detachment and Allied Diseases* (2nd ed.), (pp. 679-687). Boston, MA: Butterworth-Heinemann.
10. Schepens CL, **Hartnett ME**. (2000). Macular breaks and other macular changes. In CL Schepens, ME Hartnett, T Hirose (Eds.), *Schepens' Retinal Detachment and Allied Diseases* (2nd ed.), (pp. 435-455). Boston, MA: Butterworth-Heinemann.
11. **Hartnett ME**. (2000). Managing the crystalline lens and intraocular lenses. In CL Schepens, ME Hartnett, T Hirose (Eds.), *Schepens' Retinal Detachment and Allied Diseases* (2nd ed.), (pp. 555-565). Boston, MA: Butterworth-Heinemann.
12. **Hartnett ME**. (2000). Other traction retinal detachments. In CL Schepens, ME Hartnett, T Hirose (Eds.), *Schepens' Retinal Detachment and Allied Diseases* (2nd ed.), (pp. 671-676). Boston, MA: Butterworth-Heinemann.
13. **Hartnett ME**. (2000). Philosophy of retinal detachment management. In CL Schepens, ME Hartnett, T Hirose (Eds.), *Schepens' Retinal Detachment and Allied Diseases* (2nd ed.), (pp. 347-353). Boston, MA: Butterworth-Heinemann.
14. **Hartnett ME**. (2000). Primary rhegmatogenous retinal detachment. In Schepens CL, Hartnett ME, Hirose T (Eds.), *Schepens' Retinal Detachment and Allied Diseases* (2nd edition, pp. 291-346). Boston, MA: Butterworth-Heinemann.
15. **Hartnett ME**. (2000). Prophylaxis of retinal detachment. In CL Schepens, ME Hartnett, T Hirose

- (Eds.), *Schepens' Retinal Detachment and Allied Diseases* (2nd ed.), (pp. 271-288). Boston, MA: Butterworth-Heinemann.
16. **Hartnett ME.** (2000). Reoperations. In CL Schepens, ME Hartnett, T Hirose (Eds.), *Schepens' Retinal Detachment and Allied Diseases* (2nd ed.), (pp. 367-392). Boston, MA: Butterworth-Heinemann.
 17. **Hartnett ME,** Hirose T. (2000). Retinal detachment in the pediatric population. In CL Schepens, ME Hartnett, T Hirose (Eds.), *Schepens' Retinal Detachment and Allied Diseases* (2nd ed.), (pp. 515-554). Boston, MA: Butterworth-Heinemann.
 18. **Hartnett ME.** (2000). Surgical indications for retinal detachment associated with diabetic eye disease. In CL Schepens, ME Hartnett, T Hirose (Eds.), *Schepens' Retinal Detachment and Allied Diseases* (2nd ed.), (pp. 659-669). Boston, MA: Butterworth-Heinemann.
 19. **Hartnett ME.** (2000). Trauma classification and management. In CL Schepens, ME Hartnett, T Hirose (Eds.), *Schepens' Retinal Detachment and Allied Diseases* (2nd ed.), (pp. 689-705). Boston, MA: Butterworth-Heinemann.
 20. **Hartnett ME.** (2000). Vitreoretinal traction forces: special situations and methods of management. In CL Schepens, ME Hartnett, T Hirose (Eds.), *Schepens' Retinal Detachment and Allied Diseases* (2nd ed.), (pp. 355-365). Boston, MA: Butterworth-Heinemann.
 21. **Hartnett ME.** (2003). Diagnosis and Examination of the Pediatric Patient. In S Steidl, ME Hartnett (Eds.), *Clinical Pathways in Vitreoretinal Disease* (pp. 341-373). New York, NY: Thieme Publishers.
 22. Oh K, **Hartnett ME,** Landers ML. (2005). Pathogenetic Mechanisms of Retinal Detachment. In Ryan (Ed.), *Retina* (4th ed.), (pp. 2013-2020). St. Louis, MO: Mosby, Inc.
 23. McColm J, **Hartnett ME.** (2005). Retinopathy of Prematurity: Current Understanding Based on Clinical trials and Animal Models. In ME Hartnett (Ed.), *Pediatric Retina* (pp. 387-409). Philadelphia, PA: Lippincott Williams & Wilkins.
 24. Capone A., **Hartnett ME,** Trese MT. (2005). Treatment of Retinopathy of Prematurity: Peripheral Retinal Ablation and Vitreoretinal Surgery. In ME Hartnett (Ed.), *Pediatric Retina* (pp. 417-424). Philadelphia, PA: Lippincott Williams & Wilkins.
 25. **Hartnett ME.** (2010). Breakdown of the blood: retinal-pigmented epithelium barrier. In R Hodges, D Dartt, & P D'Amore (Eds.), *Encyclopedia of the Eye* (1, pp. 223-232). Amsterdam: Elsevier/Academic Press.
 26. **Hartnett ME.** (2010). Retinal vasculopathies: retinopathy of prematurity. In R Hodges, D Dartt, & D Bok (Eds.), *Encyclopedia of the Eye* (3, 3, pp. 118-128). Amsterdam: Elsevier/Academic Press.
 27. **Hartnett ME,** Toth CA. (2010). Retinopathy of Prematurity. In L.A. Levin and D.A. Albert (Eds.), *Ocular Disease: Mechanisms and Management* (pp. 562-571). Philadelphia, PA: Saunders/Elsevier.
 28. **Hartnett ME,** DeAngelis, MM. (2012). The Role of Reactive Oxygen Species and Oxidative Signaling in Retinopathy of Prematurity. In R.D. Stratton, W.W. Hauswirth, & T.W. Gardener (Eds.), *Studies on Retinal and Choroidal Disorders* (pp. 559-584). New York, NY: Springer.
 29. **Hartnett ME,** Shulman JP. (2014). Clinical Trials and Management of Severe Retinopathy of Prematurity. In ME Hartnett (Ed.), *Pediatric Retina* (2nd ed.), (pp. 492-512). Philadelphia, PA: Lippincott Williams & Wilkins
 30. **Hartnett ME,** Wang H. (2014). Oxidative Stress and Signaling Pathways Involved in Developmental and Aberrant Angiogenesis Relating to Retinopathy of Prematurity. In ME Hartnett (Ed.), *Pediatric Retina* (2nd ed.), (pp. 555-567). Philadelphia, PA: Lippincott Williams & Wilkins.
 31. **Hartnett ME,** Capone A, Trese MT. (2014). Treatment of Stages 4 and 5 Retinopathy of Prematurity. In ME Hartnett (Ed.), *Pediatric Retina* (2nd ed.), (pp. 597-603). Philadelphia, PA: Lippincott Williams & Wilkins.
 33. **Hartnett ME,** Trese MT, Capone A. (2014). Flecks and Spots. In ME Hartnett (Ed.), *Pediatric Retina* (2nd ed.), (pp. 746-747). Philadelphia, PA: Lippincott Williams & Wilkins.
 34. **Hartnett ME.** (2014). Retinopathy of Prematurity: A Template for Studying Retinal Vascular

- Disease. In JS Werner & LM Chalupa (Eds.), *The New Visual Neurosciences* (pp. 1483 – 1501). Cambridge, MA: The MIT Press.
35. **Hartnett ME.** (2016). The Effects of Hypoxia, Hyperoxia, and Oxygen Fluctuations on Oxidative Signaling in the Preterm Infant and Retinopathy of Prematurity. *Oxidative Stress and Antioxidant Protection. The Science of Free Radical Biology and Disease.* Edited by Donald Armstrong and Robert D. Stratton. John Wiley and Sons Inc. Hoboken, NJ.
 36. **Hartnett ME.** (2016) Pathophysiology of ROP. *Retinopathy of Prematurity.* Andres Kychenthal and Paola Dorta. Springer Science and Business Media. New York, NY.

CONFERENCE PROCEEDINGS

1. **Hartnett ME,** Hirose T, Gilbert MM, Krug JH, Richardson TM. (1990). Early detection of glaucoma in prematurity. *Schepens Alumni Society Meeting*, Boston, MA.
2. **Hartnett ME,** Katsumi O, Hirose T, Richardson T. (1993). Increased intraocular pressure as a cause of delayed visual development in infants with severe retinopathy of prematurity. *International Conference on Retinopathy of Prematurity*, Chicago, IL.
3. Elsner AE, Burns SA, Weiter JJ, **Hartnett ME.** (1994). Diagnostic application of near infrared solid-state lasers in the eye. *LEOS 1994 Conference Proceedings*, IEEE Cat. No. 94 CH3371-2, 14-15.

OTHER (Commentary/Letters/Editorials/Case Reports/Video/Film)

Letters

1. **Hartnett ME.** (2004). Features associated with surgical outcome in patients with stages 4 and 5 retinopathy of prematurity [Letter to the editor]. *Retina*, 24, 658.
2. **Hartnett ME,** McColm JR. (2005). Diode laser for ROP [Letter to the editor]. *Ophthalmology*, 112(9), 1636; author reply 1636.
3. Martiniuk D, Geisen P, **Hartnett ME.** (2006). Invited Author Response to Letter titled “Purification of triamcinolone acetate suspension for intravitreal use.” [Letter to the editor]. *Invest Ophthalmol Vis Sci.*
4. **Hartnett ME,** Lane R. (2013). Reply to “Effects of oxygen on the development and severity of retinopathy of prematurity.” *J AAPOS*, doi:pii: S1091-8531(13)00326-1.

Other

1. **Hartnett ME,** Hirose T, Gilbert MM, Richardson TM, Katsumi O. (1994). Glaucoma as a cause of poor vision in severe retinopathy of prematurity (invited publication). *Ophthalmology Digest* (3, pp. 3-4).
2. **Hartnett ME.** (2004). AMD and the generalist (invited publication, also translated into Spanish and republished in December 2004). *Review of Ophthalmology* (11, pp. 34-41).
3. **Hartnett ME.** (2004). Managing retinopathy of prematurity (invited publication). *EyeNet Magazine* (8, pp. 35-36).
4. **Hartnett ME,** Wallace D. (2004). Retinopathy of prematurity is the common cause of infant blindness (invited publication). *UNC Health Care, featured in News 14 Carolina.*
5. **Hartnett ME.** (2005). Differences in Perceived Barriers to Diabetic Eye Care (invited publication). *Diabetic Microvascular Complications Today* (2, pp. 29-31).
6. **Hartnett ME.** (2005). Lesion characteristics important in assessing therapies for AMD (invited publication). *Ocular Surgery News (Europe Asia-Pacific Edition adapted from USA version 16:6, 2005)* (23(5), pp. 46-50).
7. Abelson M, **Hartnett ME,** McLaughlin J. (2006). Cutting-Edge Therapies for Wet AMD. Review:

- Therapeutic Topics (invited publication). *Review of Ophthalmology* (pp. 100-102).
8. **Hartnett ME.** (2006). An investigation of retinal nonperfusion and its inhibition: A strategy to prevent proliferative diabetic retinopathy (invited publication). *Forefront* (3(2), pp. 11-13). American Diabetes Association.
 9. **Hartnett ME.** (2007). Risk Factors in AMD: Insight from Studies on Environmental Risk Factors, Genotype, and VEGF (invited publication). *AMD Update/Ophthalmology Management*.
 10. **Hartnett ME as consultant.** (2008). Pharmacotherapy Targeting Ocular Neovascularization (invited publication). *Focal Points AAO* (26(7)).
 11. **Hartnett ME.** (2010). Invited article: Advancing technology helpful in pediatric retinal ophthalmology cases. *Ophthalmic Surgery News*.
 12. Vegunta S, Hwang ES, **Hartnett ME.**(2015). Central Serous Chorioretinopathy – Case Report
 13. Zhu Wendy, Li Dean, **Hartnett ME,** Odelberg Shannon (2017). Researchers Identify Protein that Plays Key Role in Diabetic Blindness. University of Utah Press Release.

Video/Film/CD/Web/Podcast

1. **Hartnett ME.** (1994). Current concepts in retinopathy of prematurity, presentations to vision teachers. Audio & video [Video]. Boston, MA: Perkins School for the Blind.
2. **Hartnett ME.** (1995). Visual rehabilitation, presentation to occupational therapists, audio and video [Video]. Spaulding Rehabilitation Hospital.
3. **Hartnett ME.** (1996). Pertinence of a vitreoretinal surgical simulator [Video]. Syracuse, NY: Sixth Annual Dual-Use Technologies & Applications Conference.
4. **Hartnett ME,** Loyacano N. (2002). Retinopathy of Prematurity [Web]. Association of Technical Personnel in Ophthalmology, Internet-based online Learning CME Article. Available: <http://www.atpo.org/>.

ABSTRACTS and MEETING PRESENTATIONS

1. Mangan KF, Winkelstein SA, **Hartnett ME,** Matis SA. (1982). Natural killer cells regulate human erythropoiesis in vitro [Abstract]. Central Society for Clinical Research.
2. **Hartnett M,** Lazarus H, Murphy B, Reed M, Lass J. (1987). Topical corticosteroid versus 2-deoxycytidine therapy of systemic Ara-C induced keratitis [Abstract]. *Invest Ophthalmol Vis Sci*, Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 28(ARVO Suppl), 308.
3. Gilbert MM, **Hartnett ME,** Richardson TM, Krug JH, Hirose T. (1988). Retinopathy of prematurity: overview and findings in the anterior segment of affected eyes [Abstract]. Pediatric Festschrift, Tampa, FL.
4. **Hartnett ME,** Gilbert MM, Krug JH, Richardson TM, Hirose T. (1988). Anterior segment evaluation in infants with retinopathy of prematurity [Abstract]. American Academy of Ophthalmology National Meeting, New Orleans, LA, 167.
5. **Hartnett ME,** Jalkh AE, Weiter JJ. (1988). Classification of RPE detachments in age-related macular degeneration [Abstract]. American Academy of Ophthalmology National Meeting, New Orleans, LA, 180.
6. **Hartnett ME,** Johnson MR, Weiter JJ, Jalkh A. (1989). Classification of RPE detachments in age-related macular degeneration [Abstract]. *Invest Ophthalmol Vis Sci*, Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 30(ARVO Suppl), 271.
7. **Hartnett ME,** Gilbert MM, Richardson TM, Krug JH, Hirose T. (1989). Intraocular pressure measurements in Stage V retinopathy of prematurity [Abstract]. *Ophthalmology*, Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 96(AAO Suppl), 133.
8. Shapiro MJ, **Hartnett ME,** Lin JT, Johnson MR, Pruett RC. (1989). Ocular compatibility of alloplastic materials for scleral surgery [Abstract]. *Invest Ophthalmol Vis Sci*, Association for

- Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 30(Suppl), 271.
9. **Hartnett ME**, Sang DN, Soque J, Hirose T. (1990). Histologic characterization of early premature infant and adult iris tissue [Abstract]. *Invest Ophthalmol Vis Sci*, Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 31(Suppl), 154.
 10. **Hartnett ME**, Hirose T, Richardson TM. (1992). Aqueous outflow measurement to aid in early glaucoma detection in severe retinopathy of prematurity (ROP) [Abstract]. *Invest Ophthalmol Vis Sci*, Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 33(Suppl), 1086.
 11. Elsner AE, Burns SA, Weiter J, **Hartnett ME**. (1994). Imaging and function evaluation with the scanning laser ophthalmoscope [Abstract]. *Exp Eye Res*, 59, 68.
 12. Elsner AE, Burns SA, Weiter J, **Hartnett ME**. (1994). Imaging and function evaluation with the scanning laser ophthalmoscope [Abstract]. International Congress of Eye Research: Proceedings of the International Society for Eye Research, New Delhi, India.
 13. **Hartnett ME**. (1996). Ophthalmology and occupational therapy: collaborating for value [Abstract]. MAOT Conference, Partnerships through Productivity, Marlborough, MA.
 14. Moraes L, Elsner AE, Kunze CW, **Hartnett ME**, Trempe CL. (1997). Correlation between scanning laser ophthalmoscope perimetry and anatomic abnormalities in patients with age-related maculopathy [Abstract]. American Academy of Perimetry, San Francisco, CA.
 15. Elsner AE, **Hartnett ME**, Weiter JJ, Buzney SM, Beausencourt E, Morandi AJ, Trempe CL. (1997). Foveal cone photopigment distribution in age-related macular degeneration: association with fundus features- abstract # 4484 [Abstract]. *Invest Ophthalmol Vis Sci*, Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 38(Suppl), S967.
 16. Moraes L, **Hartnett ME**, Beausencourt E, Kunze C, Elsner AE. (1997). Improved detection in occult choroidal neovascularization associated with age-related macular degeneration [Abstract]. American Academy of Ophthalmology National Meeting, San Francisco, CA, 209.
 17. Beausencourt E, Elsner AE, **Hartnett ME**, Morales L. (1997). New objective measurements of pigment epithelial detachment in age-related macular degeneration using scanning laser tomography [Abstract]. American Academy of Ophthalmology National Meeting, San Francisco, CA, 187.
 18. Beausencourt E, Elsner AE, **Hartnett ME**, Trempe CL. (1997). Radial retinal folds in macular holes imaged with scanning laser tomography [Abstract]. American Academy of Ophthalmology National Meeting, San Francisco, CA, 187.
 19. Moraes L, Elsner AE, Kunze C, Trempe CL, **Hartnett ME**. (1998). Correlation in patients with age-related maculopathy between retinal sensitivity and anatomic abnormalities using a scanning laser ophthalmoscope- abstract # 2745 [Abstract]. *Invest Ophthalmol Vis Sci*, Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 39(Suppl), S593.
 20. Kunze C, Moraes L, Elsner AE, **Hartnett ME**. (1998). Retinal sensitivity in pigment epithelial detachments (PEDs) correlates with three-dimensional extent [Abstract]. American Academy of Ophthalmology National Meeting, New Orleans, LA, 166.
 21. Miura M, Elsner AE, Beausencourt E, Kunze C, Lashkari K, **Hartnett ME**, Trempe CL, Hirose T. (2000). Cross-sectional analysis of age-related macular degeneration with confocal scanning laser tomography- abstract # 839 [Abstract]. *Invest Ophthalmol Vis Sci*, Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 41 (Suppl), S162.
 22. **Hartnett ME**, Garcia CM, D'Amore PA. (2000). Effects of growth factors and cell-cell interactions on blood-retinal barrier function- abstract # 2170 [Abstract]. *Invest Ophthalmol Vis Sci*, Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 41 (Suppl), S411.
 23. Miura M, Elsner AE, Kunze C, Beausencourt E, **Hartnett ME**, Lashkari K, Trempe CL. (2001).

- Blind grading of infrared scanning laser tomography and color fundus photography in exudative age-related macular degeneration [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL.
24. Lovejoy SM, Darland DC, D'Amore PA, **Hartnett ME**. (2001). Contact with endothelial cells (EC) inhibits differentiation of bovine and retinal pigmented epithelium (RPE) in culture -abstract # 1203 [Abstract]. *Invest Ophthalmol Vis Sci*, Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 42 (Suppl).
 25. Coats DK, The Photo-ROP Study Group. (2001). Design and Methodology of the Internet-Based ROP Photographic Screening Trial [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL.
 26. **Hartnett ME**, Rosner B, Vincent DJ. (2001). Retinal features associated with retinal attachment in stage 4 and 5 retinopathy of prematurity- abstract # 3672 [Abstract]. *Invest Ophthalmol Vis Sci*, Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 42 (Suppl).
 27. Capone A, The Photo-ROP Study Group. (2001). The Photo-ROP Trial: an internet-based multicenter trial [Abstract]. American Academy of Ophthalmology International Meeting, New Orleans, LA.
 28. Capone A, The Photo-ROP Study Group. (2001). What's new in ROP management? [Abstract]. American Academy of Ophthalmology International Meeting, New Orleans, LA.
 29. Photo-ROP Study Group. (2002). Inadvertent skip areas in treatment of zone 1 retinopathy of prematurity [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL.
 30. Maguluri S, Khoobehi B, **Hartnett ME**, Carnahan LG, Grinstead RL, Elzembely HA. (2002). Iris neovascularization model and an innovative imaging technique for visualization of individual iris vessels [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL.
 31. **Hartnett ME**. (2002). Vision after surgery for stages 4 and 5 retinopathy of prematurity as measured by teller acuity cards and the new light perception projection scale [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL.
 32. **Hartnett ME**, DeSalvo K, Key J, Loyacano N. (2002). Exploring Barriers to Diabetic Eye Care [Abstract]. North American Primary Care Research Group 2002 Annual Meeting "Building Research Capacity;" New Orleans, LA.
 33. **Hartnett ME**, DeSalvo K, Key J, Loyacano N. (2002). Patient and Physician Perceptions of Barriers to Diabetic Eye Care [Abstract]. LSU Health Services Research Program Annual Conference, Baton Rouge, LA.
 34. **Hartnett ME**, DeSalvo K, Key J, Loyacano N. (2002). Exploring Barriers to Diabetic Eye Care [Abstract]. Sixth Annual Forum on Health Care Effectiveness, Baton Rouge, LA.
 35. Namuduri K, Thompson HW, **Hartnett ME**. (2003). A Multiscale-Multiresolution Method for Automated Retinal Feature Detection [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 4009, 165.
 36. Maguluri S, Daccache A, Loyacano N, Massare S, Thompson HW, **Hartnett ME**. (2003). Comparison Between Digital Fundus Imaging and Fundus Examination in Treatment Recommendations for Diabetic Retinopathy [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 4001, 165.
 37. Daccache A, Maguluri S, Thompson H, **Hartnett ME**. (2003). Comparison of Lens-sparing Vitrectomy and Scleral Buckling in Stage 4 Retinopathy of Prematurity [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 308, 25.
 38. **Hartnett ME**, Maguluri S, Thompson H. (2003). Comparison of Retinal Outcomes after Lens-Sparing Vitrectomy or Scleral Buckle Stage 4 Retinopathy of Prematurity [Abstract]. 3rd International Symposium on ROP Meeting (AAO), Anaheim, CA.
 39. **Hartnett ME**, Lappas A, Darland DC, McColm JR, D'Amore P. (2003). Endothelial Cells in Close

- Proximity to Retinal Pigment Epithelium Causes Outer Retinal Barrier Dysfunction via a Soluble VEGF-Dependent Mechanism [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 3923, 162.
40. **Hartnett ME**, McColm J. (2003). Retinal Features Predictive of Progression to Stage 4 ROP [Abstract]. 3rd International Symposium on ROP Meeting (AAO), Anaheim, CA.
 41. McColm J, **Hartnett ME**. (2003). VEGF Isoforms and PEDF mRNA Expression in a Rat Model of ROP [Abstract]. 3rd International Symposium on ROP Meeting (AAO), Anaheim, CA.
 42. **Hartnett ME**. (2004). Assessing Visual Acuity in Development [Abstract]. World Congress Symposium. San Antonio, TX.
 43. Escaravage GK, Cohen KL, **Hartnett ME**, Patel SB, Armstrong BB, Janowski CM. (2004). Diabetic Retinopathy, Visual Acuity, and Quality of Life after Phacoemulsification in Patients with Diabetes Mellitus [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 303, 12.
 44. **Hartnett ME**, Geisen P, McColm JR. (2004). Effects of Leukemia Inhibitory Factor on Rat Retinal Vascular Development [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 1907, 78.
 45. McColm JR, Geisen P, **Hartnett ME**. (2004). Exogenous LIF Attenuates Retinal Vascularization in Rat [Abstract]. Symposium on Retinal and Choroidal Angiogenesis Meeting. Nashville, TN.
 46. McColm JR, Geisen P, Schaeffer A, Eason E, **Hartnett ME**. (2004). Expression of VEGF and PEDF in a rat model of ROP: VEGF increases more after multiple oxygen fluctuations compared to a single hypoxic episode [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL.
 47. Geisen P, Simhan J, McColm JR, **Hartnett ME**. (2004). Intravitreal Injection of Triamcinolone Reduces Extent of Retinal Neovascularization in a Rat Model of OIR [Abstract]. Symposium on Retinal and Choroidal Angiogenesis Meeting. Nashville, TN.
 48. Patel S, Cohen KL, **Hartnett ME**, Escaravage GK, Armstrong BB, Janowski CM. (2004). Phacoemulsification in Patients with Diabetes Mellitus [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 304, 12.
 49. Geisen P, McColm JR, **Hartnett ME**. (2004). Retinal Cell Injury in a Rat Model of Retinopathy of Prematurity [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 737, 29.
 50. **Hartnett ME**. (2004). Testing of Visual Acuity and Maximizing Visual Function in Subjects with Chromosomal Abnormalities [Abstract]. World Congress on Chromosome Abnormalities, San Antonio, TX, 12.
 51. McColm JR, Geisen P, **Hartnett ME**. (2005). Exogenous Leukemia Inhibitory Factor Attenuates Retinal Vascularization [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL.
 52. **Hartnett ME**, Geisen P, McColm JR, Wittchen ES, Burrige K. (2005). PI 3-kinase mediates Choroidal Endothelial Cell Transmigration of the Retinal Pigment Epithelium and Involves Active Rac [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL.
 53. Escaravage GK, Cohen KL, Patel SB, **Hartnett ME**, Armstrong BB, Janowski CM. (2005). Quantitation of Perifoveal and Optic Disc Hyperfluorescence After Phaco and pCIOL in Patients With Diabetes Mellitus [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL.
 54. Geisen P, McColm JR, **Hartnett ME**. (2005). Soluble Vascular Endothelial Growth Factor Promotes Endothelial Cell Transmigration Across the Retinal Pigment Epithelium [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL.
 55. Zayed, MA, McFadden, A, Yuan, W, **Hartnett, ME**, Chalothorn, D, Faber, J, and Parise, LV. (2006). Critical Role of CIB1 in Endothelial Cell Function and In Vivo Ischemia-Induced Angiogenesis [Abstract]. *Blood*, 108(11).

56. Rosenberg P, Radionchenko Y, McColm J, Geisen P, Cohen K, Thompson H, Vallar C, **Hartnett M.** (2006). Predictors of postoperative macular edema in diabetic patients undergoing phacoemulsification [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL.
57. Peterson LJ, Geisen P, McColm JR, Wittchen E, Burrige K, **Hartnett ME.** (2006). The role of RPE matrix and RPE contact in choroidal endothelial cell migration [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL.
58. Martiniuk DJ, McColm JR, Geisen P, Peterson LJ, Saito Y, Smith W, **Hartnett ME.** (2006). Triamcinolone acetonide reduces intravitreal neovascularization and central capillary density in a rat model of oxygen induced retinopathy in neonatal rats [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL.
59. King B, Geisen P, McColm JR, Peterson L, **Hartnett ME.** (2006). VEGF isoform expression in RPE in transmigration of primary human choroidal endothelial cells across ARPE-19 [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL.
60. **Hartnett ME.** (2006) The Role of Cell-Associated VEGF in Choroidal Endothelial Cell Transmigration. Macula Society (International Society), San Diego, CA
61. Uppal A, Saito Y, Sutton DK, Geisen P, Cui G, Peterson LJ, **Hartnett ME.** (2007). Effects of Supplemental Oxygen Treatment on Oxygen-Induced Retinopathy in Neonatal Rats [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 3410/B557.
62. Saito Y, Uppal A, Sutton DK, Geisen P, Cui G, Lu X, Peterson LJ, **Hartnett ME.** (2007). Effects of Systemic Inhibition of Reactive Oxygen Species on Oxygen-Induced Retinopathy in Neonatal Rats [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 3408/B555.
63. Sutton DK, Martiniuk D, Geisen P, Peterson L, Saito Y, **Hartnett M.** (2007). Intravitreal Triamcinolone Injection Significantly Increases Retinal Arterial Tortuosity in the Rat Oxygen-Induced Retinopathy Model [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 3406/B553.
64. Peterson LJ, Geisen P, Saito Y, Lu X, Martiniuk D, Cui G, **Hartnett ME.** (2007). Neutralizing Antibody to VEGF164 Reduces IVNV and Capillary Density in a Rat Model of Oxygen-Induced Retinopathy [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 3411/B558.
65. Rosenberg P, Radionchenko Y, Geisen P, N Dure F, Cohen K, Thompson H, **Hartnett M.** (2007). Predictors of Postoperative Macular Edema in Diabetic and Nondiabetic Patients Undergoing Phacoemulsification-6 Month Results [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 1393/B449.
66. Geisen P, Zayed M, Parise LV, **Hartnett ME.** (2007). Vegf 189 Isoform Plays an Important Role in Retinal Pigment Epithelium/Choroidal Endothelial Cell Transmigration [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 2526/B473.
67. Watson J, Garg S, **Hartnett ME.** (2008). Clinical Outcomes From Intravitreal Bevacizumab Injection [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 318/D639.
68. Budd SJ, Cheney RE, **Hartnett ME.** (2008). Intravitreal Injections of a VEGF Receptor 2 Inhibitor Reduces Filopodia Length in Endothelial Tip Cells in the Rat Model of Oxygen Induced Retinopathy [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 516/A442.
69. Zayed MA, Wells MB, Rodriguez D, **Hartnett ME.** (2008). Maternal Pre - Eclampsia Contributes to the Severity of Infant Retinopathy of Prematurity [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 1392/A562.
70. Martiniuk DJ, Zhao Z, Wallace DK, **Hartnett ME.** (2008). Reducing the Bioactivity of VEGF With a Neutralizing Antibody Significantly Reduces Arteriole Tortuosity in a Rat Model of Oxygen

- Induced Retinopathy [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 1409/A579.
71. Byfield G, **Hartnett ME**. (2008). Signaling Through gp130 and the JAK/STAT Pathway Play a Role in Intravitreal Neovascularization and VEGF Expression in the OIR Rat Model [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 532/A458.
 72. Culp W Jr., Budd S, Geisen P, Lu X, Saito Y, **Hartnett ME**. (2008). The Role of Vegf164 in Intravitreal Neovascularization Using a Rat Model of Oxygen Induced Retinopathy [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 2637/A362.
 73. Geisen P, Wittchen E, **Hartnett ME**. (2008). Vegf 189 Isoform Is Preferentially Upregulated in Retinal Pigment Epithelium Upon Contact With Choroidal Endothelial Cells [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 862/D680.
 74. Zayed MA, Uppal A, Wells MB, Rodriguez D, **Hartnett ME**. (2008). Effects of Maternal Pre-eclampsia on Severity of Infant Retinopathy of Prematurity [Abstract]. The Retina Society, Scottsdale, AZ.
 75. Byfield G, Parker A, Budd S, **Hartnett ME**. (2009). In the Presence of VEGF, Choroidal Endothelial Cells Increase Production of Reactive Oxygen Species in a Dose and Time Dependent Manner [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 1187/D1149.
 76. Budd S, Parker A, **Hartnett ME**. (2009). NAC Decreases Reactive Oxygen Species Production for in-vitro Choroidal Endothelial Cells Stimulated With VEGF [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 3841/A134.
 77. Reynolds R, **Hartnett ME**, Rosner B, Atkinson J, Giclas PC, Seddon JM. (2009). Plasma Complement Proteins are Associated with AMD Genotypes and Phenotypes [Abstract]. Association for Research in Vision and Ophthalmology International Meeting, Fort Lauderdale, FL, 3445/D777.
 78. Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, **Hartnett ME**. (2010). Baseline Factors Predictive of visual Acuity and Central Retinal thickness outcomes in Patients with Macular Edema Secondary to Retinal Vein Occlusions in the Standard are versus corticosteroid for Retinal Vein Occlusion (SCORE) Study [Abstract].
 79. Ulrich JN, Moyer S, **Hartnett ME**. (2010). Characteristics and Treatment Outcomes of Pediatric Retinal Vascular Malformations [Abstract].
 80. Hartmann J, Huang W, Budd S, Barton K, Richardson A, **Hartnett ME**. (2010). Modulation of Vascular Endothelial Growth factor and Pigment Epithelial Derived Factor by alternating periods of hyperoxia and hypoxia in a relevant model of retinopathy of prematurity [Abstract].
 81. **Hartnett ME**. (2011). VEGF Mediated Stat3 Activation Contributes to Retinal Avascularity in Rat Model of ROP. Association for Research in Vision and Ophthalmology [Abstract]. Ft. Lauderdale, FL.
 82. Wittchen ES, Burrige K, **Hartnett ME**. (2011). Rap1 GTPase Is Involved In RPE Cell Barrier Function [Abstract].
 83. Nishimura E, McCloskey M, Jiang Y, Smith GW, Wang H, **Hartnett ME**. (2011). The Effect of Laser-Induced CNV in Rap1b-deficient Mice [Abstract].
 84. Haibo W, Byfield G, **Hartnett ME**. (2011). Vegf Mediated Stat3 Activation Contributes To Retinal Avascularity In Rat Model Of Rop [Abstract].
 85. **Hartnett ME**, Jiang Y, Hale M, Wang H, Smith GW. (2011). Intrauterine Growth Restriction Alters Retinal IGF-1 Levels in Newborn Rats [Abstract].
 86. **Hartnett ME**. (2011). Success of early limited core Vitrectomy in double Penetrating Glove Injuries [Abstract]. Association for Research in Vision and Ophthalmology. Ft. Lauderdale, FL.
 87. Smith GW, Culp WD, Byfield G, Kafri T, Flannery J, **Hartnett ME**. (2011). Targeting Mueller Cell-derived VEGF With Short Hairpin RNA [Abstract].

88. **Hartnett ME.** (2011). Targeting Mueller cell-derived VEGF with short hairpin RNE [Abstract]. Association for Research in Vision and Ophthalmology. Ft. Lauderdale, FL
89. **Hartnett ME.** (2011). Intrauterine Growth Restriction Alters Retinal IGF-1 Levels in Newborn Rats [Abstract]. Association for Research in Vision and Ophthalmology. Ft. Lauderdale, FL.
90. Shulman JP, Sider S, Moshirfar M, Harrie R, **Hartnett ME.** (2011). Success of Early Limited Core Vitrectomy in Double Penetrating Globe Injuries [Abstract].
91. Nishimura E, McCloskey M, Jiang Y, Smith GW, Wang H, Wittchen ES, Koide R. **Hartnett ME.** (2012). 8-CPT-2-O-Me-cAMP, a Rap1 activator, suppresses laser-induced CNV in Mice. Poster session presented at The Association for Research in Vision and Ophthalmology, Ft. Lauderdale, Florida.
92. Jiang Y, Numpang B, Yu Baifeng, Wang Haibo, Smith GW, McCloskey M, Patel S, DiGeronimo R, **Hartnett ME,** Lane R. (2012). Decreased IGF1 Expression Associated with Avascular Retina in Model of Retinopathy of Prematurity. Poster session presented at The Association for Research in Vision and Ophthalmology, Ft. Lauderdale, Florida.
93. Wang H, Wittchen ES, Shi D, Li DY, **Hartnett ME.** (2012). The small GTPase Rap1 regulates intracellular ROS generation in RPE. Poster session presented at The Association for Research in Vision and Ophthalmology (ARVO). Ft. Lauderdale, Florida.
94. Wang H, Nishimura E, McCloskey M, Wittchen ES, **Hartnett ME.** (2012). Activation of Rap1 reduces Reactive Oxygen Species in Retinal Pigment Epithelium and Choroidal Neovascularization in an Animal Model. The American Ophthalmology Society (AOS). Charleston, SC
95. Yang Z, Wang H, Jiang Y, Mccloskey M, **Hartnett ME.** (2013) The combined effect with Erythropoietin and VEGF in retinal angiogenesis. The Association for Research in Vision and Ophthalmology (ARVO). Seattle, Washington.
96. **Hartnett ME,** Morrison M, Page G, Cotten M, Murray J, DeAngelis M. (2013). Candidate Gene Study of Retinopathy of Prematurity in Extremely Low Birthweight Infants from the Neonatal Research Network. The Association for Research in Vision and Ophthalmology (ARVO). Seattle, Washington.
97. Wang H, McCloskey M, Wittchen ES, **Hartnett ME.** (2013). Activation of Rap1 prevents tumor necrosis factor alpha-induced ROS generation in RPE. The Association for Research in Vision and Ophthalmology (ARVO). Seattle, Washington.
98. Jiang Y, McCloskey M, Wang H, Yang Z, Strange J, Kafir T, Flannery JG, Greenberg K, Hammond S, **Hartnett ME.** (2013). Knockdown of Müller cell specific VEGF reduces retinal neovascularization in a rat model of retinopathy of prematurity. The Association for Research in Vision and Ophthalmology (ARVO). Seattle, Washington.
99. **Hartnett ME.** (2014). Targets Knockdown of Muller Cell VEGF 164 Safely & Effectively Inhibits Intravitreal Neovascularization in Rat ROP Model. The Macula Society Annual Meeting. Key Largo, Florida.
100. **Hartnett ME.** (2014). VEGF Receptor Activates and Interacts With Erythropoietin Receptor to Cause Pathologic Angiogenesis. Retina Society Annual Meeting, Philadelphia, PA.
101. Wang H, Jiang Y, **Hartnett ME.** (2014). Thy-1 regulates VEGF-induced choroidal endothelial cell migration. The Association for Research in Vision and Ophthalmology (ARVO), Orlando, FL.
102. Jiang Y, Wang H, Culp D, Yang Z, Fotheringham L, Flannery J, Hammond S, Kafri T, **Hartnett ME.** (2014). Inhibition of endothelial growth factor splice variant inhibits pathologic neovascularization safely in model of retinopathy of prematurity. American Ophthalmological Society (AOS). New York City, NY.
103. Gambhir D, Jiang Y, Smith GW, Yang Z, Wang H, Fotheringham L, **Hartnett ME.** (2014). Müller cell derived VEGF164 knockdown reduces retinal neovascularisation in the rat model of retinopathy of prematurity. The Association for Research in Vision and Ophthalmology (ARVO), Orlando, FL.
104. Wang Haibo, Wittchen E. and **Hartnett ME.** (2014). The small GTPase Rap1 regulates intracellular ROS generation in RPE. The Association for Research in Vision and Ophthalmology

- (ARVO), Orlando, FL.
105. Wang Haibo, Yu Xing and **Hartnett ME**. (2016) IQGAP1 regulates the interaction of VEGFR2 and CCR3 in Rac1 mediated choroidal endothelial cell migration. (2015) ARVO, Denver, Colorado.
 106. Wang Haibo, Han Xiaokun, Deane Sadiki, Bretz A. Colin, Becker Silke, Jingtong Liu, Kevin Yang and **Hartnett ME**. Inhibition of Choroidal Neovascularization in Rap1b^{-/-} Mice by Self complimentary-AAV2-delivered Constitutively Active Rap1a in Retinal Pigment Epithelium. ARVO, Seattle, WA.
 107. Bretz CA, Wang H, Becker S, Divoky V, Prchal J, and **Hartnett ME**. (2016). Erythropoietin receptor signaling contributes to the development of pathologic retinal angiogenesis. ARVO, Seattle, WA.
 108. Han Xiaokun, Jingtong Liu Angelina, Kunz Eric, Bretz Colin A., Haibo Wang and **Hartnett ME**. (2016). Inhibition of Uncoupling Protein 2 Promotes Postnatal Growth and Physiologic Retinal Vascular Development in a Rat Model of Oxygen Induced Retinopathy. The Association for Research in Vision and Ophthalmology (ARVO), Seattle, Washington.
 109. Becker Silke, Wang Haibo, Yu Baifeng, Lane Robert H., **Hartnett ME**, (2016). Neovascular changes and Angiogenic Factor Production During Combined Intrauterine Growth Restriction and Oxygen-Induced retinopathy. The Association for Research in Vision and Ophthalmology (ARVO).
 110. **Hartnett ME**. (2016). Thy-1Induces Activation and Migration of Choroidal Endothelial Cells: Relevance to Neovascular Age-related Macular Degeneration. The Retina Society. San Diego, CA. Research in Vision and Ophthalmology (ARVO), Seattle, Washington.
 111. Ramshekar Aniket, Bretz Colin, Prchal Josef and **Hartnett ME**. Erythropoietin Receptor Signaling and its Role in Retinal Angiogenesis. The University of Utah School of Medicine Research Trainee Symposium. Park City, UT. September 8, 2016.
 112. **Hartnett ME**. (2017) Clinical Trials on Anti-VEGF and other therapies in diabetic retinopathy. The Association for Research in Vision and Ophthalmology (ARVO). Baltimore, Maryland.
 113. Kunz Eric, Bretz Colin A., Divoky V. and **Hartnett ME**. (2017). Constitutive erythropoietin receptor signaling exacerbates pathologic choroidal neovascularization in an animal model. The Association for Research in Vision and Ophthalmology (ARVO). Baltimore, Maryland.
 114. Han Xiaokun, Wang Haibo and **Hartnett ME**. (2017). Inhibition of Uncoupling Protein 2 Promotes Physiologic Retinal Vascularization via Activation of GLUT1 and S6K1. The Association for Research in Vision and Ophthalmology (ARVO). Baltimore, Maryland.
 115. Becker Silke, Brown R., Brown A., Fung C. and **Hartnett ME**. (2017). Analysis of Wnt pathway components during combined intrauterine growth restriction and oxygen-induced retinopathy. The Association for Research in Vision and Ophthalmology (ARVO). Baltimore, Maryland.
 116. Ramshekar Aniket, **Hartnett ME** and Coats Brittany. Quantifying Changes in Retinal Vessel Morphology as a Diagnostic Precursor to Aberrant Angiogenesis in Retinopathy of Prematurity. The 20th Annual University of Utah Frank Tyler Fall Medical Student Research Symposium. Park City, UT. September 7, 2017.
 117. Vajzovic Lejla, Baumal Caroline R, Berrocal Audina M, **Hartnett ME** and Ells Anna L. (2017). Diagnosis and Management of Pediatric Retina Dilemmas. (AAO) Annual Meeting. New Orleans, LA.
 118. Wang Haibo, Han Xiaokun, Sacks B. David and **Hartnett ME**. (2018) Serine phosphorylation of IQGAP1 regulates VEGF-mediated Rac1 activation and choroidal endothelial cell migration. ARVO, Honolulu, Hawaii.
 119. **Hartnett ME**. (2018) Specific Knockdown of Muller Cell Vascular Endothelial Growth Factor (VEGF) thins Photoreceptors without reducing Retinal Function via Increased Expression of Retinal Neurotrophic Factors in a Model of Retinopathy of Prematurity (ROP). Macula Society Annual Meeting 2018. Beverly Hills, California.
 120. Bretz CA, Kunz E, Suwanmanee T, Kafri T, and **Hartnett ME**. (2018). Endothelial Cell STAT3 Knockdown Inhibits Intravitreal Neovascularization in a Rat Model of Oxygen Induced

- Retinopathy. ARVO; Honolulu, HI
121. Simmons A, Kunz E, Wang H, Bretz CA, Suwanmanee T, Kafri T, and **Hartnett ME**. (2018). Knockdown of endothelial cell VEGFR2 reduces intravitreal neovascularization in the rat model of Retinopathy of Prematurity. ARVO; Honolulu, HI.
 122. Wang Haibo, Ramshekar Aniket, Kunz Eric, Hauswirth William A. and **Hartnett ME**. (2019). VMD2 Promoter-mediated Gene Therapy Optimizes Active Rap1a Expression in the Retinal Pigment Epithelium of Wild Type Mice. ARVO, Vancouver, Canada.
 123. Simmons A, Kunz E, Bretz CA, Wang H, Suwanmanee T, Kafri T, and **Hartnett ME**. (2019). Knockdown of the erythropoietin receptor in endothelial cells extends physiological retinal vascular development in a model of retinopathy of prematurity. ARVO, Vancouver, Canada.
 124. Kunz E, Cheng A, Bretz CA, Simmons A. and **Hartnett ME**. (2019). Generic UNet machine learning architecture can be trained to accurately and consistently identify retinal vascular features. ARVO, Vancouver, Canada.

ORAL PRESENTATIONS

Meeting Presentations (without printed abstracts)

International

- | | |
|------|---|
| 1997 | International Symposium in Ocular and Orbital Echography Panel on Ultrasonography. Sao Paulo, Brazil |
| 1997 | Importance of Ultrasonography in Management of Advanced Retinopathy of Prematurity; International Symposium in Ocular and Orbital Echography. Sao Paulo, Brazil |
| 1997 | Directional Ultrasound for Treatment of Retinal Breaks Associated with Hemorrhage; International Symposium in Ocular and Orbital Echography. Sao Paulo, Brazil |
| 1999 | Aging Retina and Early Degeneration; Boston, MA |
| 2004 | The Senses; (in conjunction with Bronya Keats, PhD, Charles Berlin, PhD) at the World Congress on Chromosome Abnormalities San Antonio, TX |
| 2005 | Features Predictive of Progressive Stage 4 Retinopathy of Prematurity. First International Pediatric Retina Meeting, Key West FL |
| 2009 | Plus disease in Retinopathy of Prematurity, presented at the Association of Pediatric Retinal Surgeons International Meeting, Duck Key, FL |
| 2009 | Current Thoughts on Retinopathy of Prematurity. Presented at the Pan American Ophthalmological Organization. San Francisco, CA |
| 2010 | Gene-environment Interactions and Retinal Disease. Association for Research in Vision and Ophthalmology (ARVO), Ft. Lauderdale, Florida |
| 2010 | Retinopathy of Prematurity: Genetics and Environment. Association for Research in Vision and Ophthalmology (ARVO), Ft. Lauderdale, Florida |
| 2011 | VEGF Induced Activation of Rac1 and NADPH Oxidase in Choroidal Endothelial Cells Leads to Choroidal Neovascularization In Vivo. International Symposium on Ocular Pharmaceuticals & Therapies (ISOPT). Vienna, Austria. |
| 2013 | The Role of Age-related CCR3 Activation in Choroidal ECS in AMD. Association for Research in Vision and Ophthalmology (ARVO). Seattle, Washington. |
| 2014 | Targeted Knockdown of VEGF164 Safely & Effectively Inhibits Intravitreal Neovascularization. Association of Pediatric Retina Surgeons (APRS) Annual Meeting 2014. Cabo San Lucas, Mexico. |
| 2014 | Studying Mechanisms in ROP. Symposium Presentation. Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Orlando, Florida |
| 2014 | RPE Barriers in AMD. SIG Presentation. Association for Research in Vision and |

- Ophthalmology (ARVO) Annual Meeting. Orlando, Florida.
- 2015 Active Rap1 inhibits TNF α -induced CEC Migration via NADPH oxidase and NF κ B mediated Rac1 Activation. Retina Society Annual Meeting. Paris, France.
- 2015 Rationale, Evidence and Safety for Anti VEGF in Proliferative Angiogenesis. International Conference in Advanced Retinal Teaching (ART) 2015 of the Medical University Vienna. Vienna, Austria.
- 2016 Experimental Models of Retinopathy Based on Preterm Infant Stress. (APRS) Annual Meeting. Los Cabos, Mexico.
- 2016 Pediatric Retina: Pearls to Diagnose and Treat Retinopathy of Prematurity. (AAPOS) Annual Meeting. Vancouver, Canada.
- 2016 Studying Effects of Intrauterine Growth Restriction on Retinopathy of Prematurity with Rodent Models. International Society for Eye Research (ISER). Tokyo, Japan.
- 2017 Retinopathy of Prematurity Diagnosis and Management. XXXIII Congreso Panamericano de Oftalmología (PAAO) 2017. Lima, Perú.
- 2018 Activation of Neuroprotective Mechanisms after Inhibition of VEGF in Retinopathy models. Association of Pediatric Retinal Surgeons (APRS) Annual Meeting 2018. Cabo San Lucas, Mexico.
- 2018 Discovering mechanisms in the changing and Diverse pathology of ROP. Weisenfeld Award and Lecture. Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Honolulu, Hawaii.
- 2018 Neuro and Glial-Vascular Effects in the Pathogenesis of Diabetic Retinopathy. American Diabetes Association (ADA) Annual Meeting Orlando FL.
- 2018 IQGAP1 Regulates VEGF-induced Choroidal Endothelial Cell Migration through Rac1. International Society for Eye Research-Belfast, Northern Ireland, UK.
- 2018 IQGAP1 Regulates VEGF-induced Choroidal Endothelial Cell Migration through Rac1. 18th EURORETINA Congress. Vienna, Austria.
- 2019 Research in Academia. Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2019. Vancouver, Canada.
- 2019 Moderator International Ocular Circulation Society Meeting 2019. Extending physiologic retinal vascularization by specific knockdown of retinal endothelial cell vascular endothelial growth factor receptor 2 (VEGFR2). Portland, OR.
- 2019 Moderator Retina Society Meeting 2019. Protective Effects of Erythropoietin in Oxygen-induced retinopathy. London, England.
- 2020 Co-moderator EVRS ROP Virtual Course 2020. Experimental Evidence Supporting Safe Strategies of anti-VEGF in ROP: Vaso and Neuro-Protective Aspects.

National

- 1994 Age-Related Macular Degeneration; The Celebration of Vision Research in Boston, Washburn Lecture Series, National Eye Institute, Boston Museum of Science, Boston, MA
- 1996 Moderator, University of Illinois, Chicago, International Surgical Forum on Retinopathy of Prematurity; October 1996 and 1997
- 2000 The Effects of Cell-Cell Interactions and Growth Factors on RPE Barrier Function; Scientific Advisory Committee; Schepens Eye Research Institute; Boston, MA
- 2000 Moderator: Prevention and Rehabilitation; Vision for the Future – A Scientific Symposium Celebrating 50 Years of Excellence in Vision Research; Boston, MA
- 2001 Retinal Surgery: The Team Approach; American Society for Operating Room Nurses ASORN annual meeting; New Orleans, LA
- 2002 Retinal Surgery: The Team Approach; American Society of Ophthalmic Registered Nurses Annual Meeting; Orlando, FL

- 2003 Dietary Supplements in Age-related Macular Degeneration, presented in Anaheim CA at the National Association of Technical Personnel in Ophthalmology Meeting
- 2004 Surgical Considerations in Pediatric Retina: Stage 4 ROP; Pediatric Ophthalmology and Strabismus Section. Women in Ophthalmology National Annual Meeting
- 2006 Presentation to Advisory Committee for the 2006 Burroughs Wellcome Fund Clinical Scientist Awards in Translational Research, Research Triangle Park, NC
- 2007 Anti-VEGF Agents to Inhibit IVNV and Avascular Retina in a Model of ROP, Association of Pediatric Retinal Surgeons, St. Thomas
- 2009 On Behalf of the Diabetic Retinopathy Clinical Research Network. A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide to Focal/Grid Photocoagulation for Diabetic Macular Edema. The Retina Congress, New York City, NY
- 2011 The Association of Increased VEGF Expression with Avascular Retina in a Rat. American Ophthalmological Society Meeting. Dana Point, CA.
- 2012 Personal and Historical Insights into the Henrietta Lacks Story. The Association for Research in Vision and Ophthalmology (ARVO). Ft. Lauderdale, Florida.
- 2012 Rap1. American Ophthalmological Society (AOS) annual meeting. Charleston, SC.
- 2013 Targeted silencing of VEGF reduces aberrant intravitreal angiogenesis in model of retinopathy of prematurity. American Ophthalmological Society (AOS), Annual Meeting. La Jolla, California.
- 2014 Inhibition Of Vascular Endothelial Growth Factor Splice Variant Inhibits Pathologic Neovascularization Safely in Model of Retinopathy of Prematurity. American Ophthalmological Society (AOS) Annual Meeting. New York City, NY.
- 2014 Wang Haibo, Jiang Yanchao and Hartnett ME. Thy-1 regulates VEGF-induced choroidal endothelial cell migration. ARVO, Orlando, FL.
- 2014 Retinopathy of Prematurity: The Role of VEGF in Pathogenesis and Health. WIO Summer Symposium. Leesburg, VA.
- 2014 Pediatric Retina Disease. Retina Subspecialty Day. AAO Annual Meeting, Chicago, IL.
- 2014 Genetic Variants Associated with Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants. AAO Annual Meeting, Chicago IL.
- 2015 Wang Haibo, Yu Xing and Hartnett ME. IQGAP1 regulates the interaction of VEGFR2 and CCR3 in Rac1 mediated choroidal endothelial cell migration. ARVO, Denver, Colorado.
- 2015 Mechanisms of Aberrant Angiogenesis. Harvard Medical School, Annual Meeting & Alumni Reunion Weekend.
- 2015 Mechanisms of Anti-VEGF and Prospects for Future Treatments of ROP. Retina Subspecialty Day. AAO Annual Meeting, Las Vegas NV.
- 2016 Wang Haibo, Han Xiaokun, Deane Sadiki, Bretz A. Colin, Becker Silke, Angelina Jingtong Liu, Kevin Yang and ME Hartnett. Inhibition of Choroidal Neovascularization in Rap1b^{-/-} Mice by Self complimentary-AAV2-delivered Constitutively Active Rap1a in Retinal Pigment Epithelium. ARVO, Seattle, WA.
- 2016 Han X, Liu A.J, Kunz E, Bretz CA, Hartnett ME and Wang H. Inhibition of Uncoupling Protein 2 Promotes Postnatal Growth and Physiologic Retinal Vascular Development in a Rat Model of Oxygen Induced Retinopathy. ARVO; Seattle, WA.
- 2016 Bretz CA, Wang H, Becker S, Divoky V, Prchal J, and Hartnett ME. Erythropoietin receptor signaling contributes to the development of pathologic retinal angiogenesis. ARVO, Seattle, WA.
- 2016 Thy-1 Activated Choroidal Endothelial Cell: Relevance to AMD. The Retina Society 49th Annual Scientific Meeting. San Diego, CA.
- 2016 Ramshekar Aniket, Bretz Colin, Prchal Josef and Hartnett ME. Erythropoietin

- Receptor Signaling and its Role in Retinal Angiogenesis. The University of Utah School of Medicine Research Trainee Symposium. Park City, UT. September 8, 2016.
- 2017 Kunz E, Bretz CA, Divoky V, Prchal J, and Hartnett M.E. Constitutive erythropoietin receptor signaling exacerbates pathologic choroidal neovascularization in an animal model. ARVO; Baltimore, MD.
- 2017 Moderator Pediatric Retina Disease, Retina Society Annual Meeting 2017. Boston Massachusetts.
- 2017 Panelist Section VIII Pediatric Retina, AAO Annual Meeting 2017. New Orleans, LA.
- 2018 Anti-VEGF Treatment for ROP: Clinical Trials and Phenotypic Differences Worldwide. AAO Annual Meeting 2018. Chicago, IL.
- 2018 Diagnosis and management of pediatric retina dilemmas. AAO Annual Meeting 2018. Chicago, IL.
- 2018 New Horizons and Next Steps. Retinopathy of Prematurity Conference 2018, Children's Hospital of Philadelphia. Philadelphia, PA.
- 2018 Wang Haibo, Han Xiaokun, Sacks B. David and Hartnett ME. Serine phosphorylation of IQGAP1 regulates VEGF-mediated Rac1 activation and choroidal endothelial cell migration. ARVO, Honolulu, Hawaii.
- 2018 Simmons A, Kunz E, Bretz CA, Wang H, Suwanmanee T, Kafri T, and Hartnett M.E. Knockdown of the erythropoietin receptor in endothelial cells extends physiological retinal vascular development in a model of retinopathy of prematurity. ARVO; Vancouver, Canada.
- 2018 Simmons A, Kunz E, Wang H, Bretz CA, Suwanmanee T, Kafri T, and Hartnett ME. Knockdown of endothelial cell VEGFR2 reduces intravitreal neovascularization in the rat model of Retinopathy of Prematurity. ARVO; Honolulu, HI.
- 2018 Bretz CA, Kunz E, Suwanmanee T, Kafri T, and Hartnett ME. Endothelial Cell STAT3 Knockdown Inhibits Intravitreal Neovascularization in a Rat Model of Oxygen Induced Retinopathy. ARVO, Honolulu, HI.
- 2019 Bretz CA, Kunz E, Suwanmanee T, Kafri T, and Hartnett ME. Endothelial Cell STAT3 Knockdown Inhibits Intravitreal Neovascularization in a Rat Model of Oxygen Induced Retinopathy. ARVO; Honolulu, HI
- 2019 VMD2 Promoter Shows Optimal Specificity and Expression of Protective Rap1a in Retinal Pigment Epithelium. The Macula Society Annual Meeting 2019. Bonita Springs, FL.
- 2019 Wang Haibo, Ramshekar Aniket, Kunz Eric, Hauswirth William A. and Hartnett ME. VMD2 Promoter-mediated Gene Therapy Optimizes Active Rap1a Expression in the Retinal Pigment Epithelium of Wild Type Mice. ARVO, Vancouver, Canada.
- 2019 Simmons A, Kunz E, Bretz CA, Wang H, Suwanmanee T, Kafri T, and Hartnett M.E. Knockdown of the erythropoietin receptor in endothelial cells extends physiological retinal vascular development in a model of retinopathy of prematurity. ARVO, Vancouver, Canada.
- 2019 Kunz E, Cheng A, Bretz CA, Simmons A, Hartnett ME. Generic UNet machine learning architecture can be trained to accurately and consistently identify retinal vascular features. ARVO, Vancouver, Canada.
- 2019 Pediatric Vitreoretinal Surgical Techniques. ASRS July 2019. Chicago, IL.
- 2019 Diagnosis and management of pediatric retina dilemmas. AAO Annual Meeting 2019. San Francisco, CA.
- 2019 Panelist Flame On, Not Flame Out. Fighting Burnout and Passing the Torch. The Macula Society Annual Meeting 2019. Bonita Springs, FL.
- 2019 Regulating VEGF signaling to Reduce Stage 3 and Extend Normal Vascular

- 2020 Development. Advances in Pediatric Retina 2019, Salt Lake City, UT. June 2019.
Moderator Pediatric Retina, ROP Symposium 2. ASRS Virtual Meeting, July 25, 2020.
- 2020 Panelist Pediatric Retina Subspecialty Day. American Association of Ophthalmology (AAO) November 2020.
- 2020 Panelist AOS/ABO Symposium, Professionalism in Ophthalmology: Maintaining Resilience and Avoiding Burnout. American Association of Ophthalmology (AAO) November 2020.
- 2020 Course Pediatric Retina Conditions. . American Association of Ophthalmology (AAO) November 2020.

Local/Regional

- 1980 Inhibition of Erythroid Burst Forming Unit (BFU-E) Proliferation In Vitro by Sodium Aurothiomalate: Studies on its Mechanism of Action; Albany Medical College, Albany, NY
- 1990 Retinopathy of Prematurity; Erie Ophthalmology Club, Erie, PA
- 1991 Ocular Manifestations of AIDS; Western NY Fall Conference on AIDS, Buffalo, NY
- 1995 Maximizing Progress in the Premature Infant Through Timely Interdisciplinary Rehabilitation, Spaulding Rehabilitation Hospital, Boston, MA
- 1995 Current Thinking & Management in Retinopathy of Prematurity (ROP); AER, Eighth Annual Symposium on the Medical and Educational Issues Related to the Young Child with Vision Impairments, including Multiple Disabilities
- 1995 Retinopathy of Prematurity; Perkins School for the Blind, Watertown, MA
- 1996 Diabetic Retinopathy; Ocular Symposium; Boston, MA
- 1996 Current Thinking & Management in Retinopathy of Prematurity (ROP); American Association of Certified Orthoptists, Eastern Region Meeting, Boston, MA
- 1996 What's New - Update and Perspectives; New England Ophthalmological Society, Boston, MA
- 1997 Retinopathy of Prematurity; Perkins School for the Blind, Watertown, MA
- 1997 Age-Related Macular Degeneration; Ocular Symposium; Boston, MA
- 1998 Improving Care and Understanding of Retinopathy of Prematurity: Current Directions in Treatment; Perkins School for the Blind, Watertown, MA
- 1999 Age-Related Macular Degeneration; talk and panel open to the public. Visual Rehabilitation Program, South Shore Hospital, South Weymouth, MA
- 1999 Treatment Strategies in AMD; Visual Rehabilitation Center at Massachusetts Eye and Ear Infirmary, Boston, MA
- 1999 Discussant for paper, "Wide Angle Viewing Systems for Vitreoretinal Surgery"; Interactive New England Retina Specialists Meeting, New England Ophthalmological Society, Boston, MA
- 2002 Uveitis and Retinitis; LSU/Ochsner Clinic Foundation Broadcast Lecture Series
- 2002 Retinal Laser: Techniques and Indications; LSU/Ochsner Clinic Foundation Broadcast Lecture Series
- 2002 Retinal Detachment and Repair; LSU/Ochsner Clinic Foundation Broadcast Lecture Series Vitreous Surgery
- 2002 Retinopathy of Prematurity; Louisiana Association of Technical Personnel in Ophthalmology; New Orleans, LA
- 2002 Age-Related Macular Degeneration; public lecture; Lighthouse for the Blind, New Orleans, LA
- 2005 Barriers to Diabetic Eye Screening: A Qualitative Approach, University of North

- Carolina
- 2005 Mechanisms of VEGF Related to AMD, University of North Carolina
- 2005 Diabetic Retinopathy. *Frontiers in Medicine: Complications of Diabetes Mellitus. Clinical Challenges and Research Advances*, University of North Carolina
- 2006 Whitehead Lecture Panel for Medical Students: Ophthalmology and Otolaryngology, Chapel Hill, UNC
- 2007 Retinopathy of Prematurity: Recent Progress and Future Challenges, invited speaker to Science of Disease, Duke University, Durham, NC
- 2007 Age-related Macular Degeneration: New Thoughts regarding Causes and Treatment, Case Department of Pharmacology
- 2007 Updates on Treatment and Pathophysiology on Retinopathy of Prematurity, Case Department of Ophthalmology
- 2008 Considerations of new treatments in ROP: Knowledge from animal models. New England Eye Center and Tufts Medical School
- 2008 Examination of the Relationship of Diabetes and Hypertension to the Onset of Eye Disease, specifically Cataracts and Glaucoma, among African Americans. The Institute for Health, Social, and Community Research at Shaw University Shaw University M-RISP Minority Elderly Research Center Shaw University Project Export R24 Program on Racial Health Disparity Research
- 2008 Neovascular age-related macular degeneration: studies using retinal pigment epithelial and choroidal endothelial cocultures. Inflammation and Adhesion PPG, University of North Carolina
- 2009 Plus Disease in ROP: Determining Mechanism, presented to Wilmer Retina Service
- 2009 Retinopathy of prematurity: Research and clinical aspects, presented to Moran Eye Center, Salt Lake City, UT
- 2009 Aberrant Angiogenesis: Impact on Clinical Retinopathy of Prematurity, seminar to department of Cell and Molecular Physiology, University of North Carolina, Chapel Hill NC
- 2010 Retinal Detachment. John A. Moran Eye Center, Salt Lake City, Utah
- 2010 Understanding the Changing Role of Oxygen as a Causative Factor in Retinopathy of Prematurity. 61st Annual Post-Graduate Review. American Medical Association. Syracuse, New York
- 2011 RPE-Choroidal EC Interactions in EC Transmigration: Modeling Choroidal Neovascularization. John A. Moran Eye Center, Salt Lake City, Utah
- 2011 Pathologic Angiogenesis in Retinal Diseases: Focus on ROP. Utah North Star Optometry Seminar. John A. Moran Eye Center. Salt Lake City, Utah
- 2011 Retinopathy of Prematurity. Utah North Star Optometry Seminars. John A. Moran Eye Center, Salt Lake City, Utah
- 2011 Delayed Retinal Vascular Development: Relevance to ROP. Pediatric Vascular Development Meeting. Duck Key, Florida
- 2011 Impaired Retinal Vascular Development; Relevance to ROP. Pediatric Retinal Surgeons. Duck Key, Florida
- 2011 ROP - Update from Clinical and Lab. Grand Rounds, John A. Moran Eye Center. Salt Lake City, Utah
- 2011 Grand Rounds and Research Talk.
- 2011 Retinopathy of Prematurity: Clinical Management. Brown University. Providence, Rhode Island
- 2011 Pathologic Angiogenesis in Models of Retinopathy. Brown University. Providence, Rhode Island
- 2011 Research on age-related Macular Degeneration. University of Utah. Salt Lake City, Utah

- 2011 Animal Models in the study of Human Retin visual diseases. University of Utah. Salt Lake City, Utah
- 2011 Retinal Vascular Development and Disease. John A. Moran Eye Center, Salt Lake City, Utah
- 2012 Retina Lecture: Diabetic Retinopathy. John A. Moran Eye Center. Salt Lake City, Utah
- 2012 Mechanisms involved in Neovascular Age-related Macular Degeneration. Vision Discovery Institute Distinguished Seminar Series. Augusta, Georgia
- 2012 Considerations Regarding Anti-VEGF Treatments in Severe ROP. Faculty Alumni Day. John A. Moran Eye Center, University of Utah, Salt Lake City, Utah

Invited/Visiting Professor Presentations

International

- 2006 Prevention of Choroidal Endothelial Cell Transmigration: Toward Preventing Vision Loss in Neovascular AMD. Invited to ARVO Summer Eye Research Conference, Sanibel FL Considerations of anti-VEGF agents in Retinopathy of Prematurity. Portuguese Congress of Ophthalmology. Porto, Portugal (KEYNOTE SPEAKER)
- 2007 Progressive Stage 4 Retinopathy of Prematurity. Annual Portuguese Congress of Ophthalmology. Porto, Portugal
- 2008 Foundation Fighting Blindness Visions 2008 conference. Visiting expert speaking on Age-related macular degeneration and involved in 2 sessions of “Doctor is In” discussing gene therapy and new clinical trials for retinal degenerations. Crystal City, MD.
- 2009 Featured invited speaker at 115th annual French Congress of Ophthalmology: "Research Insights into Retinopathy of Prematurity", Paris, France.
- 2010 Gene-environment Interactions and Retinal Disease.” Retinopathy of Prematurity: Genetics and Environment.” Association for Research in Vision and Ophthalmology (ARVO), Ft. Lauderdale, Florida
- 2011 VEGF-Induced Activation of Rac1 and NADPH Oxidase in Choroidal Endothelial Cells Leads to Choroidal Neovascularization in vivo. ISOPT. Vienna, Austria
- 2011 Upregulated Chemokine Receptor - 3 by Age - Related Stresses Promotes Choroidal EC Migration via VEGF-Dependent and Independent Mechanisms. ISOPT. Vienna, Austria
- 2011 Progressive Stage 4 Retinopathy of Prematurity. 54th Annual Portuguese Congress of Ophthalmology. Porto, Portugal
- 2012 Delayed Retinal Angiogenesis by VEGF-mediated downregulation of Erythropoietin, Pediatric Retinal Vascular Meeting. San Francisco, California
- 2013 Rap1 GTPase improves RPE barrier integrity and resists choroidal neovascularization. Macula Society Meeting. Dana Point, California.
- 2013 Moderator for Basic Science/AMD and Diabetic Retinopathy. Macula Society Meeting. Dana Point, California.
- 2014 Physiologic Retina Vascular Development and ROP: What Went Wrong? 11th Annual Dialogues in Neonatal-Perinatal Medicine Conference. Duke University. Raleigh, North Carolina
- 2015 Rationale, Evidence and Safety for Anti-VEGF in Proliferative Angiogenesis, 12. International Conference in Advanced Retinal Teaching (ART) 2015 of the Medical University Vienna, Vienna, Austria

National Invited Speaker/Visiting Professor/Named Lectureships

- 2002 Retina Repair, Vitrectomy, and Laser; Visiting Professor at University of North

- Carolina Department
- 2006 Current Thinking of Angiogenesis in Retinal Disease. Invited Professor to Case University, Cleveland OH
- 2006 Chalk Talk: Angiogenesis in Retinal Diseases. Invited Professor to University of Rochester, Rochester, NY v(to national visiting prof/named lectures
- 2007 Anti-VEGF Agents in a Model of Retinopathy of Prematurity, invited speaker University of Rochester, Rochester NY
- 2007 New Thoughts Regarding Treatment for Neovascular Age-related Macular Degeneration". Bausch and Lomb Visiting Professor, University of Rochester, Rochester, NY.
- 2007 Retina as a Model of Angiogenesis and to Study Retinal Diseases, invited speaker University of North Carolina, annual Vascular meeting.
- 2007 New Thoughts regarding Treatment for Neovascular Age-related Macular Degeneration, invited speaker to University of Chicago Department of Ophthalmology, Chicago IL
- 2008 Mayo Clinic Invited Professorship. Retinopathy of Prematurity: Clinical and Research Experience
- 2010 Science and Disease Lecture, "Retinopathy of Prematurity: Angiogenesis Inhibition to Reduce Avascular Retina." Duke University, Durham, North Carolina.
- 2010 Loris and David Rich Lecture Series. "Pathologic angiogenesis in Retinal Diseases: Focus on ROP." University of Alabama, Birmingham, Alabama.
- 2010 Invited talk to Residents and Faculty, "Retinopathy of Prematurity." University of Alabama, Birmingham, Alabama.
- 2011 Pathologic Antiogenesis in Models of Retinopathy. Brown University, Providence, Rhode Island
- 2011 Retinopathy of Prematurity: Clinical Management. University of Kentucky. Lexington, Kentucky
- 2011 Endothelial Transmigration in Age-related Macular Degeneration. University of Kentucky Mini Symposium. Lexington, Kentucky
- 2012 Mechanisms involved in Neovascular Age-related Macular Degeneration. Vision Discovery Institute Distinguished Seminar Series. Augusta, Georgia.
- 2014 Update on Oxygenation and Risk of Retinopathy of Prematurity. Jules Stein Eye Institute Leonard Apt Meeting: Advanced Topics in Pediatric Ophthalmology and Strabismus. UCLA. Los Angeles, California.
- 2014 Genetic Variants Associated with ROP in Extremely Low Birth Weight Infants. Duke University Department of Ophthalmology.
- 2014 Retinopathy of Prematurity: The Effects of VEGF in Health and Pathology. Clinical Translational Lectureship, keynote speaker. Kresge Eye Institute, Wayne State University, Michigan.
- 2014 Mechanisms of Retinopathy of Prematurity. Vision Science Distinguished Lecture Series. Medical College of Wisconsin.
- 2015 Distinguished Visiting Lecturer, Department of Ophthalmology, University at Buffalo, State University of NY.
- 2015 Distinguished speaker for 2015 Research lecture series at SUNY Downstate.
- 2017 Distinguished Visiting Lecturer, Department of Ophthalmology and Visual Sciences, Clinical Conference Lecture series 2017-2018, University of Iowa, Iowa City Iowa.
- 2018 Distinguished Visitor Lecture Series Program, Cole Eye Institute. Regulation of Angiogenesis in Retinal Diseases. Cleveland, OH.
- 2019 "Regulating Signaling Pathways to Promote Physiologic Angiogenesis". Diabetic Eye Disease Center of Excellence Distinguished Lecture. Massachusetts Eye and Ear Infirmary.

- 2020 “Regulating Angiogenesis in retinal Disease”. Departmental Research Seminar Series Byers Eye Institute at Stanford.

Local/Regional

- 1976 The Effect of Normal and Inactivated Erythropoietin on Transformed Target Cells in Laboratory Mice; Roswell Park Memorial Institute, Buffalo, NY Invited Research Presentation
- 2001 Retinopathy of Prematurity; invited lecture to regional pediatricians; Louisiana State University; Baton Rouge, LA
- 2002 Retinopathy of Prematurity; invited lecture to the Respiratory Care PR actioners Association Fall Symposium, East Jefferson Hospital, Metairie, LA
- 2005 Angiogenesis in Retinovascular and Choroidal Vascular Diseases, Invited Professor, Momenta Pharmaceuticals, Cambridge, MA
- 2007 Anti-VEGF Agents: Effects in an ROP Model, invited speaker to the Chandler Ophthalmology Symposium, University of North Carolina, Chapel Hill.
- 2007 Retinopathy of Prematurity: Updates on Treatment and Pathophysiology, invited speaker, Duke University, Durham NC.

Grand Rounds Presentations

- 1994 Retinopathy of Prematurity; Pediatrics Grand Rounds, Beverly Hospital, Beverly, MA
- 1994 Age-Related Macular Degeneration; Grand Rounds, Spaulding Rehabilitation Hospital, Boston, MA
- 1994 Medical Grand Rounds, Low-Vision Service, Spaulding Rehabilitation Hospital, Boston, MA
- 1995 Medical Grand Rounds, Low-Vision Service, Spaulding Rehabilitation Hospital, Boston, MA
- 1995 Age-Related Macular Degeneration; Grand Rounds, Spaulding Rehabilitation Hospital, Boston, MA
- 1995 Recognizing Visual Deficits in the Rehabilitation Patient; Grand Rounds, Spaulding Rehabilitation Hospital, Boston, MA
- 1998 Current Concepts in Retinopathy of Prematurity; Neonatology Grand Rounds, Massachusetts General Hospital
- 2000 Treatment of Retinopathy of Prematurity; Children’s Hospital of Boston, Grand Rounds; Harvard Medical School, Boston, MA
- 2002 Stages 4 and 5 ROP; Visiting Professor at University of North Carolina Department Ophthalmology Grand Rounds, Charlotte, NC
- 2005 Retinopathy of Prematurity. Neonatology Grand Rounds. University of North Carolina
- 2008 Neonatology Grand Rounds, “Retinopathy of Prematurity”, University of North Carolina
- 2011 Retinopathy of Prematurity Current Clinical Management. Grand Rounds, Brown University. Providence, Rhode Island
- 2011 ROP update from Clinical and Lab. Ophthalmology Grand Rounds. University of Utah, John Moran Eye Center. Salt Lake City, Utah
- 2012 Retinopathy of Prematurity. Neonatal – Perinatal Conference. University of Utah, Primary Children’s Medical Center, Salt Lake City, Utah
- 2013 Insights into Recurrent Neovascularization after Anti-VEGF Treatment in ROP. University of Utah, John Moran Eye Center, Salt Lake City, Utah.

2013	Retinopathy of Prematurity: Current Clinical Management. Ophthalmology Grand Rounds. University of Louisville, School of Medicine. Louisville, Kentucky.
2014	Ophthalmology Grand Rounds. "Update on VEGF and Neuroprotection in Retinopathy of Prematurity", John A. Moran Eye Center, University of Utah
2015	Obstetrics and Gynecology Grand Rounds. "Eye Health in Women", The University of Utah. Salt Lake City, Utah.
2017	Grand Rounds Nationwide Children's Hospital Columbus. "Retinopathy of Prematurity", and open discussion with Residents, The Ohio State University. Columbus, Ohio.
2017	Endocrine Grand Rounds. "What's New in Diabetic Retinopathy: Updates for the Endocrinologist?" The University of Utah. Salt Lake City, Utah.
2018	"Update on Retinopathy of Prematurity". Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine Grand Rounds.
2019	"Current Considerations in the Management of Retinopathy of Prematurity". Grand Rounds University of Colorado, Aurora, Colorado.
2019	"Understanding and Managing Retinopathy of Prematurity". Grand rounds Emory University, Atlanta, Georgia.

OTHER SCHOLARLY ACTIVITY

2002 - 2003	Founded Louisiana State University Eye Center Lecture Series in Ophthalmologic Research. Monthly one-hour sessions of invited regional clinical and laboratory ophthalmologic research speakers open to all ophthalmologists. (Initiated September 2002).
2003 - 2010	Developed the clinical trial studies focusing on diabetic retinopathy through the Diabetic Retinopathy Clinical Research Network (DRCR.net) University of North Carolina. Chapel Hill, North Carolina National Eye Institute Role: Site Principal Investigator
2010 – Present	Organized national Retinopathy of prematurity/Genetics study
2012	Organized/hosted annual Association of Pediatric Retina Surgeons, APRS meeting. Park City, Utah.
2016-2017	Developed educational module through ARVO's Research Training Planning Committee. ARVO's guide to human subject's research.
2018	Matt Byrne MS Thesis Committee Member, "Morphology and Mechanics of Retinal Vasculature in Abusive Head Trauma." University of Utah.
2020	Christopher Creveling PhD Dissertation Committee Member, "Characterization and Modeling of Vitreoretinal Adhesion in the Eye". University of Utah.
2020	Emmanuel Kofi Addo Ph.D. Committee Member, "Raman Genetics: The effect of immediate versus deferred disclosure of AMD genetic risk on biomarkers of ocular and systemic carotenoid status". University of Utah.
2020	Aniket Ramshekar PhD Thesis Committee Chair "Investigating Rap1/IQGAP1 interactions in Macular Degeneration". University of Utah.

LEADERSHIP TRAINING

2005	AAMC Mid-Career Women Faculty Professional Development Seminar.
2005	Southern Women in Academic Medicine Conference. Little Rock, Arkansas
2014 - Present	Mentor for Women in Ophthalmology (WIO)
2014 - Present	Mentor for Women in Retina (WinR)

2015 - Present SOM Benning Speaker Selection Committee
2016 Inaugural Mentor in the ARVO Women's Leadership Program
2017 – 2018 Mentor in the ARVO Leadership Development Program for Women
2017 Chosen to be the Representative from + for the AAO Leadership Development Program. ARVO 2017 Annual Meeting. Baltimore, MD.
2017 AAO 2017 Annual Meeting Leadership Development Program (LDP XX, Class of 2018)
2018 AAO Mid-Year Forum 2018. Washington DC.
2018 Faculty Mentor at The University of Utah Grant Writing Academy (GWA), May 18-20, 2018. Deer Valley UT.
2018 AAO 2018 Annual Meeting Leadership Development Program (LDP XX, Class of 2018)
2019 Members in Training Career Forum, "Research in Academia". ARVO Annual Meeting 2019, Vancouver, Canada.